<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
   xmlns:ao="http://www.w3.org/ns/oa#"
   xmlns:dailymed="http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/"
   xmlns:dct="http://purl.org/dc/terms/"
   xmlns:domeo="http://www.w3.org/ns/domeo#"
   xmlns:foafx="http://xmlns.com/foaf/0.1/"
   xmlns:ncit="http://purl.bioontology.org/ontology/NCIT#"
   xmlns:pav="http://purl.org/pav/"
   xmlns:permissions="http://vocab.deri.ie/cpo#"
   xmlns:poc="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns:sio="http://semanticscience.org/resource/"
>
  <rdf:Description rdf:about="urn:linkedspls:uuid:56C8F2E9-AF26-4426-BB59-4CD390E7331B">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>HLA-B</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6DDAC665-7DFB-4C64-B420-F830A1422FBC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0EA628AE-BE06-4131-BE59-DA6952BF359E">
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-19 17:21:27 -0400</pav:createdOn>
    <domeo:uuid>0EA628AE-BE06-4131-BE59-DA6952BF359E</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0EA628AE-BE06-4131-BE59-DA6952BF359E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact> Citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <ao:suffix> (see </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5B898CA8-06CF-4BC5-A5CE-22DD70C9926F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F50B183E-3A4A-4608-9BA1-5AA2440B5042">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdfs:label>Clopidogrel</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A5DA69F3-FE26-4B23-8B10-DE4FAD465EFE">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#USE IN SPECIFIC POPULATIONS (43684-0)</poc:productLabelSection>
    <sio:SIO_000111>USE IN SPECIFIC POPULATIONS (43684-0)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2D300706-432D-4D5C-9785-589A22B4DDD8">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOKINETICS (43682-4)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>PHARMACOKINETICS (43682-4)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B84CD8FE-68DC-40CD-BB96-5CD2D1B661AC">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8FF0BA45-8601-4BA3-93DE-624CDEB7252D">
    <rdfs:label>Do not restart</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E7EFBC4B-D9D1-4473-91DB-7C0C8598F7C2">
    <ao:body rdf:resource="urn:linkedspls:uuid:EDDDD608-4E61-4DF5-BA25-8A9EC1ACEDE0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:C752899B-CF9A-46F9-96A0-E6AB69BA169E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A46086E-FF21-48B1-B671-934A55E76909"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:1D67CEB8-320D-4F19-B27C-288A430F69B8"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-03-20 20:28:44 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:EFE396DB-81F0-4AC0-8B87-1686C1A96C72"/>
    <pav:lineageUri>urn:domeoserver:annotation:6B4FC6D6-03B4-42EC-853D-7AC35D749CD9</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:ECA57656-0536-490E-955F-FEB7DCA6DEF0"/>
    <pav:lastSavedOn>2014-03-20 20:40:11 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:82F5062E-31A0-414E-BBFB-6F8ACED740D1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:37C0B650-B957-4703-8BA7-E837AB41C9EB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F8AA27F7-14D2-42E8-95F6-B665098D6514">
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.0alpha-040">
    <foafx:build>040</foafx:build>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <foafx:homepage></foafx:homepage>
    <foafx:version>2.0alpha</foafx:version>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E734BCF1-1BFA-46A3-A518-2D55813C1447">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:695FC10C-154E-4098-9F43-0AF0F1EA9835">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2658F016-478C-4479-90F4-133D10DB8856">
    <ao:context rdf:resource="urn:domeoclient:uuid:FACFAB8E-E4E7-4839-99E1-C538E44B51EF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:04B8FB02-40E6-4372-9368-1BDAB97E3DDF"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:5068F1DA-26C7-4793-BA0D-1AF56AC4AB6F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:EB6B9E12-2611-4E3B-AD60-57C861B70E1F</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-20 20:40:11 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E4A19D01-A42A-4688-9E0E-C59D62B8E9BA"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdOn>2014-03-20 20:33:05 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:11D183FE-EFBF-40D7-B7E9-31A55FF71D35"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3F848B10-8225-4608-8CB2-1C2EC8D42CC2">
    <ao:body rdf:resource="urn:linkedspls:uuid:E5FD17E7-CB15-4DD1-AD11-B0EFC1C8D0D1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4CD7D289-EEE7-4212-8B2E-8D6E467AEA31"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:C7C7CFB7-46C2-4C99-8550-35FC75802F77"/>
    <pav:lastSavedOn>2014-03-20 20:25:07 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:EB59BEC3-604E-402B-9DDF-0F0C39C79DB8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E2F3A1BE-A0E3-424C-9092-15F166B370F7</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:60D74402-BDAA-4C5B-8066-D016D4F770F8"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-20 20:08:37 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:41927305-045E-43DF-BF77-E61DF51C69D5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:189A726D-4325-4768-92CF-C992BB68B068">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB8B6E3D-6F2E-4D76-BA26-F521F389FF42">
    <ao:body rdf:resource="urn:linkedspls:uuid:A7E98374-CD92-4BA1-A421-B4AAF18FD95E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:488A5C56-4D60-4046-8C9D-69D96FCF2E4C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E0107363-A1EB-491B-84DF-E54542AAA8DF"/>
    <pav:createdOn>2014-03-19 16:15:11 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:75CC2873-0C93-47EA-9993-334949D55561</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:F52DD4D1-B020-4D5D-A1DD-FBC62006D5D2"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B767998-2127-4EF1-AA11-8FB04F279BAA"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:18611A83-6C34-4526-B84E-847C0318CF09"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:126C8363-44D4-4E38-8AC6-7298DCFEE8AE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FAE060A9-40D1-4C40-886F-AA0F44F8F279">
    <ao:body rdf:resource="urn:linkedspls:uuid:7CFCE65D-C6A6-4397-9497-D4AA84C41038"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:AA2A1633-B19F-4CE2-835E-FE12EB3A7340"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:FFE334F5-EADA-48A9-9C71-93A006B991CE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-19 22:53:11 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:ACE64BA1-1115-4621-8E99-F15218492103"/>
    <pav:lineageUri>urn:domeoserver:annotation:A633923A-6CED-4D88-9573-6B7CA53E4BF2</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdOn>2014-03-19 22:49:05 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B97602D5-1BED-471F-BD91-5F10B24278CE"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:D4DA286E-73B7-4DA4-8095-952301ABA032</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:83D62FE5-34B9-4708-9A61-72F48F88D12A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:83D62FE5-34B9-4708-9A61-72F48F88D12A"/>
    <pav:createdOn>2014-03-20 19:04:53 -0400</pav:createdOn>
    <ao:exact>Nursing mothers who are ultra-rapid metabolizers may also experience overdose symptoms such as extreme sleepiness, confusion, or shallow breathing. </ao:exact>
    <ao:suffix>Prescribers should closely monitor mother-infant pairs and notify treating pediatricians about the use of codeine during breastfeeding </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>ng codeine should be informed about when to seek immediate medical care and how to identify the signs and symptoms of neonatal toxicity, such as drowsiness or sedation, difficulty breastfeeding, breathing difficulties, and decreased tone, in their baby. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>83D62FE5-34B9-4708-9A61-72F48F88D12A</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2EBD924F-F4C6-4C96-B6F0-EF6EC2553B9C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2EBD924F-F4C6-4C96-B6F0-EF6EC2553B9C"/>
    <ao:prefix>A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:suffix> Tests are available to determine a patient’s CYP2C19 genotype.  </ao:suffix>
    <ao:exact>Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese.</ao:exact>
    <pav:createdOn>2014-03-20 22:41:37 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>2EBD924F-F4C6-4C96-B6F0-EF6EC2553B9C</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:723FE4B0-6EE0-41F8-8690-750CFF2EE285">
    <pav:lineageUri>urn:domeoserver:annotation:30367CFA-9AD0-4083-9261-0900B749BA39</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:B8BFADA5-C34A-4483-9C3C-F661DA89CE85"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:23BB932E-45FB-42A9-8902-7FFDBE68F3C1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7C2DA914-B2F9-4FA8-BD2A-A13628950AE5"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:D4DA286E-73B7-4DA4-8095-952301ABA032</domeo:belongsToSet>
    <pav:createdOn>2014-03-19 22:43:40 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-19 22:53:11 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:2D5E2F9C-71DA-4E84-A2D0-5632F955EF10"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F7EC48B0-0AAD-4A4B-B2DE-786B06DF7675"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AC7F9D61-2FFD-4538-94F4-B586AB8C3E36">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3548156E-1ABB-4659-8621-34BAA76E6E81">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1D67CEB8-320D-4F19-B27C-288A430F69B8">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:376874CE-BA12-4B2A-9A64-3F35F96FB9D4">
    <ao:body rdf:resource="urn:linkedspls:uuid:F32C2053-82E9-4FD1-836F-8149193CCD98"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdOn>2014-03-19 14:31:27 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:67DA6A8D-7870-427A-BF14-B797B21B9F8A</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:270ED847-DC14-417F-84EA-100C7ABD4F78"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:84DB2E2F-3B1E-478C-8BE4-8B29EF42F52C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:A9BDEBDF-56CE-4C76-93F7-5A4E57E3EC4C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1C79CA9B-388B-440F-81D1-4A78C148CD26"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F690C8FB-747D-409B-98B4-0C18F0BDF5B4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:695FC10C-154E-4098-9F43-0AF0F1EA9835"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-19 15:09:38 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:73564A21-2417-4602-B23F-E7ACBAB17A27">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD274EE0-898F-4F50-9BE4-692E87FB190A">
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-20 20:39:16 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:83B1759A-375E-4EDF-BE66-3B416808B8A4"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4DD36BFE-C659-4270-8CDB-6026EECED60F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:34C7F252-0062-4084-85B9-D44C474C8E00"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:27DA8C45-15B2-411B-8C9C-A82433D90E5D</pav:lineageUri>
    <pav:lastSavedOn>2014-03-20 20:40:11 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:332D6CE3-0165-43D9-B008-7A2EE57C659B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C85F2569-E1BA-41FE-8EBF-518BE5F38995"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0A708736-453D-44F0-8285-2ED07935FE60"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DCBD54B3-8254-4593-9093-F0C2CE0C55E6">
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D0D03BCE-8134-411C-A0D0-875CB9EEF2FD">
    <ao:context rdf:resource="urn:domeoclient:uuid:947765BA-B0F4-430E-BE23-3094A2EBE8C6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E64D1BEE-DB99-42E4-87F5-B2748A80B7AD"/>
    <pav:lastSavedOn>2014-03-20 22:01:22 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:5B3A7C05-9902-476C-85DF-1A73D7737071</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:BBC07988-801B-4827-92EF-2E665B8075E7"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-20 21:08:54 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:A07E8945-D86E-4589-AB9F-776A7460CB34"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:A509C3C1-79A4-4C5F-82C8-1785B52A5B76"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:2F488DA9-7951-41E1-A46B-E4C64261E539</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A7E5813-7417-4AE0-B84A-C3EFC7D8DD8B">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lastSavedOn>2014-03-20 22:01:22 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:A7B5E2D3-3FDB-4BC6-A57F-543654FA9B26"/>
    <pav:createdOn>2014-03-20 21:16:02 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AE4F92D8-FEA4-4B14-97CA-1F03130C26F5"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:5B3A7C05-9902-476C-85DF-1A73D7737071</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:6A62D7B4-4A81-4BFB-BC4F-852478D86522</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3EC23021-7DE8-434F-9BF8-2280E24D021B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:4C55291A-ABA6-436F-B897-73BC705396A2"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:DABCA597-D5CF-49A3-ADAE-B2FBAA9BAA2B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6337DC86-4ACC-49B2-8039-45920702A769">
    <pav:lastSavedOn>2014-03-20 20:40:11 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:2D68CA32-F35F-4606-BCDC-904734C7EA56</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:F0CC6ECD-5A08-470E-A24D-C36BFA00A465"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F3D15F27-B83B-43CF-8CBD-9EB95EEDAED3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A3D3C8D7-AAB7-4C87-9E7A-704CD7F9AACA"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-03-20 20:35:50 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:D72742CB-6E6A-4D6D-A623-22D40BC78ED8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:65C194F0-EA24-44FE-B791-26F5A26398F4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:63122E82-2B89-4A5C-A089-2430DC780844">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E68C8718-225C-4D4A-A225-4283D9CCC53F">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>VKORC1</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:241A40BB-DB23-4291-B6C0-21AC0A7FFB5B">
    <domeo:uuid>241A40BB-DB23-4291-B6C0-21AC0A7FFB5B</domeo:uuid>
    <ao:exact>Discontinue ZIAGEN as soon as a hypersensitivity reaction is suspected. Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:241A40BB-DB23-4291-B6C0-21AC0A7FFB5B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-04-14 13:44:41 -0400</pav:createdOn>
    <ao:suffix> (5.1)</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07">
    <ao:item rdf:resource="urn:domeoclient:uuid:E81BD5D1-A9EF-4142-B75D-7087E758B27C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:8D887387-F3F3-4768-9757-1F38D8339194"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:annotatesResource>
    <pav:previousVersion>urn:domeoserver:annotationset:D1447398-E265-4A69-9E21-0E5C03346A83</pav:previousVersion>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lastSavedOn>2014-04-14 14:31:20 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896e94ef0008"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:39F89B5F-9160-4437-BE6A-4025DA07E04C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:831642BA-AFB2-42BB-83BD-94A20F56AF4F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A06D588B-932F-4A73-A67A-20DD78A56D96"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F61D97EB-8403-42C8-9DED-0D17173ADB71"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D75DFCB7-9EDF-433A-A085-7AEB57EA4738"/>
    <pav:lineageUri>urn:domeoserver:annotationset:13DDC676-F835-48F3-8F51-F14D640EC90D</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:0F15E322-D2CA-4F51-9094-89C0F1480643"/>
    <permissions:permissions rdf:nodeID="N60a51e347e8f49b2965286fa6dd65fa5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2E87036C-1F2B-43FA-9AAC-9313A2C17B72"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3A800ED5-E7D2-4218-86D9-A0B72F60A5D9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:22AEACAD-5E17-4751-AFD4-7D1FB542F6AD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C16B7C24-8DD5-45BE-8CC6-CE2B04315F70"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:38EFA0C1-70C0-492E-A761-1908DF799548"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:60873B48-9633-4268-AB9A-F0AFF0F3F1DA"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8C4879CD-D381-439A-9611-B0B648A2A9C0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3B5CBFCB-DB0C-4D0C-BD42-D00EA4781827"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:69BAE4D0-A413-4DA0-9A58-F4F38BEC9D18"/>
    <pav:createdOn>2014-03-19 14:24:47 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:376874CE-BA12-4B2A-9A64-3F35F96FB9D4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7EB2A18A-0205-402D-B7BF-B8929228341B"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0071CFBB-57EB-4CCD-9932-E6D4379EE341"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:A7758925-D681-48DC-A2EB-CF8FCBD330C8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B02C332C-3C59-4BBA-B444-05ACCC3ACFED"/>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D35B4597-1344-48A3-9073-D141AD298E55">
    <ao:prefix>Patients with intermediate TPMT activity may be at increased risk of myelotoxicity if receiving conventional doses of azathioprine tablets. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-19 15:41:20 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>D35B4597-1344-48A3-9073-D141AD298E55</domeo:uuid>
    <ao:exact>Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine tablets.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D35B4597-1344-48A3-9073-D141AD298E55"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:072E3834-D19E-4AC9-9B6C-150D00630C47">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-19 16:34:59 -0400</pav:createdOn>
    <domeo:uuid>072E3834-D19E-4AC9-9B6C-150D00630C47</domeo:uuid>
    <ao:exact>PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:072E3834-D19E-4AC9-9B6C-150D00630C47"/>
    <ao:suffix> PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES UNLESS THE BENEFIT CLEARLY OUTWEIGHS THE RISK (SEE </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:85D32C89-4D16-45F0-ABBE-C44A2C8E2431">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9CB83DC6-BEAE-43DE-B4ED-8EC46D502DAF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:87FA6A3B-13A4-46BB-8108-F72177F44C54">
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F706BF25-87AE-4F15-B5E1-3089D8EABE98">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6AC9FCAF-FC9E-4667-8690-9CD344FF4E48">
    <ao:suffix>(Table 1).</ao:suffix>
    <ao:exact>The S-enantiomer of warfarin is mainly metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme. The variant alleles CYP2C9*2 and CYP2C9*3 result in decreased in vitro CYP2C9 enzymatic 7-hydroxylation of S-warfarin. The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9*2 and CYP2C9*3, respectively1. Patients with one or more of these variant CYP2C9 alleles have decreased S-warfarin clearance </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-20 19:57:58 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6AC9FCAF-FC9E-4667-8690-9CD344FF4E48"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>6AC9FCAF-FC9E-4667-8690-9CD344FF4E48</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D162ED96-AF00-4F63-8951-E46CE09C60F1">
    <ao:body rdf:resource="urn:linkedspls:uuid:50477C9C-C07C-4BF7-9255-E776B4E927D7"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E2F3A1BE-A0E3-424C-9092-15F166B370F7</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:3780F7CF-E5F2-40B4-8003-6D6860CF2526"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7F6A639F-125F-488A-B8C4-B4A1638FF139"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC95AE15-E92F-4EA8-AF21-263E73007B0B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:A550D1FF-C849-4071-8505-6521E13346EE"/>
    <pav:lastSavedOn>2014-03-20 20:25:07 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-20 20:06:32 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:38479107-6F0D-4BAB-B37C-E0DB18985DBB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B4C399AF-0017-42F0-803E-494E69F18558"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:464DE32B-0AC3-41E4-AF18-D97ACF984784">
    <ao:body rdf:resource="urn:linkedspls:uuid:8DA0EAB4-1460-4BAD-9318-332AEE052E6F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:8FCFBC4B-2D11-4A03-B03F-702FDEA66364"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:B050FCFA-B2E9-452D-B857-ACCEC8B748FC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:60BB6B78-9554-4AED-A8E0-25E6BA3CD14E"/>
    <pav:lineageUri>urn:domeoserver:annotation:53B8CFAC-34BA-42C3-93FD-7FF5FFF14B76</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:56FBC717-C251-4B51-876F-9D9C56BF108A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5CA6C5AE-7870-48BD-9F38-0DF2F4374D6D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D1EAF051-F5FD-472A-B36C-EFAA72D24733"/>
    <pav:createdOn>2014-03-20 22:46:11 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B5641ED3-B460-4677-9B48-65FA926C6CCA">
    <pav:createdOn>2014-03-20 20:34:07 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B5641ED3-B460-4677-9B48-65FA926C6CCA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>B5641ED3-B460-4677-9B48-65FA926C6CCA</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:prefix>The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. </ao:prefix>
    <ao:exact>The maintenance dose needed to achieve a target PT/INR is influenced by:\n●\n     Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\n●\n     Genetic factors (CYP2C9 and VKORC1 genotypes).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8581CC27-A637-44E6-AF81-0464010E2DD5">
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7468F4D5-D948-4433-9E13-7A82807364E2">
    <pav:createdOn>2014-03-20 21:18:14 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DAF496AA-6469-45CE-9F26-E5D4567B24A6"/>
    <pav:lineageUri>urn:domeoserver:annotation:A4D1D9E4-B0EC-4445-8036-E5CD18984CDA</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-20 22:01:22 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:F6233671-F202-4725-8382-9CACBFF9139E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B55BA90D-D154-4640-8258-0D3B09980F2A"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:5B3A7C05-9902-476C-85DF-1A73D7737071</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:096631E7-B679-44F0-BF4C-5C78641EDC47"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:24A4AB19-56D9-4F4E-BB6D-ADFC1BD34080"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B753CDD1-D145-4047-BFFA-9C8883FE3B21">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A63C8000-F228-4B4B-8E88-A4D9AB087B72">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:E4955692-2C70-4BC8-BF5F-ECB899015ED8"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-19 22:49:43 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:7777D4B3-D59B-4394-B038-3981A5A98A83</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:E784DB61-BA27-4B3F-9EE7-1D1B27899F12"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C60729CB-9B3A-4CB7-A3BE-139D9C75D74B"/>
    <pav:lastSavedOn>2014-03-19 22:53:11 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E8E570A-A44C-40C0-9C80-1CFEA54A881E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:D4DA286E-73B7-4DA4-8095-952301ABA032</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:936169F4-4F94-4CC9-AEAE-2EB3953990AB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:665A645B-6C92-4E27-AFF9-5F1B36B5E91C">
    <pav:lineageUri>urn:domeoserver:annotation:26CEFED7-15D8-4630-9FAB-8D89AC0D9228</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:C2C66B07-0775-4664-9FB4-AD89C89EFD17"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D85B4938-A869-4D0D-8B34-F6E21FA6F439"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0FED8C9E-A7A7-4BC8-8996-A86A1CC42A81"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1EAB2D72-EEBB-4792-AE12-53BB256D5230"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:41F02CF2-FB4F-4D83-8AB6-E4FE27855F37"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CCC5CEBF-4F5C-40BC-8432-C8616DEB89B8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:85D52AA7-FDC8-4655-9611-1744EA3D7D23"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1FB8172B-C5AB-4A3E-83B6-1B3D4A875C59"/>
    <pav:createdOn>2014-03-20 18:52:53 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7AA7955D-C25C-40D2-91DC-39F41614113F">
    <ao:exact>Patients with intermediate thiopurine S-methyl transferase (TPMT) activity may be at an increased risk of myelotoxicity if receiving conventional doses of azathioprine.</ao:exact>
    <ao:suffix> Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine. TPMT genotyping or phenotyping can help identify patients who are at an increased ri</ao:suffix>
    <domeo:uuid>7AA7955D-C25C-40D2-91DC-39F41614113F</domeo:uuid>
    <pav:createdOn>2014-03-19 15:46:19 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7AA7955D-C25C-40D2-91DC-39F41614113F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:prefix>Severe leukopenia, thrombocytopenia, anemias including macrocytic anemia, and/or pancytopenia may occur in patients being treated with azathioprine. Severe bone marrow suppression may also occur. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A0B17F68-66EC-4025-B8CA-ED6C651ECBDA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Approximately 8% of Caucasians lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are extensive metabolizers (EM)</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A0B17F68-66EC-4025-B8CA-ED6C651ECBDA"/>
    <domeo:uuid>A0B17F68-66EC-4025-B8CA-ED6C651ECBDA</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>. PMs have about an 80% increase in aripiprazole exposure and about a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to E</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-11 17:26:12 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3AC5D8A5-495B-4264-B7A9-2AFA05F2B52D">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:41C8DD7A-65D4-4F5D-AF9A-2FE4C02CA551">
    <ao:exact>TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS. TPMT genotyping or phenotyping can be used to identify patients with absent or reduced TPMT activity. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:41C8DD7A-65D4-4F5D-AF9A-2FE4C02CA551"/>
    <ao:suffix>Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity from azathioprine tablets if conventional doses are given. Physicians may consider alternative therapies for patients who have low or </ao:suffix>
    <domeo:uuid>41C8DD7A-65D4-4F5D-AF9A-2FE4C02CA551</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-19 16:06:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B5CBFCB-DB0C-4D0C-BD42-D00EA4781827">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:77702DAE-17B5-4010-957C-3EBC5127E1C3</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:964FB36C-BB63-4DA5-BD48-BBA2F92383FE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D0AFD7D1-C7EC-43E6-B600-C3B8DFF8BC0F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:BFDF6A90-E557-41DF-B69E-EA49B2525A61"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:6F6B2D02-8BBC-419F-9821-E6FBB9339357"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D5B5870B-85D9-41EA-A232-5BDF0EC5C8A3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3D4F4559-2283-409C-A0F9-08D0F189EBDA"/>
    <pav:lineageUri>urn:domeoserver:annotationset:13DDC676-F835-48F3-8F51-F14D640EC90D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:F676C298-0089-445D-A9F5-0C5FE5A96A09"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-04-14 14:29:30 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-04-14 14:28:57 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:25A24201-EB9D-487D-9890-2A94BFEBFDE2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D2FC18AA-9712-4180-8420-0DA19F207ECE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:22CD49DD-C11F-4F6D-BA7B-ED26605122FB">
    <ao:exact> The variant alleles CYP2C9*2 and CYP2C9*3 result in decreased in vitro CYP2C9 enzymatic 7-hydroxylation of S-warfarin. The frequencies of these alleles in Caucasians are approximately 11% and 7% for CYP2C9*2 and CYP2C9*3, respectively1.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>The S-enantiomer of warfarin is mainly metabolized to 7-hydroxywarfarin by CYP2C9, a polymorphic enzyme.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> Patients with one or more of these variant CYP2C9 alleles have decreased S-warfarin clearance</ao:suffix>
    <domeo:uuid>22CD49DD-C11F-4F6D-BA7B-ED26605122FB</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:22CD49DD-C11F-4F6D-BA7B-ED26605122FB"/>
    <pav:createdOn>2014-03-20 19:58:37 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8BBFDA4C-F86F-49C1-A0CA-1389579B4ABE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:095A6800-43FD-4F3C-82D4-3E4D7EBABB29">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-20 19:03:51 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:99A6ABE1-7C62-4DE1-B04E-6FDBBD34469B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1AB22EA0-5F80-4945-90BC-00B104FDF449"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:8AC8ED67-8297-48E9-A7A0-FDEB9D8F0D35"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:77BCF8BD-CBFA-4952-8CAD-0DF8A9BC2580"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:C636DDBA-45C2-45BB-99D4-0A818A94731E"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:C5168F97-3868-46CA-B8C8-E479D151B333</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:55369393-EE8A-44FA-AE5C-15E3C85D41EB"/>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:3FC9605F-B92B-4A1D-9BEB-A309956EA46F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:85D32C89-4D16-45F0-ABBE-C44A2C8E2431"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2D868D9C-FA37-4BD5-8B63-47087C1BDD22">
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D035860-EC07-4DDE-B01C-43C426004F86">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76009EAA-93A3-4E8E-AA36-AE8A78A5C92C">
    <pav:createdOn>2014-03-20 20:00:10 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:12AF3EC0-5149-462D-B594-7D4A5B58A3C0"/>
    <pav:lastSavedOn>2014-03-20 20:25:07 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:C399634B-DD99-4D60-B4CB-963EF1AC5ECD"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E2F3A1BE-A0E3-424C-9092-15F166B370F7</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:C29D2C65-749E-4E86-B844-84B4799E8AEA"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:04F17089-EB4F-448F-A658-F68748B6A0D4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:27562935-5D9B-4A37-9270-D938370A5A0F"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7E22EB94-909B-4255-A39B-77E8CB0A1617"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:26061102-D4B3-4910-AC2D-FA5290506799"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60873B48-9633-4268-AB9A-F0AFF0F3F1DA">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E355F710-73FD-453F-B1AA-BF17D98B29DF"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-04-14 13:58:11 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E3BF2EFB-927E-43FB-9F53-841BB201C8CB"/>
    <pav:lastSavedOn>2014-04-14 14:29:30 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:EDD525B8-1877-42B2-9255-44B871888B01"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D1777314-B777-4730-A945-CAA44C34C68D"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:CFBF78C8-CA07-4FEB-A6F7-6ACD860BF582"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F0CD9201-E82C-44F3-A548-518FCB0F8EF9"/>
    <pav:previousVersion>urn:domeoserver:annotationset:77702DAE-17B5-4010-957C-3EBC5127E1C3</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FBD7F4E6-824A-406D-87B2-EED87E7CB4E0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:15B985B9-8445-442E-818A-8FE35608146B"/>
    <pav:lineageUri>urn:domeoserver:annotationset:13DDC676-F835-48F3-8F51-F14D640EC90D</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3404B806-583F-43ED-AEB1-AC92F1892C39">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1FB8172B-C5AB-4A3E-83B6-1B3D4A875C59">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:exact>Respiratory depression and death have occurred in children who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 [CYP2D6] or high morphine concentrations).</ao:exact>
    <pav:createdOn>2014-03-20 18:52:53 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1FB8172B-C5AB-4A3E-83B6-1B3D4A875C59"/>
    <domeo:uuid>1FB8172B-C5AB-4A3E-83B6-1B3D4A875C59</domeo:uuid>
    <ao:suffix> Deaths have also occurred in nursing infants who were exposed to high levels of morphine in breast milk because their mothers were ultra-rapid metabolizers of codeine </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B2CCECE-9EC1-44D5-B80E-9A833BEEE5C3">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9488A015-DE92-4E36-85C8-27717D2B062C">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>HLA-B</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E212844-5E5B-409F-888E-6AC2FCEAE81D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:420D8184-0E6E-48E0-B8E2-1E4A7917EAB8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:exact>CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite. Clopidogrel active metabolite pharmacokinetics and antiplatelet effects, as measured by ex vivo platelet aggregation assays, differ according to CYP2C19 genotype. </ao:exact>
    <domeo:uuid>420D8184-0E6E-48E0-B8E2-1E4A7917EAB8</domeo:uuid>
    <ao:suffix>Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel’s active metabolite.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:420D8184-0E6E-48E0-B8E2-1E4A7917EAB8"/>
    <pav:createdOn>2014-03-20 22:36:49 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C39C1F18-36AB-468E-914F-356DB58806F4">
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:936169F4-4F94-4CC9-AEAE-2EB3953990AB">
    <domeo:uuid>936169F4-4F94-4CC9-AEAE-2EB3953990AB</domeo:uuid>
    <pav:createdOn>2014-03-19 22:49:43 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>Letrozole tablets are also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy </ao:suffix>
    <ao:exact>Letrozole tablets are indicated for first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:936169F4-4F94-4CC9-AEAE-2EB3953990AB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BC18F5F3-B5EF-41FF-BAC9-5377DC3319D5">
    <pav:lastSavedOn>2014-03-20 20:40:11 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0EF5824B-CA82-45E9-884B-B73638E3E247"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:A180150E-99C2-4938-B28B-33BC6B91E08A"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:BC8865C0-9E2F-4008-8E98-CFF867AC7FF5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:35E757C7-BFAD-42E7-B024-35B79808AF7B"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:30A60BD8-5A6F-4229-B800-4178C57A1D14"/>
    <pav:lineageUri>urn:domeoserver:annotation:EF9FA240-A41A-46CC-B594-1984EC1E3A4D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:2F7BDBAE-756A-482C-931B-156CF386F13B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D1F3C31-0D4C-4492-BF3E-1BE0D084C7B8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:23DA55C9-D21B-497B-BB23-1A122F42DB5E"/>
    <pav:createdOn>2014-03-20 20:29:52 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2AF41E6A-E572-484D-B95D-47FB86A5CDC1">
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E20AB0C9-9DE7-4111-BE3C-1EAE90E85BAC"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:83D62FE5-34B9-4708-9A61-72F48F88D12A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F0F59389-90C3-4613-B2D4-FDBCEA6672F4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:23163DD7-72F5-484C-81C4-CECD4AAADD6F</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-20 19:04:53 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:464AED20-F655-4945-AF18-7042C0EBABEC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7FD1DC92-DB35-47C7-8DB5-EB042CE34E34"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1F132845-D7D5-44BD-BC30-74AA604F9AFD"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E13235C1-A9F7-4F57-BDCF-72938209FBCA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:288E9102-375C-4335-8BF9-34A4E5332C92">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:126C8363-44D4-4E38-8AC6-7298DCFEE8AE">
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D1F3C31-0D4C-4492-BF3E-1BE0D084C7B8">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>VKORC1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D4E1BD6-AF96-45A2-BC62-F8E9F81097E2">
    <ao:body rdf:resource="urn:linkedspls:uuid:CAFFD0F8-4834-4696-9950-BBB6C6B5F0C2"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA17AD62-DB44-44A7-9BF5-12DF3076DD2A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:53DDCB7D-A534-4685-9A88-72F9D60B1D79"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:34710D04-23D6-4A7D-A3F3-D3F13D01D010"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:66E3A213-A8AB-4E72-92BE-AF051FE5B1BC</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:B5641ED3-B460-4677-9B48-65FA926C6CCA"/>
    <pav:lastSavedOn>2014-03-20 20:40:11 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-20 20:34:07 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FE9B0A31-7348-4F48-BFD0-4E8CE5A7E68C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E9C13579-71B7-4CE0-B4B3-004DD38AB73A">
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:150EFAD6-5D00-4EC5-BF9C-E28CA08A0508">
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:484978AE-117C-41D5-8B5A-15EF2EC9872E</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:13C42E00-3952-40FA-972E-82FEEB78F6B1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:17FD3FD1-104A-4750-B5D0-75B91610E2B0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:FCEFC622-B8CA-44D0-9E12-E9DFD3669AA4"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-03-19 16:03:15 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:A2898998-BCA5-4476-9A7A-BEFE82F41B44"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:78FCAD88-6AEB-423F-9B5D-DEA6A551B786"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:837B6602-715D-4F18-A3ED-28CE066A752A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EFC9F4DB-F33E-4B41-97FA-E68BACCDAAD1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4EE4429C-CE58-4EB7-B1F7-FD08C4CDCD73"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:912BEDA7-8AC3-4D55-9D03-03EFE94BCA65">
    <ao:prefix>Retrospective case-control studies have found that in patients of Chinese ancestry there is a strong association between the risk of developing SJS/TEN with carbamazepine treatment and the presence of an inherited variant of the HLA-B gene, HLA-B*1502. The occurrence of higher rates of these reactions in countries with higher frequencies of this allele suggests that the risk may be increased in allele-positive individuals of any ethnicity. </ao:prefix>
    <domeo:uuid>912BEDA7-8AC3-4D55-9D03-03EFE94BCA65</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:912BEDA7-8AC3-4D55-9D03-03EFE94BCA65"/>
    <pav:createdOn>2014-03-19 16:49:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Across Asian populations, notable variation exists in the prevalence of HLA-B*1502. Greater than 15% of the population is reported positive in Hong Kong, Thailand, Malaysia, and parts of the Philippines, compared to about 10% in Taiwan and 4% in North China. South Asians, including Indians, appear to have intermediate prevalence of HLA-B*1502, averaging 2 to 4%, but higher in some groups. HLA-B*1502 is present in &lt;1% of the population in Japan and Korea.\nHLA-B*1502 is largely absent in individuals not of Asian origin (e.g., Caucasians, African-Americans, Hispanics, and Native Americans).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4CD7D289-EEE7-4212-8B2E-8D6E467AEA31">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdfs:label>VKORC1</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6BB856A9-F8D3-4849-B8E6-4B89E8567BF7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>death, lactation</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:309F99D7-D68C-4BDF-BAF0-CBD35C2C992A">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:16E75B4D-108A-4272-8958-7E17188ED33A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4DE26374-B1A7-4E60-A7F0-2045ACABBB4F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:229EED02-11F2-4F51-AE34-1EE50968AC03"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:420D8184-0E6E-48E0-B8E2-1E4A7917EAB8"/>
    <pav:lineageUri>urn:domeoserver:annotation:20796417-5021-401C-A114-734BFB5826F5</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <pav:createdOn>2014-03-20 22:36:49 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:8F13F4CF-9694-4090-AAFE-A3962211B89E"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17FD3FD1-104A-4750-B5D0-75B91610E2B0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>ADVERSE REACTIONS (34084-4)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ADVERSE REACTIONS (34084-4)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8E4638B7-B16A-4D3A-99CA-0403DD062E24">
    <domeo:uuid>8E4638B7-B16A-4D3A-99CA-0403DD062E24</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>Genetic variants of other CYP450 enzymes may also affect the formation of clopidogrel’s active metabolite. </ao:prefix>
    <pav:createdOn>2014-03-20 22:42:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8E4638B7-B16A-4D3A-99CA-0403DD062E24"/>
    <ao:exact>The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional. CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A7A766EA-7BFD-4F32-B2B8-70CC2A57E721">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3C121592-72F2-4313-BD69-DE2FC5E96BE4">
    <ao:body rdf:resource="urn:linkedspls:uuid:9B40E5C5-3CFB-4714-A088-BF9949C167E9"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E2F3A1BE-A0E3-424C-9092-15F166B370F7</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:26E622D0-1E17-4FF4-9203-6A81E16AA7E1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F5CB30B-363A-4D08-96DA-E83CAC1EA2A7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-03-20 20:09:24 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:43C2902C-8868-45FA-ABB0-3A30A3DE954D"/>
    <pav:lastSavedOn>2014-03-20 20:25:07 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:584E2975-B2BA-492A-8D6E-0060FC808B81"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91BDADC2-23F0-4FE9-84A8-B81CF55B13A1">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E107DCD8-E29B-413A-8765-E807980746B3">
    <ao:body rdf:resource="urn:linkedspls:uuid:9356452C-B0C6-4623-92D2-84FAEB4BF736"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6A5168DB-1BDC-4A88-A8AB-15701D6A2026"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5010F461-BF1A-440D-84CC-7AAE239F97AE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D994E0B2-223A-465B-980E-73FF62AC8B7B"/>
    <pav:lineageUri>urn:domeoserver:annotation:0DF4F8D8-A5A1-4B07-A45A-862584C47D88</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-20 22:01:22 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdOn>2014-03-20 21:36:34 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:5B3A7C05-9902-476C-85DF-1A73D7737071</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:AAF90B4C-DC63-4760-8FC0-796F0F517E23"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37CA3A6B-B6D5-4421-8FBC-643139576CB9">
    <ao:suffix>. For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.</ao:suffix>
    <ao:exact> Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-04-14 14:24:04 -0400</pav:createdOn>
    <domeo:uuid>37CA3A6B-B6D5-4421-8FBC-643139576CB9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:37CA3A6B-B6D5-4421-8FBC-643139576CB9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D5F11F6B-7CAC-4FC3-811F-9D17899FDE76">
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6935F08E-8BBA-4930-85D2-B5D54EEA0D24"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:60888F43-22F9-49A5-975F-8BD8F7B386D2"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdOn>2014-03-20 22:41:37 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:7812985A-E5A0-489B-9C2E-15C12833BB75</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:4CB2B800-F0C5-424F-9EFF-EF45FAADCCF0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:99D6EA05-465E-467A-B6FD-26A96C37CA70"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2EBD924F-F4C6-4C96-B6F0-EF6EC2553B9C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:DA47A1ED-4A05-4A02-B376-308E15EAA84E"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:5BE813F9-5F5F-4492-9EDD-F0745867B9C5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:08ACA31F-17B2-4FEC-A7A0-B0F61243A2BE">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:857F4EFE-0FC2-4B64-9203-9763734FF417">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F47A9D67-55E8-47B7-890E-5A1E2162206C">
    <pav:lineageUri>urn:domeoserver:annotation:BEDADA7E-6DCA-4422-A961-D2885BE0DC77</pav:lineageUri>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7A526AF5-A26E-4663-B3C4-F248A63D9CFA"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:D0345A71-8F6C-4414-AA43-7B6F6C5DECCA"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:CFE9BDB9-329C-4806-8ECD-73344FAA71B6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:15DAD636-7458-40A9-B728-4F7F0DDC7C55"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4541C54B-FCC9-492E-9947-595488AC3029"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A81E4B42-7133-4D90-89EC-725EF963A8E9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-19 15:58:53 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B01F30E9-B810-44B0-89FE-485A1B0468A8">
    <ao:body rdf:resource="urn:linkedspls:uuid:F706BF25-87AE-4F15-B5E1-3089D8EABE98"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:86638828-3118-4DFB-8090-100B156FE8CF"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:BDC1906D-04B4-4201-993B-304905A5DB50"/>
    <pav:lineageUri>urn:domeoserver:annotation:577D51E7-FC12-4E3A-8B55-DAEDA226104D</pav:lineageUri>
    <pav:createdOn>2014-03-19 15:29:30 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:33DFCB1C-B95D-45BD-9781-477E4B5118A1"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:86660018-204F-46DD-8151-FDA019715902"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C5682862-173B-4C14-A67F-4A642EE35D23"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F9EEF8DB-BC07-4A2A-854A-C3944AF34AB7</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-19 15:31:31 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C54930A3-93C6-4ACE-B9E0-56DBE72CD1F6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:46231A2B-0712-4D96-B7E2-610C19A1CBB5">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:26E622D0-1E17-4FF4-9203-6A81E16AA7E1">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EFC93F78-DB18-4BB9-B9A7-9921E94DF61B">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2E87036C-1F2B-43FA-9AAC-9313A2C17B72">
    <ao:body rdf:resource="urn:linkedspls:uuid:56C8F2E9-AF26-4426-BB59-4CD390E7331B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9A685D2C-0B73-4C52-A00C-D056ADF96A0C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:13DDC676-F835-48F3-8F51-F14D640EC90D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:C122F3DA-A8F1-426B-B1BC-FBC714A553A5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:AC7F9D61-2FFD-4538-94F4-B586AB8C3E36"/>
    <pav:previousVersion>urn:domeoserver:annotationset:77702DAE-17B5-4010-957C-3EBC5127E1C3</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:5214C21A-B853-4722-BA59-29C024D30BC1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:73DCCFF2-F6C1-4008-8B91-3A58F4C755B9"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-04-14 14:29:30 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:2AE1EF63-AB7F-4B86-B3C8-78D8BB81869B"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdOn>2014-04-14 14:08:26 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:D7F23C76-17C4-4B0E-B8AA-4012643CC231"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:8581CC27-A637-44E6-AF81-0464010E2DD5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B8EA9953-FB04-4512-8E6B-27BDF9A1249E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9FC53C46-B34A-4B30-9420-DE11D722FE1C">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E1E53C32-75F9-4E3B-835F-235CB7A6316D">
    <ao:exact>Children with this genetic variation who were prescribed codeine after tonsillectomy and/or adenoidectomy for obstructive sleep apnea may be at greatest risk based on reports of several deaths in this population due to respiratory depression. Codeine is contraindicated in children who undergo tonsillectomy and/or adenoidectomy. Advise caregivers of children receiving codeine for other reasons to monitor for signs of respiratory depression.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E1E53C32-75F9-4E3B-835F-235CB7A6316D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-20 19:12:02 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>E1E53C32-75F9-4E3B-835F-235CB7A6316D</domeo:uuid>
    <ao:prefix> These higher-than-normal levels of morphine in the blood may lead to life-threatening or fatal respiratory depression or signs of overdose such as extreme sleepiness, confusion, or shallow breathing. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0">
    <ao:item rdf:resource="urn:domeoclient:uuid:41A245A9-4AD2-4C8C-B264-2E8CC092E666"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:150EFAD6-5D00-4EC5-BF9C-E28CA08A0508"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:58C404E3-EC75-4C0F-B9E8-658653FEA5A8"/>
    <pav:lineageUri>urn:domeoserver:annotationset:36AFBDB3-9C5D-4729-BBAE-345466A7D940</pav:lineageUri>
    <pav:createdOn>2014-03-19 15:37:30 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:423FC157-938C-41DB-A7E6-49D962EE43E3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0C663D1B-B0AB-4F60-A689-EE835C935346"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:79225B69-2795-4041-8C9A-C417EDC89C37"/>
    <permissions:permissions rdf:nodeID="N52117184b6254fc695c9c0fbe6e8c5e8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:411E83BB-2A2D-48B3-9CC1-26FC791C1671"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:52A59B8C-7964-4D04-A568-51DD8EAEE380"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:74A863F8-7B50-49CA-8318-E36E17B8C2AD"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:62549B39-78C4-40E5-B0CB-7213E18247E0"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:C17AE157-C30F-43EE-B1A5-AD7FF93A1D94"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F47A9D67-55E8-47B7-890E-5A1E2162206C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0E9B5FD6-EC91-4BC5-AF81-8AB55F862322"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896e94ef0008"/>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:4B104C62-0511-4DB8-93A3-E0A92490BE3E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E5DF412B-BA42-4111-9774-DFF523912D2B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6F87C146-25D6-4E61-B095-3CCD2F31965D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DB8B6E3D-6F2E-4D76-BA26-F521F389FF42"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:E128EDCB-5790-4905-9875-43ECE6F280A4"/>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:35309FCF-FCD0-4723-868F-BD8FEFF9D0B7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-04-14 14:04:20 -0400</pav:createdOn>
    <ao:exact>HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:35309FCF-FCD0-4723-868F-BD8FEFF9D0B7"/>
    <ao:prefix> </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>35309FCF-FCD0-4723-868F-BD8FEFF9D0B7</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3F78835B-41A0-475E-BA87-66E2DF3543B5">
    <pav:lineageUri>urn:domeoserver:annotation:8CBD9945-9C6A-4967-9CA2-00C98D1ED566</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:041E9114-BFF4-457E-A928-3273DE95930A"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-19 17:13:40 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:86185D7F-20A4-4606-AEA1-FE698024BBE1"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:21DD16EE-FA7C-4344-8260-A84AEB3E29CD</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:06E50AF2-762B-492C-9206-8A2F9517B7E1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3E60CFA3-8CF6-4E28-B0FE-CFD577274D72"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:CA0753D5-7FF1-475C-BBBD-AFB1463982F2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BCDA1F7F-6CEA-4FCF-ABF0-C2D16F3F4B91"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:74C31B89-4CE7-44DD-93F6-9133D4960032"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-03-19 17:12:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:29C001AD-36AB-40D7-9EB0-9665BBBA6974"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:04B8FB02-40E6-4372-9368-1BDAB97E3DDF">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5">
    <ao:item rdf:resource="urn:domeoclient:uuid:02015096-BC32-4D01-A1C4-0FABFA6BEA3D"/>
    <pav:createdOn>2014-03-20 18:45:44 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:2C51BD0E-D330-4A02-B381-E294154E7A95"/>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:BE32A3A7-7BE5-461D-B9F3-8C5B0826D572"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:23BCB91A-EF16-452F-A13D-DF92BF632DF1"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AF0A819E-CE05-4A94-AD95-1F9019D8E061"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F20362F8-6662-4FC3-939F-3ECF49746AE8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E39BF86B-CE64-46BC-A24B-114C31040DF6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:665A645B-6C92-4E27-AFF9-5F1B36B5E91C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:36FEF956-CB04-4A80-A0CB-BCE97758C351"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AD8C9612-7301-4579-89DE-2A247E83BB83"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4A6A83D6-CF48-4CD3-AB4F-306B555CAC20"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:456C97BA-AD85-4C4D-B482-F52F3568E94F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896e94ef0008"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3788A0F0-64AC-42E0-8B16-BEC05E7A37C9"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:annotatesResource>
    <pav:lineageUri>urn:domeoserver:annotationset:2F8F579E-7D81-405D-BE57-C22E3D048659</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:095A6800-43FD-4F3C-82D4-3E4D7EBABB29"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2AF41E6A-E572-484D-B95D-47FB86A5CDC1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FA8B7722-407C-4E13-B8AD-B23FDAB4C77F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F1EDE4F8-4A2C-4149-A8A2-B73AB772FB2E"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <permissions:permissions rdf:nodeID="N5398fbdd09474f40a089d7e75f172dfb"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:F6512FEE-BDC6-477E-9110-59CB3E6DA941"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9D3AA319-9C23-4A34-8153-490CB098742D">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:AA680961-423A-43CC-956A-05167805B7F3</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:FE9B0A31-7348-4F48-BFD0-4E8CE5A7E68C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:80B1A553-5D75-488A-9451-0DECDEE80FCC"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdOn>2014-03-11 17:26:12 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:2451CE8E-3677-432C-8358-4096FF88FBCC"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:A0B17F68-66EC-4025-B8CA-ED6C651ECBDA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D7789554-93DB-4789-BF51-0CE3DA15344D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0B5B52E0-9DAC-4CB4-B1C4-0F3EAFFB91E4"/>
    <pav:lineageUri>urn:domeoserver:annotation:ED697DEB-B301-4A76-B24A-EFEBE3F7262E</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-11 17:28:08 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2451CE8E-3677-432C-8358-4096FF88FBCC">
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6A31654-265C-488E-B64A-BEEF81375401">
    <ao:prefix> [see Clinical Pharmacology (12.5)].  </ao:prefix>
    <domeo:uuid>E6A31654-265C-488E-B64A-BEEF81375401</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> [see Dosage and Administration (2.3)].</ao:suffix>
    <pav:createdOn>2014-03-20 22:27:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:exact>Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E6A31654-265C-488E-B64A-BEEF81375401"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D14FC746-3F6A-4E55-9F96-4E22C6CABA23">
    <rdfs:label>HLA-B</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0">
    <ao:item rdf:resource="urn:domeoclient:uuid:2658F016-478C-4479-90F4-133D10DB8856"/>
    <permissions:permissions rdf:nodeID="N124e61b629904cc5ae3dab752a547bb4"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:3F848B10-8225-4608-8CB2-1C2EC8D42CC2"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:7F1DEDC8-E1B5-40F3-8C95-881913F63D28"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3D4E1BD6-AF96-45A2-BC62-F8E9F81097E2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2F95F308-3C1E-43D7-882A-244ED74B53D9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:76009EAA-93A3-4E8E-AA36-AE8A78A5C92C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:D9D7F622-E7CE-405D-8F1B-3D694C9F1350"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AD274EE0-898F-4F50-9BE4-692E87FB190A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:694DB8A0-BF33-40DC-9652-A8143C01A873"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D162ED96-AF00-4F63-8951-E46CE09C60F1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3C121592-72F2-4313-BD69-DE2FC5E96BE4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BAC5935C-9A78-4CFA-949D-FDA6F537CE63"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CBDCE031-C57C-4568-8C5F-36FAF0B3CA1D"/>
    <pav:lastSavedOn>2014-03-20 20:40:11 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:6C2D516D-CFFB-42E9-91F5-9F1900F93DEF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CDFFE457-BE14-4490-A7E4-63DC61D06178"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E2F3A1BE-A0E3-424C-9092-15F166B370F7</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:FA4DE3DB-4929-4D5B-A554-712E5364895F</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:BC18F5F3-B5EF-41FF-BAC9-5377DC3319D5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6337DC86-4ACC-49B2-8039-45920702A769"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896e94ef0008"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E7EFBC4B-D9D1-4473-91DB-7C0C8598F7C2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8E980092-8C70-4922-A9D1-6D9173A4D90C"/>
    <pav:createdOn>2014-03-20 19:52:17 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:78D88E4B-3BC5-4B64-986D-11331F289F14">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:91705977-64A5-48C1-92F9-A25510FF3AB2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52D9C9F2-D2C1-428A-93AD-1BEDDD4110E5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:13C42E00-3952-40FA-972E-82FEEB78F6B1">
    <rdfs:label>Recommend</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8AC8ED67-8297-48E9-A7A0-FDEB9D8F0D35">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8CDBF9B4-EDB3-42AF-B230-AB55E8DF4770">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-20 22:16:15 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:BC466093-874A-42F7-A3CE-241B6326737F</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:502618F5-0CE3-4C0C-AF6B-646B7731D238"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:96DEB430-2EA2-4E60-89AD-D232852FFEE5"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:43677430-F682-424F-904C-5302CB1987BC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:47FD3A82-57E6-4F64-8B93-B05E50339AFA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:90BF3029-9D80-4C7A-B47A-CFC7D3BE4878"/>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:F2314090-70D9-4C6F-A607-F132BEB66275"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:94E3545F-40DC-490F-A4F2-7788593E77D4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:718393AB-AE6E-4A8E-BB27-D5AFEEB92B89">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CDFFE457-BE14-4490-A7E4-63DC61D06178">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:33CED7AF-D333-4B88-8EE7-51A7C0450AB5"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:DD147F9C-BFFF-472E-A982-C4136D85B262"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DA44CF9D-652F-4CB3-BDE7-8160F714C759"/>
    <pav:lastSavedOn>2014-03-20 20:25:07 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-20 20:17:18 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:E2F3A1BE-A0E3-424C-9092-15F166B370F7</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:FCBB8AFB-3044-4010-96AE-0FE8F49B5685"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:16C8E827-DCF4-4847-9720-20A316160CAD"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DABCA597-D5CF-49A3-ADAE-B2FBAA9BAA2B">
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:853C9107-EDC0-4B10-8520-945B2E4CE113">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#increase-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to increase the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Increase from baseline</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D8A55E0C-91C8-48B0-BD33-2650DAA3AE53">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-03-20 21:24:58 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen citrate tablets are an alternative to oophorectomy or ovarian irradiation. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D8A55E0C-91C8-48B0-BD33-2650DAA3AE53"/>
    <ao:exact>Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablet therapy.</ao:exact>
    <domeo:uuid>D8A55E0C-91C8-48B0-BD33-2650DAA3AE53</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4EE4429C-CE58-4EB7-B1F7-FD08C4CDCD73">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:39F89B5F-9160-4437-BE6A-4025DA07E04C">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:80169097-6751-4C6C-911B-B7D60C8CC2AC"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:02E74D0E-3586-4121-BAAC-0DBD593E38D7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-19 15:09:38 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DBA5D636-95FA-4E98-99EC-6A8B826AC897"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:140278A4-AFD4-43AC-A3A0-071109D0C7DF"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:2D1E4C83-436F-425B-894F-D74698251674"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:18E46735-0029-413E-9BB6-763A55537CE4"/>
    <pav:lineageUri>urn:domeoserver:annotation:4985140C-169A-4E51-A4D5-A84D85FDD4E8</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:6DA0D70B-05AD-4868-82B5-0A76998EA516"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF1B43FA-C434-4873-99EC-E33EF6CCC7C3"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-03-19 15:01:34 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:471A7EED-7EB6-4664-99C2-ECC7326C6BA7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>Benefit is less clear for wome</ao:suffix>
    <domeo:uuid>471A7EED-7EB6-4664-99C2-ECC7326C6BA7</domeo:uuid>
    <pav:createdOn>2014-03-20 21:18:46 -0400</pav:createdOn>
    <ao:exact>The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) conducted worldwide overviews of systemic adjuvant therapy for early breast cancer in 1985, 1990, and again in 1995. In 1998, 10 year outcome data were reported for 36,689 women in 55 randomized trials of adjuvant tamoxifen using doses of 20 to 40 mg/day for 1 to 5+ years. Twenty-five percent of patients received one year or less of trial treatment, 52% received 2 years, and 23% received about 5 years. Forty-eight percent of tumors were estrogen receptor (ER) positive (&gt; 10 fmol/mg), 21% were ER poor (&lt; 10 fmol/l), and 31% were ER unknown. Among 29,441 patients with ER positive or unknown breast cancer, 58% were entered into trials comparing tamoxifen to no adjuvant therapy and 42% were entered into trials comparing tamoxifen in combination with chemotherapy vs. the same chemotherapy alone. Among these patients, 54% had node-positive disease and 46% had node-negative disease.\nAmong women with ER positive or unknown breast cancer and positive nodes who received about 5 years of treatment, overall survival at 10 years was 61.4% for tamoxifen vs. 50.5% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 59.7% for tamoxifen vs. 44.5% for control (logrank 2p &lt; 0.00001). Among women with ER positive or unknown breast cancer and negative nodes who received about 5 years of treatment, overall survival at 10 years was 78.9% for tamoxifen vs. 73.3% for control (logrank 2p &lt; 0.00001). The recurrence-free rate at 10 years was 79.2% for tamoxifen vs. 64.3% for control (logrank 2p &lt; 0.00001).\nThe effect of the scheduled duration of tamoxifen may be described as follows. In women with ER positive or unknown breast cancer receiving 1 year or less, 2 years or about 5 years of tamoxifen, the proportional reductions in mortality were 12%, 17% and 26%, respectively (trend significant at 2p &lt; 0.003). The corresponding reductions in breast cancer recurrence were 21%, 29% and 47% (trend significant at 2p &lt; 0.00001).</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:471A7EED-7EB6-4664-99C2-ECC7326C6BA7"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37B35D47-83BF-45C0-9194-419BB92327E7">
    <ao:body rdf:resource="urn:linkedspls:uuid:1BC80E01-8BD0-40A4-AEF3-A77C9162ED89"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:EA45E928-A8B1-42CE-A40C-5C1A3F7D3EB0"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:F197EC05-91FE-492C-8A76-D9C6E191B8E8</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:B1FFD629-C717-4C46-B744-8540409605AB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9F4CC90D-622C-4CAE-BF61-3570274C4C71"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CD38F700-9A3D-43BC-ADBC-B0DF3A711ECC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D3B563A4-755C-4E86-AFDE-4D4F02369381"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B6C4505F-63A6-4A28-9A8A-5234445CDF87"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-03-19 16:33:55 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-19 17:13:40 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:21DD16EE-FA7C-4344-8260-A84AEB3E29CD</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:1A7567C7-44CC-4C05-BBDF-31CF039E50AE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:35E757C7-BFAD-42E7-B024-35B79808AF7B">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:172BC00D-8382-4639-9CE8-3E3C0E0C3F09">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:79225B69-2795-4041-8C9A-C417EDC89C37">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:B160A445-5A76-4F0C-9088-8398F49765EF</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:C8A6B20C-1596-4A8E-8FB2-97FEB7159D88"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:88A10D43-5AEF-49A4-8D15-491A2F78D4EB"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:091D0AF1-54D0-439E-8F7E-F03DEEBD1C89"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:225D0593-0F65-4C63-95B6-E46596A47E7E"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:55125755-6679-4972-8FDF-7DB40547D0FA"/>
    <pav:createdOn>2014-03-19 15:42:39 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:2A5B7268-7A7A-4FD9-B5A5-81F7999F51A5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D57D0BEE-F8FD-481D-A147-06C62753C684">
    <pav:createdOn>2014-03-19 15:52:27 -0400</pav:createdOn>
    <ao:prefix>It is recommended that consideration be given to either genotype or phenotype patients for TPMT. Phenotyping and genotyping methods are commercially available. </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D57D0BEE-F8FD-481D-A147-06C62753C684"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D57D0BEE-F8FD-481D-A147-06C62753C684</domeo:uuid>
    <ao:exact>The most common non-functional alleles associated with reduced levels of TPMT activity are TPMT*2, TPMT*3A and TPMT*3C. Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D7F23C76-17C4-4B0E-B8AA-4012643CC231">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D7F23C76-17C4-4B0E-B8AA-4012643CC231"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>D7F23C76-17C4-4B0E-B8AA-4012643CC231</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <pav:createdOn>2014-04-14 14:08:26 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:prefix>HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CE140622-34AD-4483-8319-3C90AB9E161E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>intermediate-activity</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AE29FADF-5969-4BB7-B98E-DF8FBE87A54B">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:997340C9-004B-4BA9-8E41-DCCC93877594"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:83C90105-5813-4D15-85BB-4732B9C7B3DC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:936DA545-AB12-4AE4-855C-9382992D7967"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5A18A56F-E016-44DA-8AD6-FA3E2DD90422"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6B5EE4B6-5414-471F-AF7F-2E31AA0BF02E"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:D0993E5E-D9C1-4F6B-A459-7D75E85C5CF7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:21BF8638-7FCA-4267-A195-B96685142B06"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-20 22:48:21 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:290C3A08-E459-4387-A0BE-1757CE4962DF</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:16912952-C01C-46AA-BAFA-1BA75EA86EAA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:63B2C21B-611C-40CD-8C4D-2F089E0D457B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:63B2C21B-611C-40CD-8C4D-2F089E0D457B"/>
    <pav:createdOn>2014-03-19 17:11:07 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>63B2C21B-611C-40CD-8C4D-2F089E0D457B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>For genetically at-risk patients [See WARNINGS], high-resolution 'HLA-B*1502 typing' is recommended. The test is positive if either one or two HLA-B*1502 alleles are detected and negative if no HLA-B*1502 alleles are detected.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:suffix> Complete pretreatment blood c</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B84B8305-B20A-4B3F-9282-8E038F655EE6">
    <pav:lastSavedOn>2014-03-19 17:13:40 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:21DD16EE-FA7C-4344-8260-A84AEB3E29CD</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:9C0BC915-82A5-4369-B176-F4722F09AE0C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:80703674-6299-4823-BA1B-C4DB0986A1F5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:DC92B793-6170-4FBB-A444-41CAFB7DFF4D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:D82616FF-F1E3-4588-B77D-A0700BBCF108"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA7509B9-BE8D-41BC-BD05-A33DD7051A6C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:63122E82-2B89-4A5C-A089-2430DC780844"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ABE2012B-44F0-45AF-9056-37E53CE301A4"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-03-19 16:52:23 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A06D588B-932F-4A73-A67A-20DD78A56D96">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-19 14:45:36 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:D17DEB87-4BEF-4CF3-A8DB-A059D9E41A81"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A65064F-9472-420E-AF20-016F63E68883"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:2B9C984E-CEDF-4811-80A1-F75F94A333FA"/>
    <pav:lastSavedOn>2014-03-19 15:09:38 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E5082080-9E96-4A7D-B916-6253B001E40A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:61E1822F-ACC7-4361-AF07-FFB1FB4522E1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF29538B-2B45-4554-B2BA-23EB29D76597"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:31CE42A3-047E-4B44-ABDF-CB0A8D32275F</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DF75D1C2-568E-434C-BCC0-87919E941465">
    <ao:body rdf:resource="urn:linkedspls:uuid:C7B7A1F5-2837-4503-B82F-E26857CD2B90"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F3EBB707-A58D-47BE-BA15-8E869B3C1408"/>
    <pav:lineageUri>urn:domeoserver:annotation:D9DF3CE0-6A7D-4611-BEA7-CD6D4BD85E4C</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:8FEB9CC5-B9C9-440B-9DF4-33282FA9CEBC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BDC2DC01-4301-40A7-8086-E7F3C5210DF7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-03-19 16:34:59 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:072E3834-D19E-4AC9-9B6C-150D00630C47"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-19 17:13:40 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:86F97ED0-2C1A-46D0-ADB8-AFB0FD398137"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:21DD16EE-FA7C-4344-8260-A84AEB3E29CD</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:07397697-2E09-4D7D-9C80-18B8547A20E7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:738089B1-21DC-46E1-9B72-69F59723CC92">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>myelotoxicity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4125A44-1047-411C-BCBB-96E8BFAD8D73">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:C4F6317C-F28C-415A-9908-9B252949CEF9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A3DABBC2-F048-4AAF-9572-E463E73EFDF2"/>
    <pav:lineageUri>urn:domeoserver:annotation:727796F6-680F-4AD3-8553-F227FDAA9846</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:F9EEF8DB-BC07-4A2A-854A-C3944AF34AB7</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:4EDC9DEF-73AC-4123-8526-7D4132AF8B8D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-19 15:31:31 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:8FA66EE0-DBF1-41BF-B87F-0A660C89020A"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:23A1ABEE-A833-45F0-A6AC-00D3AF79ADE4"/>
    <pav:createdOn>2014-03-19 15:31:28 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:386D05E2-9CFF-469B-B0FB-AABF67E3F139"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E71FE8C7-6F4E-4994-89E6-4CD04DCB3739">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:25CA2E7B-8CB5-4571-B190-2CECDE4A49D9</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:9389F7F5-892D-4B03-95B8-4480A7685CC3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9C3ED506-C942-4716-BB2D-BA9AD96C12AB"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:16C1652F-220E-4CC4-AC5C-5924F77FC89A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A1314343-110C-47F5-A059-25796F7F6822"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:1F088F02-171F-42E6-8931-69F5EC5DF809"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5A087626-5413-403C-A734-C03C00484FD6"/>
    <pav:createdOn>2014-03-20 22:44:21 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5217D8E8-8873-4079-9259-5A816D82124A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D2953B7-3453-41E8-A669-77E054F7AD5C">
    <ao:body rdf:resource="urn:linkedspls:uuid:25247B65-25B8-4263-9212-BB85B73D1C58"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C4D96DE4-EE69-485B-AC45-9A04E3FC7B40"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FAFDE9FE-DF29-4F7A-93AE-8511529B033F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F06F1104-C4A2-49B6-A9CA-457753888C50"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:799F2E16-9794-48F5-A646-B0ACD8D76E8D</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:49190F98-EB06-4A32-9340-5356EE1B85B9</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:790B16C1-64F0-4219-B594-344C794C3A69"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A4ED175-6888-4AE9-9908-DE1F0A533EB7"/>
    <pav:lastSavedOn>2014-03-19 17:45:50 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-19 17:19:29 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D92B3265-2BD2-4471-B165-9C0BFAC0471A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-20 21:18:56 -0400</pav:createdOn>
    <domeo:uuid>D92B3265-2BD2-4471-B165-9C0BFAC0471A</domeo:uuid>
    <ao:exact>In the Hubay study, patients with a positive (more than 3 fmol) estrogen receptor were more likely to benefit.</ao:exact>
    <ao:suffix> In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estr</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D92B3265-2BD2-4471-B165-9C0BFAC0471A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3561EC2B-135E-43D7-A0DB-4708CD4113A0">
    <ao:suffix>Codeine is contraindicated in children who undergo tonsillectomy and/or adenoidectomy. Advise caregivers of children receiving codeine for other reasons to monitor for signs of respiratory depression</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3561EC2B-135E-43D7-A0DB-4708CD4113A0"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <domeo:uuid>3561EC2B-135E-43D7-A0DB-4708CD4113A0</domeo:uuid>
    <ao:exact>Advise patients that some people have a genetic variation that results in codeine changing into morphine more rapidly and completely than other people. Most people are unaware of whether they are an ultra-rapid codeine metabolizer or not. These higher-than-normal levels of morphine in the blood may lead to life-threatening or fatal respiratory depression or signs of overdose such as extreme sleepiness, confusion, or shallow breathing. Children with this genetic variation who were prescribed codeine after tonsillectomy and/or adenoidectomy for obstructive sleep apnea may be at greatest risk based on reports of several deaths in this population due to respiratory depression. </ao:exact>
    <pav:createdOn>2014-03-20 19:11:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1A7567C7-44CC-4C05-BBDF-31CF039E50AE">
    <rdfs:label>Carbamazepine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF8BAE66-1A7E-496F-83AD-CED870C08374">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8C4879CD-D381-439A-9611-B0B648A2A9C0">
    <pav:lineageUri>urn:domeoserver:annotation:07C9091C-0045-454A-A910-B8C79FF49CC8</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:EFE999A9-D0B3-463F-B964-665F55247B66"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2769A95A-FAE1-4921-9631-2E94C9BF581D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:83B886FC-2F6C-447E-B922-9E1004D2BEFD"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lastSavedOn>2014-03-19 15:09:38 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-19 14:46:46 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C0B1EF2F-B9D3-4FCB-BED1-ACD2887E8C2D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8FF0BA45-8601-4BA3-93DE-624CDEB7252D"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:6E8C3116-4C83-460F-B4A9-FDC40A4495C9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EB382F6A-3E55-4140-81FD-529415503DD2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:484121CB-C92D-490C-A450-25D30BC26DA9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:270ED847-DC14-417F-84EA-100C7ABD4F78">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3A800ED5-E7D2-4218-86D9-A0B72F60A5D9">
    <ao:context rdf:resource="urn:domeoclient:uuid:F654E302-4271-4ED9-B9AC-E44B926B80F6"/>
    <pav:lineageUri>urn:domeoserver:annotation:BE25AF2C-31A8-4C96-A98C-AC01C7179EEA</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:48DAFCD9-7E3A-4349-8AED-177E2B11DE9F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AFF6CA95-CE75-4F8F-B143-753BF6CD8B43"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:5AB30AFB-FAB4-4851-A252-6DC5B019BF5C"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:2C0DEEB7-91B1-41E9-80BE-BA8171BD1AA7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8C6A85F6-9525-446B-8CD3-3E0A9FE880F1"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-03-19 14:48:21 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-19 15:09:38 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:2FC2D65B-C101-4C01-9723-FE0D2DD18E01"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:65DC62F2-954D-42E0-9CEE-DFF0AC96DA2A">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34E8E3AD-68FE-4EE5-96EA-4C3965E2F421">
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52A59B8C-7964-4D04-A568-51DD8EAEE380">
    <ao:context rdf:resource="urn:domeoclient:uuid:7B1C0FB9-E3F3-4EBA-ACAA-939C4A2F15D5"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:946FE3A8-81C0-4961-AF40-EAF6F7268D4E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:820B501F-7AC9-4307-8366-DBB27F816F99"/>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:731D209C-5EFA-43B8-A1DB-088AD320A254"/>
    <pav:lineageUri>urn:domeoserver:annotation:BB5E12F8-1AD1-4B22-8CAA-1B068687A5E3</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:B06937D6-3BA3-4694-8368-7BCAF8FD2788"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DC17624C-3F5B-452A-92F0-8FECF2C76223"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-19 15:47:29 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E22EB94-909B-4255-A39B-77E8CB0A1617">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-20 20:04:59 -0400</pav:createdOn>
    <ao:prefix>Patients with one or more of these variant CYP2C9 alleles have decreased S-warfarin clearance (Table 1).2 </ao:prefix>
    <domeo:uuid>7E22EB94-909B-4255-A39B-77E8CB0A1617</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Table 1 Relationship between S-Warfarin Clearance and CYP2C9 Genotype in Caucasian Patients\nCYP2C9 GenotypeNS-Warfarin Clearance/Lean Body Weight(mL/min/kg)Mean (SD)**SD=standard deviation.p&lt;0.001. Pairwise comparisons indicated significant differences among all 3 genotypes.*1/*11180.065 (0.025)*1/*2 or*1/*3590.041 (0.021)*2/*2, *2/*3or *3/*3110.020 (0.011)Total188Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9 and *11 alleles in Caucasians.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7E22EB94-909B-4255-A39B-77E8CB0A1617"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B300FDFE-4BB0-4631-BE80-9623FABA6B14">
    <ao:body rdf:resource="urn:linkedspls:uuid:0DE0AC90-9691-47BD-A883-1AC4F8A597A3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:AA680961-423A-43CC-956A-05167805B7F3</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7CB63A09-E30C-4A2B-B101-6AC7950DBA21"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:444A5707-FFEE-4D8C-BC63-4289C317B0C5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2D5D0C6C-A326-4837-9705-A127A053E74C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2D300706-432D-4D5C-9785-589A22B4DDD8"/>
    <pav:createdOn>2014-03-11 17:27:12 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-11 17:28:08 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:AF9C975F-23C8-4427-9F07-3DE0F92A0721</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B6C4505F-63A6-4A28-9A8A-5234445CDF87">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>toxic epidermal necrolysis, stevens-johnson syndrome</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3F3B45B-4233-41B6-A7DC-CFC7D893E5C7">
    <ao:exact>CYP2C19 poor metabolizer status is associated with diminished antiplatelet response to clopidogrel.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-20 22:27:52 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A3F3B45B-4233-41B6-A7DC-CFC7D893E5C7"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Although a higher dose regimen in poor metabolizers increases antiplatelet response </ao:suffix>
    <domeo:uuid>A3F3B45B-4233-41B6-A7DC-CFC7D893E5C7</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2CE2C5DF-B221-4257-9366-793880469BB9">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:958DF405-A04D-405E-B141-E70F9657C2E0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Carbamazepine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4E6299BE-003A-4F7F-8242-78481F6A96D6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>*2, *3</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4DA286E-73B7-4DA4-8095-952301ABA032">
    <ao:item rdf:resource="urn:domeoclient:uuid:A63C8000-F228-4B4B-8E88-A4D9AB087B72"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:CFF5279B-388D-4904-ACEE-C3E520119D73</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896e94ef0008"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdOn>2014-03-19 22:30:52 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6616F81E-9E32-4964-B665-1159F90D3792"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-19 22:53:11 -0400</pav:lastSavedOn>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <permissions:permissions rdf:nodeID="N6ba7a2fbccac4f2e8040838077d708fc"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:723FE4B0-6EE0-41F8-8690-750CFF2EE285"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FAE060A9-40D1-4C40-886F-AA0F44F8F279"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:121CECC9-16C6-44C0-B062-D491DABD7F22">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B607061-A310-4096-926A-8CD6D3A23B41">
    <ao:exact>Codeine is secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine’s active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. </ao:exact>
    <pav:createdOn>2014-03-20 19:02:36 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9B607061-A310-4096-926A-8CD6D3A23B41"/>
    <domeo:uuid>9B607061-A310-4096-926A-8CD6D3A23B41</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants. </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4D96DE4-EE69-485B-AC45-9A04E3FC7B40">
    <ao:exact>In CYP2C19 poor metabolizers, citalopram steady state Cmax and AUC was increased by 68% and 107%, respectively.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C4D96DE4-EE69-485B-AC45-9A04E3FC7B40"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> Citalopram 20 mg/day is the maximum recommended dose in CYP2C19 poor metabolizers due to the risk of QT prolongation (see</ao:suffix>
    <pav:createdOn>2014-03-19 17:19:29 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>C4D96DE4-EE69-485B-AC45-9A04E3FC7B40</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8A656D94-29CF-4067-B1C7-E0B5241CA8CB">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:96393F2F-EC36-4589-94C4-DC6DFCB2312B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:2038B1B9-B6D0-425B-A700-00834013A177"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:96900B00-F7D0-4B92-9193-B2375101EAF1"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5A290E25-535E-4590-B03B-639616244934"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:52B9C004-5A1A-4BB2-A551-C9850DD315EB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8E5026D0-9091-4B42-84F7-174D096A299F"/>
    <pav:lineageUri>urn:domeoserver:annotation:DE1C8D35-720E-449F-9900-271FADF8A4DC</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:8E364A00-9E36-406E-8B4A-C359FA92A5DC"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:CF070D3B-45DC-41F6-9FE6-8F8A14B5CCE6"/>
    <pav:createdOn>2014-03-20 22:40:18 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C16B7C24-8DD5-45BE-8CC6-CE2B04315F70">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:38E9AC24-472D-4E6F-BD3A-301209D96170"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:1CEF1F00-4F1E-490B-AC5B-C38E38AC7C1B</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB3E419E-69E3-47C5-A04D-6193B228402D"/>
    <pav:createdOn>2014-04-14 14:30:40 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-04-14 14:31:20 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:AF618930-45D6-49B6-9888-1F2A03961467"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F2E1EF2A-6933-46FD-8E56-3CD264CFFF03"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:1ADB949E-07A2-48D9-8316-7C7B105A8F0E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:51840A8F-E4BA-4DCE-89DE-6B9833FE7C19"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:54E68980-2A91-4156-9812-000324FF6AA6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8300C6E1-442F-43F3-9412-59C34B272DE8"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:C033DD05-A979-476F-B099-5B46FED13115"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C8492505-5E55-4CB7-B5B0-C5FDB227BADF">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BFDF6A90-E557-41DF-B69E-EA49B2525A61">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:43677430-F682-424F-904C-5302CB1987BC">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F6A639F-125F-488A-B8C4-B4A1638FF139">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7F6A639F-125F-488A-B8C4-B4A1638FF139"/>
    <domeo:uuid>7F6A639F-125F-488A-B8C4-B4A1638FF139</domeo:uuid>
    <ao:exact>In an observational study, the risk of achieving INR &gt;3 during the first 3 weeks of warfarin therapy was determined in 219 Swedish patients retrospectively grouped by CYP2C9 genotype. The relative risk of over anticoagulation as measured by INR &gt;3 during the first 2 weeks of therapy was approximately doubled for those patients classified as *2 or *3 compared to patients who were homozygous for the *1 allele.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <pav:createdOn>2014-03-20 20:06:32 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix>4</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E2DEA87-B14E-4146-B5A4-2ACDCAB5D4CB">
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A0D58291-9E95-4BB2-A875-80E619169B9E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-19 16:16:46 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A0D58291-9E95-4BB2-A875-80E619169B9E"/>
    <domeo:uuid>A0D58291-9E95-4BB2-A875-80E619169B9E</domeo:uuid>
    <ao:suffix>. Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:exact>Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for non-functional alleles)</ao:exact>
    <ao:prefix> </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FCBB8AFB-3044-4010-96AE-0FE8F49B5685">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0E41FCF8-03E0-4664-BC89-9E2E8DEFC26E">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:068A961C-4C85-4256-B4EF-CE547C6F4679">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A290E25-535E-4590-B03B-639616244934">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-20 22:40:18 -0400</pav:createdOn>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <domeo:uuid>5A290E25-535E-4590-B03B-639616244934</domeo:uuid>
    <ao:suffix>A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. Published frequencies for poor CYP2C19 metabolizer genotypes are approximately 2% for whites, 4% for blacks and 14% for Chinese. Tests are available to det</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5A290E25-535E-4590-B03B-639616244934"/>
    <ao:exact>Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:847E5DB7-F232-483C-9589-B27ADD46F1C3">
    <ao:body rdf:resource="urn:linkedspls:uuid:7F31E097-6939-4259-909F-89C84FD7447C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3D152E4D-029F-4E54-BBF7-ACD9D674C2F0"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:912BEDA7-8AC3-4D55-9D03-03EFE94BCA65"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-19 17:13:40 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:21DD16EE-FA7C-4344-8260-A84AEB3E29CD</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:958DF405-A04D-405E-B141-E70F9657C2E0"/>
    <pav:lineageUri>urn:domeoserver:annotation:8E9C5004-DB87-46C7-9DCA-A33D4D84A4D3</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-03-19 16:49:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4916A699-FFEE-4E5E-92CB-43C4B79DBD60"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:08CC424F-2134-4DDC-A8C4-A5FE3DDAD858"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E2779FF-0284-4754-9414-2DB12979F639">
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E001988C-65C5-466E-8290-5CD2EA3F6252">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:63A02BF2-6DC0-4921-BA28-6D22A5924699"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-03-20 22:22:11 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:07018B80-896F-4037-97BD-E62570D90896"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0C1A9B4F-DEC2-448A-8FA5-882ED83EAFC2"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:A6320B59-FC42-4B7B-9D50-844645FF936E</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:A0ED0120-25AD-40A5-B337-7AEB1CE08F04"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9CB83DC6-BEAE-43DE-B4ED-8EC46D502DAF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:15B985B9-8445-442E-818A-8FE35608146B">
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:37C0B650-B957-4703-8BA7-E837AB41C9EB">
    <rdfs:label>Recommended</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7EB2A18A-0205-402D-B7BF-B8929228341B">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:085ECEB2-432F-4BCD-9F0B-828C2694033E"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:15882D27-AE28-45D5-84BB-5E4CCF5671D2</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:839A281F-6660-4350-9005-224DB3EB58C1"/>
    <pav:lineageUri>urn:domeoserver:annotationset:13DDC676-F835-48F3-8F51-F14D640EC90D</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:241A40BB-DB23-4291-B6C0-21AC0A7FFB5B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0E41FCF8-03E0-4664-BC89-9E2E8DEFC26E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2785A080-7F3F-4620-A188-EFD008FF16ED"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D055AE88-C376-4C64-BF03-58DA3D8C4A16"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E920DEBC-AA60-423C-B3BF-D7C127930FCD"/>
    <pav:createdOn>2014-03-19 14:32:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3B983561-19E5-459C-847C-1CF1D4B9CED4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:87650245-E4B7-4482-A532-2162F9407D34"/>
    <pav:lastSavedOn>2014-04-14 13:44:59 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:267922F0-150C-4837-AD72-3B878579D8CE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:exact>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir. </ao:exact>
    <pav:createdOn>2014-04-14 13:50:34 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:267922F0-150C-4837-AD72-3B878579D8CE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>267922F0-150C-4837-AD72-3B878579D8CE</domeo:uuid>
    <ao:suffix> Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2EFE435-FABA-49D7-A275-E413E595C352">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <domeo:uuid>B2EFE435-FABA-49D7-A275-E413E595C352</domeo:uuid>
    <ao:prefix>(maculopapular eruption [MPE]). </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B2EFE435-FABA-49D7-A275-E413E595C352"/>
    <pav:createdOn>2014-03-19 17:03:35 -0400</pav:createdOn>
    <ao:exact>Limited evidence suggests that HLA-B*1502 may be a risk factor for the development of SJS/TEN in patients of Chinese ancestry taking other anti-epileptic drugs associated with SJS/TEN. Consideration should be given to avoiding use of other drugs associated with SJS/TEN in HLA-B* 1502 positive patients, when alternative therapies are otherwise equally acceptable.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B3A7C05-9902-476C-85DF-1A73D7737071">
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896e94ef0008"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8A7E5813-7417-4AE0-B84A-C3EFC7D8DD8B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:344D4D68-4BAF-49E2-8BD2-AC75E874A331"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C528AA21-62CA-4475-99E4-8C90C95AF8E8</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-03-20 21:06:37 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:E107DCD8-E29B-413A-8765-E807980746B3"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:EDDC8D7C-06F1-4AB4-82D8-BB6BF3AC682A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7468F4D5-D948-4433-9E13-7A82807364E2"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:D0D03BCE-8134-411C-A0D0-875CB9EEF2FD"/>
    <permissions:permissions rdf:nodeID="Nc072075ff6044f6cb889d228c6442b8c"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E1E902EF-9315-4204-BEE2-7DEB1FEEC648"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:6982E4BC-F901-498C-847B-315128ECB57A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7BE97BD6-BC19-4947-8AB3-022240F6D937"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:30BA851A-23EE-432B-84BA-979A616ADC7D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-20 22:01:22 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1FFC62E9-8D4F-4064-8277-51C4CAEE435C"/>
    <rdfs:label>Default Set</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3BD796FE-2AFC-4D99-826F-91329C46BFD8">
    <domeo:uuid>3BD796FE-2AFC-4D99-826F-91329C46BFD8</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3BD796FE-2AFC-4D99-826F-91329C46BFD8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-20 18:48:34 -0400</pav:createdOn>
    <ao:suffix> (5.1)</ao:suffix>
    <ao:exact>Risk of death in ultra-rapid metabolizers: Conversion of codeine into its active metabolite, morphine, may occur more rapidly and completely resulting in higher than expected morphine levels and respiratory depression or death.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E5DF412B-BA42-4111-9774-DFF523912D2B">
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:4BC940B0-14FC-410D-B129-38FB2DD22422"/>
    <pav:createdOn>2014-03-19 15:40:37 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9C93C849-2DE0-4CBE-9D2E-DA2AB0530965"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:764C0ACF-BCB4-41BD-84E4-FB5CFB4BF8A0"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6DDAC665-7DFB-4C64-B420-F830A1422FBC"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:CE140622-34AD-4483-8319-3C90AB9E161E"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:694CA4DF-FB37-4ED1-978B-D265DBD7A3D7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:7EFB9D14-8636-4D3E-996B-2F7AAE64CBD9"/>
    <pav:lineageUri>urn:domeoserver:annotation:66C8E72C-B50E-46C7-82CC-2ED07728B5FD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E084DC2B-773F-4E31-A007-983AEDA3D8B4">
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6DA0D70B-05AD-4868-82B5-0A76998EA516">
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D1ADDFFF-3DB7-43B3-9E80-A13335BEBAC8">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#excretion-increase</poc:PharmacokineticImpact>
    <rdfs:label>Excretion Increase</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a increase in excretion of the drug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0886EC50-FACB-487C-AF46-0B8888567E2E">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DRUG INTERACTIONS (34073-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>DRUG INTERACTIONS (34073-7)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8FA66EE0-DBF1-41BF-B87F-0A660C89020A">
    <rdfs:label>Aripiprazole</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01238</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC76684A-68AE-44B6-8B8B-E2C2F561BF9C">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:48D2176F-5F8B-4993-A51B-337969C52A2C">
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A5168DB-1BDC-4A88-A8AB-15701D6A2026">
    <pav:createdOn>2014-03-20 21:36:53 -0400</pav:createdOn>
    <ao:prefix>). Women should understand that tamoxifen reduces the incidence of breast cancer, but may not eliminate risk. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6A5168DB-1BDC-4A88-A8AB-15701D6A2026"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> In women with breast cancer who are at high risk of developing a second breast cancer, treatment with about 5 years of tamoxifen reduced the annual incidence rate of a second breast cancer by approximately 50%.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Tamoxifen decreased the incidence of small estrogen receptor positive tumors, but did not alter the incidence of estrogen receptor negative tumors or larger tumors.</ao:exact>
    <domeo:uuid>6A5168DB-1BDC-4A88-A8AB-15701D6A2026</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A42E3A3-BDCF-4094-930E-A318AB2A67DA">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6A42E3A3-BDCF-4094-930E-A318AB2A67DA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.</ao:exact>
    <ao:prefix>In any patient treated with abacavir, the clinical diagnosis of hypersensitivity reaction must remain the basis of clinical decision-making. </ao:prefix>
    <pav:createdOn>2014-03-19 14:56:04 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2A602B2F-02AB-4E05-A03D-F79B1D47EC2E">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-restart</poc:DrugSelectionRecommendation>
    <rdfs:label>Do not restart</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:839A281F-6660-4350-9005-224DB3EB58C1">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3756B300-651E-4B6A-BD79-03AD1FDE59FB">
    <ao:exact>A meta-analysis of 9 qualified studies including 2775 patients (99% Caucasian) was performed to examine the clinical outcomes associated with CYP2C9 gene variants in warfarin-treated patients.3 In this meta-analysis, 3 studies assessed bleeding risks and 8 studies assessed daily dose requirements. The analysis suggested an increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 alleles. Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele. For patients carrying at least one copy of the CYP2C9*3 allele, the mean daily warfarin dose was 37% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele.</ao:exact>
    <pav:createdOn>2014-03-20 20:04:01 -0400</pav:createdOn>
    <domeo:uuid>3756B300-651E-4B6A-BD79-03AD1FDE59FB</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:prefix>Total188Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9 and *11 alleles in Caucasians. Excretion: Pharmacogenomics </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3756B300-651E-4B6A-BD79-03AD1FDE59FB"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7EFB9D14-8636-4D3E-996B-2F7AAE64CBD9">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>myelotoxicity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:22AEACAD-5E17-4751-AFD4-7D1FB542F6AD">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-19 15:09:38 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:44C16CD2-5AFA-4FAB-B34B-D3D24872A619"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF1A37D6-AEDA-48F2-A45F-2355A82206A8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CD7435AE-EAF0-4D90-9338-E1766641DEA8"/>
    <pav:lineageUri>urn:domeoserver:annotation:C087076D-EB3A-468D-831B-592F9E0092B9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-19 15:02:47 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B211438A-E8DA-4137-A21B-834C2FE11556"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB7921EC-2D95-4653-BADB-16A70CADFBF0"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1D33813B-065B-4E5C-B61B-1395C3854AAD"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6AB54036-4BD8-46F0-8048-87FE255730EE">
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:14B3ABE9-0D4F-4C2B-B55C-066483D76530">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F1DEDC8-E1B5-40F3-8C95-881913F63D28">
    <ao:body rdf:resource="urn:linkedspls:uuid:061D7981-BEE5-49D4-ADDE-49306A0E3D19"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB9915C0-1869-41E0-9C17-0B5A3867E70F"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:CD7A5DE3-B966-40F9-B6DD-C4405D8D9D02"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:E2F3A1BE-A0E3-424C-9092-15F166B370F7</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BEA86691-81E4-4B89-AD1A-4E918E43CED1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB450397-838F-4918-A73F-B6CB95A87A1C"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-20 20:25:07 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:3756B300-651E-4B6A-BD79-03AD1FDE59FB"/>
    <pav:createdOn>2014-03-20 20:04:01 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:286B6F87-0802-488E-ACF0-99D5D33DA185">
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:18E46735-0029-413E-9BB6-763A55537CE4">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:18E46735-0029-413E-9BB6-763A55537CE4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2014-03-19 15:01:34 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Your risk of this allergic reaction is much higher if you have a gene variation called HLA-B*5701 than if you do not. Your doctor can determine with a blood test if you have this gene variation.</ao:exact>
    <ao:suffix> If you get a symptom from 2 or more of the following groups while taking ZIAGEN, call your doctor right away to determine if you should stop taking this medicine.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8723B05B-A9E1-4639-B855-00F252E0878C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <domeo:uuid>8723B05B-A9E1-4639-B855-00F252E0878C</domeo:uuid>
    <pav:createdOn>2014-03-20 22:41:59 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8723B05B-A9E1-4639-B855-00F252E0878C"/>
    <ao:exact>Tests are available to determine a patient’s CYP2C19 genotype.  </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:096631E7-B679-44F0-BF4C-5C78641EDC47">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:096631E7-B679-44F0-BF4C-5C78641EDC47"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>on, axillary dissection, and breast radiation). After 5 years of treatment, there was a significant improvement in disease-free survival in women receiving tamoxifen. This benefit was apparent both in women under age 50 and in women at or beyond age 50. </ao:prefix>
    <domeo:uuid>096631E7-B679-44F0-BF4C-5C78641EDC47</domeo:uuid>
    <ao:exact>One additional randomized study (NATO) demonstrated improved disease-free survival for tamoxifen compared to no adjuvant therapy following total mastectomy and axillary dissection in postmenopausal women with axillary node-negative breast cancer. In this study, the benefits of tamoxifen appeared to be independent of estrogen receptor status.</ao:exact>
    <pav:createdOn>2014-03-20 21:19:22 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:72B97D5E-D7C1-456A-BBE7-ABD7DB0DC3F0">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D3B563A4-755C-4E86-AFDE-4D4F02369381">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BEE69943-3E37-498C-866B-5107E90B6DB6">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Letrozole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C399634B-DD99-4D60-B4CB-963EF1AC5ECD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8D82EE50-C8EC-4407-BCEB-862623BE43F2">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B1A2835-2E09-461E-BBDE-905DF0D100F0"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A6763EEC-9065-43A4-BFDA-C0410A212881"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F9E37760-DF14-4EF7-AFA1-B814F95E946E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:78D88E4B-3BC5-4B64-986D-11331F289F14"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdOn>2014-03-20 22:49:45 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:70F70517-9BF8-4F58-80D7-69E0A3B8B6C5"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:11D1EAA3-3937-4086-A7D7-AB8C01669617"/>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:9D9999AD-FB08-4711-8283-408230FFF2CC"/>
    <pav:lineageUri>urn:domeoserver:annotation:002933FC-4C04-49FE-9606-6B02CC484D15</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:322A6B4D-89A4-46F6-8F81-2715CB42BCE6"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:90BF3029-9D80-4C7A-B47A-CFC7D3BE4878">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CBDCE031-C57C-4568-8C5F-36FAF0B3CA1D">
    <ao:body rdf:resource="urn:linkedspls:uuid:370FC4A2-3B97-4E36-A22C-2AB668893D29"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:36E8A1E2-255C-46F2-B3B6-FE1C93F847ED"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:03604D36-40FC-4B02-BED6-2995A00D47EF"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-20 20:25:07 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:21512851-50BF-4561-9F41-61A5C4960B12"/>
    <pav:createdOn>2014-03-20 19:57:58 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:959C282F-18BC-4D7F-B5CC-77D9B157A0C6"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:E2F3A1BE-A0E3-424C-9092-15F166B370F7</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:6AC9FCAF-FC9E-4667-8690-9CD344FF4E48"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:694DB8A0-BF33-40DC-9652-A8143C01A873">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B116C4D5-D059-4C0E-9ACF-67C01A265602"/>
    <pav:createdOn>2014-03-20 20:16:17 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AB58E868-7CBD-4BB0-BF71-DABA7507AEFF"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lastSavedOn>2014-03-20 20:25:07 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:E2F3A1BE-A0E3-424C-9092-15F166B370F7</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:95BD23BD-F5B9-4E4D-B595-916CFD631406"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6AB54036-4BD8-46F0-8048-87FE255730EE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3B667FA8-40E7-4E2C-9B60-47819070F07C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13AA4D6E-A2AD-4CDF-8385-FCEFDEE8FAFA">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <domeo:uuid>13AA4D6E-A2AD-4CDF-8385-FCEFDEE8FAFA</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:13AA4D6E-A2AD-4CDF-8385-FCEFDEE8FAFA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>One additional randomized stud</ao:suffix>
    <pav:createdOn>2014-03-20 21:19:18 -0400</pav:createdOn>
    <ao:exact>NSABP B-14, a prospective, double-blind, randomized study, compared tamoxifen to placebo in women with axillary node-negative, estrogen receptor positive (≥ 10 fmol/mg cytosol protein) breast cancer (as adjuvant therapy, following total mastectomy and axillary dissection, or segmental resection, axillary dissection, and breast radiation). After 5 years of treatment, there was a significant improvement in disease-free survival in women receiving tamoxifen. This benefit was apparent both in women under age 50 and in women at or beyond age 50.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FBD7F4E6-824A-406D-87B2-EED87E7CB4E0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C961CB2-F6D5-490A-B247-E2E0EC342D63">
    <ao:body rdf:resource="urn:linkedspls:uuid:E4AF7BA8-EC06-4619-BCB2-5C85DAF8AD61"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:7244F12F-1C68-4476-A926-6F110F163218"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:9BAD21E0-A813-4CC6-BF58-E7E34520383C"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:11889468-ECDB-493B-8E8D-449CF0F064EF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FBDB937C-1ECC-43F6-AD77-306885A170D2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C7363099-1D78-4C0C-B870-1C8C5868B730"/>
    <pav:lineageUri>urn:domeoserver:annotation:9A53AB31-FC10-41E7-8631-3258801B18DF</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:49190F98-EB06-4A32-9340-5356EE1B85B9</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:0EA628AE-BE06-4131-BE59-DA6952BF359E"/>
    <pav:lastSavedOn>2014-03-19 17:45:50 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-19 17:20:24 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:189A726D-4325-4768-92CF-C992BB68B068"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:05876B0E-1AED-42F3-861C-BC3C9D098451">
    <pav:createdOn>2014-03-19 17:22:16 -0400</pav:createdOn>
    <ao:exact>Citalopram steady state levels were not significantly different in poor metabolizers and extensive metabolizers of CYP2D6</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:05876B0E-1AED-42F3-861C-BC3C9D098451"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>05876B0E-1AED-42F3-861C-BC3C9D098451</domeo:uuid>
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60D74402-BDAA-4C5B-8066-D016D4F770F8">
    <ncit:Alleles>-1639G&gt;A</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3C073DF6-1B5E-4DF7-8F70-98F8EA093887">
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FD2CDD01-8EEB-4842-9F2B-CDECA35F97D4">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8703680-3459-491E-A31C-052B5FE206DB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B8703680-3459-491E-A31C-052B5FE206DB"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:exact>Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-20 22:21:34 -0400</pav:createdOn>
    <ao:suffix> Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy [see Clinical Pharmacology (12.5)].  Consider alternative treatment or treatment strategies in patients identified as CYP</ao:suffix>
    <domeo:uuid>B8703680-3459-491E-A31C-052B5FE206DB</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4A6A83D6-CF48-4CD3-AB4F-306B555CAC20">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3A13C9D0-35CB-4326-93DB-04D1BCE21136"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5B9CE094-EF08-4EB5-9ABA-F60BEE4812A3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D489C4C2-91A7-4E25-8BB9-14803AC158E1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B66F17A9-EC80-4D4E-B55A-0281D4B9C2A7"/>
    <pav:createdOn>2014-03-20 18:58:54 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:CDC6726D-F01E-422C-A6B9-A8E2CBA8EF72"/>
    <pav:lineageUri>urn:domeoserver:annotation:9EA7040A-9258-438E-BA3B-3BB2C51C9DB2</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:07397697-2E09-4D7D-9C80-18B8547A20E7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A8FE1AD1-497E-4CCE-996B-14B4022E3B4E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E6597CD9-7B75-4A58-92F4-C9646C4344D3"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE32A3A7-7BE5-461D-B9F3-8C5B0826D572">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <pav:createdOn>2014-03-20 19:10:01 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C8492505-5E55-4CB7-B5B0-C5FDB227BADF"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:D39F3BCB-9288-4357-95F5-CCC21A19753E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:65033D61-BB48-4B9A-90E7-A2E9978D5DA6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:ADD89EDA-BA30-4500-91DB-2D2B34A120A1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:D01A362B-EF20-4CF0-8010-8DDA819D44A6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:D51DB2CF-BE16-4142-8FFF-1AA808E22C7D"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:64FCF20E-F646-4CC6-AB1F-4E5521777093"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB59BEC3-604E-402B-9DDF-0F0C39C79DB8">
    <ao:suffix>6,7</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>EB59BEC3-604E-402B-9DDF-0F0C39C79DB8</domeo:uuid>
    <pav:createdOn>2014-03-20 20:08:37 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>Warfarin reduces the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle, through inhibition of vitamin K epoxide reductase (VKOR), a multiprotein enzyme complex. Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G&gt;A allele) have been associated with lower dose requirements for warfarin. In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been reported in Asian patients.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EB59BEC3-604E-402B-9DDF-0F0C39C79DB8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:03604D36-40FC-4B02-BED6-2995A00D47EF">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACOKINETICS (43682-4)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOKINETICS (43682-4)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B573E1F3-D13D-42D0-A610-72F4F658192F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8953F953-4F43-4928-9D69-4A1790C216C9">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Azathioprine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD8C9612-7301-4579-89DE-2A247E83BB83">
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:C8371F64-1E7B-4D94-8A91-8CDDE9B4E470"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AD7743D9-096E-4D1E-83A2-682326657AEF"/>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:3561EC2B-135E-43D7-A0DB-4708CD4113A0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AD19F056-C839-4C2F-8E73-AD43128606E9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B0ADFEE-17F3-4E13-B976-84247AB7814F"/>
    <pav:lineageUri>urn:domeoserver:annotation:3948FFA4-41D9-4B23-8E7D-C555A3F2A2F6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:A1112824-175A-4D8B-BBBB-626DE8042CF6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A6B987CA-7179-4CC6-9E0C-49AEDD8B1333"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:1DDC2DA3-6B7A-4158-A95C-3638A487A766"/>
    <pav:createdOn>2014-03-20 19:11:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16912952-C01C-46AA-BAFA-1BA75EA86EAA">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16912952-C01C-46AA-BAFA-1BA75EA86EAA"/>
    <pav:createdOn>2014-03-20 22:49:53 -0400</pav:createdOn>
    <ao:exact>The relationship between CYP2C19 genotype and clopidogrel bisulfate treatment outcome was evaluated in retrospective analyses of clopidogrel bisulfate-treated subjects in CHARISMA (n=2428) and TRITON-TIMI 38 (n=1477), and in several published cohort studies. In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolizers. </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>16912952-C01C-46AA-BAFA-1BA75EA86EAA</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DABA53EA-77F0-4679-9064-7C6B291E66FF">
    <pav:lineageUri>urn:domeoserver:annotation:8AC80E13-EAE8-4AB1-95EF-3FE0AFB120BB</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:DCBD54B3-8254-4593-9093-F0C2CE0C55E6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:22F2A90E-E97E-49BE-AAA8-3643DE41845D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:59DEDDBC-F3EF-4CDD-B293-B9FB573EE032"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A3F3B45B-4233-41B6-A7DC-CFC7D893E5C7"/>
    <pav:createdOn>2014-03-20 22:27:40 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:227586CE-1E8C-47CE-A2E6-A55AFC74F904"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F50B183E-3A4A-4608-9BA1-5AA2440B5042"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:627D2B6E-0E5C-457E-8623-11C11BA016A8"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C2D516D-CFFB-42E9-91F5-9F1900F93DEF">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E814119-6F39-4A90-9695-C4357BC61540"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:1F0E8B3A-F586-46EA-9CB4-CA63642105D5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E2F3A1BE-A0E3-424C-9092-15F166B370F7</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <pav:createdOn>2014-03-20 19:53:35 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:393D42B6-EA22-479F-9BBD-C69B63B73A63"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:111CEACC-F91E-446D-B3FC-B76210CDB7AF"/>
    <pav:lastSavedOn>2014-03-20 20:25:07 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:611B4F99-3AA6-4E9F-9932-DBA32D027D64"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB7921EC-2D95-4653-BADB-16A70CADFBF0">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:936DA545-AB12-4AE4-855C-9382992D7967">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C18BF956-ACC7-4F76-992F-882DB148E736">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:322A6B4D-89A4-46F6-8F81-2715CB42BCE6">
    <poc:MedicalCondition>cardiovascular events, death, myocardial infarction, stroke</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C17AE157-C30F-43EE-B1A5-AD7FF93A1D94">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:733702D3-3AF2-47A3-8F50-44D9D0D506F6"/>
    <pav:createdOn>2014-03-19 16:19:07 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:59C88ED2-F997-4A97-A3B9-600D5DA7A8ED</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:3AC5D8A5-495B-4264-B7A9-2AFA05F2B52D"/>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:FA6FEC88-82CF-4290-8B9A-93A451707E75"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:7F4BE61E-FC90-4CE1-B16F-1CCEFA05F994"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D0D80898-E33B-4022-8E8C-1079A65A4782"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:F8D4350A-1668-4224-8A2F-998908C92922"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C8A6B20C-1596-4A8E-8FB2-97FEB7159D88">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdfs:label>TPMT</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3FAE84F2-0F2F-499B-A7B6-7E43583797CB">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3092E8A1-2F97-4A8C-9DA0-646015CDCAF4">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4B104C62-0511-4DB8-93A3-E0A92490BE3E">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:A47EAFF1-DDE8-4DB0-AFAB-BC566DDEF27E"/>
    <pav:lineageUri>urn:domeoserver:annotation:F513F1AD-F416-4DD0-854C-CF7DE27AFDE4</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:E084DC2B-773F-4E31-A007-983AEDA3D8B4"/>
    <pav:createdOn>2014-03-19 15:39:49 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E8E1303-5FCE-471A-B82D-3E6CDA2D262C"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:92402A2C-AB91-484F-9D03-27250A8159D3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2D868D9C-FA37-4BD5-8B63-47087C1BDD22"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:DBD1F540-47B0-493A-B41A-ACC8A6BACA62"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:B4DF83AA-EC7E-49FD-85C2-57158CD44F16"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EFE999A9-D0B3-463F-B964-665F55247B66">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EFE999A9-D0B3-463F-B964-665F55247B66"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-19 14:46:46 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:exact> Even in the absence of the HLA-B*5701 allele, it is important to permanently discontinue abacavir and not rechallenge with abacavir if a hypersensitivity reaction cannot be ruled out on clinical grounds, due to the potential for a severe or even fatal reaction.</ao:exact>
    <ao:prefix>If hypersensitivity cannot be ruled out, DO NOT reintroduce ZIAGEN or any other abacavir-containing product.</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AD19F056-C839-4C2F-8E73-AD43128606E9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D489C4C2-91A7-4E25-8BB9-14803AC158E1">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B52ABCB-7FE9-4E60-94F1-D5DB30DA6457">
    <ao:suffix>r (1.3</ao:suffix>
    <domeo:uuid>5B52ABCB-7FE9-4E60-94F1-D5DB30DA6457</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5B52ABCB-7FE9-4E60-94F1-D5DB30DA6457"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-19 22:48:30 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <ao:exact>Letrozole tablet is an aromatase inhibitor indicated for: \nAdjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer (1.1)\nExtended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy (1.2)\nFirst and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cance</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C7363099-1D78-4C0C-B870-1C8C5868B730">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4916A699-FFEE-4E5E-92CB-43C4B79DBD60">
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F374CAE1-4037-4056-9B02-3FB7229BAAD5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>morphine toxicity, lactation</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:28FB9894-294D-4AF9-9A23-72B6607DF835">
    <ao:context rdf:resource="urn:domeoclient:uuid:A55C5F9D-CE0B-400C-8014-0AAA5D450CBF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-03-20 22:38:41 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:35628CF2-F997-441C-B71C-6E3047E3E202"/>
    <pav:lineageUri>urn:domeoserver:annotation:2F67128C-144B-4D84-B7CA-A578CA2A11C0</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:DFD7FA46-889E-4749-B556-55DE45D28952"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A9FE9022-79EE-4050-8A20-C65B1555F57E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:51372240-0FF1-46A6-8C2F-C9BA81F53A52"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:51705378-2D9E-48E5-961A-8B2F152D3F73"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C710F5D3-69C0-42C9-99BB-26C9B724250E">
    <ao:context rdf:resource="urn:domeoclient:uuid:B8703680-3459-491E-A31C-052B5FE206DB"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5FA44327-04D3-4E57-91F7-BEB90393EF82"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:52D9C9F2-D2C1-428A-93AD-1BEDDD4110E5"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F2437485-F4C1-46BA-8F55-3A2734C01F73"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7B837903-CB79-4F77-9017-75910F285B45"/>
    <pav:createdOn>2014-03-20 22:21:34 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:A1C960C2-FD84-40FC-AC08-9AD3C56E51E0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9E212844-5E5B-409F-888E-6AC2FCEAE81D"/>
    <pav:lineageUri>urn:domeoserver:annotation:0DE97F7E-F637-42F9-A245-8A091C6DDA88</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:07638D4B-0972-4F15-982F-380CBCA245EF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8E5026D0-9091-4B42-84F7-174D096A299F">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34CA7071-235A-4D52-82B4-09F2E160DEAE">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:63A02BF2-6DC0-4921-BA28-6D22A5924699">
    <pav:createdOn>2014-03-20 22:22:11 -0400</pav:createdOn>
    <ao:exact> Tests are available to identify a patient's CYP2C19 genotype; these tests can be used as an aid in determining therapeutic strategy</ao:exact>
    <ao:suffix> [see Clinical Pharmacology (12.5)].  Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers [see Dosage and Administration (2.3)].</ao:suffix>
    <domeo:uuid>63A02BF2-6DC0-4921-BA28-6D22A5924699</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:63A02BF2-6DC0-4921-BA28-6D22A5924699"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6B5EE4B6-5414-471F-AF7F-2E31AA0BF02E">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>cardiovascular events, death, myocardial infarction, stroke, stent thrombosis</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8EC147BF-A56C-42AA-9287-D412A6568342">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N124e61b629904cc5ae3dab752a547bb4">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BDC1906D-04B4-4201-993B-304905A5DB50">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BDC1906D-04B4-4201-993B-304905A5DB50"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Approximately 8% of Caucasians lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are extensive metabolizers (EM). PMs have about an 80% increase in aripiprazole exposure and about a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to EMs. Coadministration of ABILIFY with known inhibitors of CYP2D6, such as quinidine or fluoxetine in EMs, approximately doubles aripiprazole plasma exposure, and dose adjustment is needed [see DRUG INTERACTIONS (7.1)]. The mean elimination half-lives are about 75 hours and 146 hours for aripiprazole in EMs and PMs, respectively. Aripiprazole does not inhibit or induce the CYP2D6 pathway.</ao:exact>
    <pav:createdOn>2014-03-19 15:29:30 -0400</pav:createdOn>
    <ao:prefix>studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalyzed by CYP3A4. Aripiprazole is the predominant drug moiety in the systemic circulation. At steady-state, dehydro-aripiprazole, the active metabolite, represents about 40% of aripiprazole AUC in plasma. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DC74E568-7776-43A7-88B6-E5B65BCA3B95">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1FAB4375-A7DA-4C51-8154-B457F9FE858A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOKINETICS (43682-4)</poc:productLabelSection>
    <sio:SIO_000111>PHARMACOKINETICS (43682-4)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:30BA851A-23EE-432B-84BA-979A616ADC7D">
    <pav:lastSavedOn>2014-03-20 22:01:22 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:9E73876B-10AC-409A-A828-4AB857992E20"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:5B3A7C05-9902-476C-85DF-1A73D7737071</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:BC1982C7-B09F-4EBD-B2EE-4843A4A42789"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DEBF80EA-8241-48D8-8257-730A33EFEC1F"/>
    <pav:createdOn>2014-03-20 21:16:41 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:D62B81DA-0F12-4CE9-9FCC-11BF50B39C52"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A69958AC-75DD-4DB5-95B7-115AA9D11FB2"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:55030DF7-3E75-445C-A0BA-A168AB107EC2</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:968A785F-0FD3-485A-91A5-F75C203C76B6">
    <sio:SIO_000111>PHARMACOKINETICS (43682-4)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOKINETICS (43682-4)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4CB2B800-F0C5-424F-9EFF-EF45FAADCCF0">
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55125755-6679-4972-8FDF-7DB40547D0FA">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF1B43FA-C434-4873-99EC-E33EF6CCC7C3">
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4DE23BEF-58E5-4064-9C4E-F3EF6C71BFB0">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Azathioprine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A56BDA41-6FBB-42B1-B760-90D3207ED7E4">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:41016AAF-9332-438E-A35B-94F6746112BF">
    <pav:createdOn>2014-03-20 22:39:26 -0400</pav:createdOn>
    <domeo:uuid>41016AAF-9332-438E-A35B-94F6746112BF</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:suffix> Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6, *7, and *8. A patient with poor metabolizer status will possess two loss-of-function alleles as defined above. Publishe</ao:suffix>
    <ao:exact>CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:41016AAF-9332-438E-A35B-94F6746112BF"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D51DB2CF-BE16-4142-8FFF-1AA808E22C7D">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdfs:label>Metabolism Increase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D5B5870B-85D9-41EA-A232-5BDF0EC5C8A3">
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B2697248-A2E1-49C7-BE41-D98A166EBA4F">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3CB5705F-1919-41F9-A808-F0BF6A54032A">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E857A63C-360A-4082-8C42-635E2BEA2FD0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E857A63C-360A-4082-8C42-635E2BEA2FD0"/>
    <domeo:uuid>E857A63C-360A-4082-8C42-635E2BEA2FD0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <pav:createdOn>2014-03-20 21:26:27 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The estrogen- and progesterone-receptor values may help to predict whether adjuvant tamoxifen citrate tablet therapy is likely to be beneficial.</ao:exact>
    <ao:prefix>Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1FFC62E9-8D4F-4064-8277-51C4CAEE435C">
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:5B3A7C05-9902-476C-85DF-1A73D7737071</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:708591B4-F61B-476A-B315-B75ABE1E1E96"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A9FA8158-3484-4254-A774-4ED4FB44B337"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:C61A2DD1-7A8A-40F1-AB97-02B2A2604FE8</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E857A63C-360A-4082-8C42-635E2BEA2FD0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5B99B41A-A06F-483A-B796-FF0AEC0CD216"/>
    <pav:createdOn>2014-03-20 21:26:14 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:91BDADC2-23F0-4FE9-84A8-B81CF55B13A1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-20 22:01:22 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:15DAD636-7458-40A9-B728-4F7F0DDC7C55">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#LABORATORY TESTS (34075-2)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>LABORATORY TESTS (34075-2)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:059A9475-981D-45CC-90D3-8423D4048B6E">
    <ao:body rdf:resource="urn:linkedspls:uuid:0F75FD68-ED1E-476B-97B2-4ADFC4307BD2"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A407CD9D-EB51-4069-99B0-62441488DF51"/>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:BD616A26-9F05-4B02-AEA7-78A27C174955</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:73564A21-2417-4602-B23F-E7ACBAB17A27"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E7A8CFAA-6C0D-47D3-AFB5-E3B47ECE2B68"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B068224B-82C0-4964-AC65-7378AACB8351"/>
    <pav:createdOn>2014-03-20 22:47:52 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F554429E-2AF1-4FD2-817F-ACCA570855FC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5F14DDDE-5746-4056-B0EB-0730B9877BAF"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:134676FD-D77B-4168-89F4-5B90E0DB8E5D"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:061D7981-BEE5-49D4-ADDE-49306A0E3D19">
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>*2, *3, </ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2D5E2F9C-71DA-4E84-A2D0-5632F955EF10">
    <pav:createdOn>2014-03-19 22:44:09 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2D5E2F9C-71DA-4E84-A2D0-5632F955EF10"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <domeo:uuid>2D5E2F9C-71DA-4E84-A2D0-5632F955EF10</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Treatment of breast cancer thought to be hormonally responsive (i.e., estrogen and/or progesterone receptor positive or receptor unknown) has included a variety of efforts to decrease estrogen levels (ovariectomy, adrenalectomy, hypophysectomy) or inhibit estrogen effects (antiestrogens and progestational agents). These interventions lead to decreased tumor mass or delayed progression of tumor growth in some women.</ao:exact>
    <ao:prefix>The growth of some cancers of the breast is stimulated or maintained by estrogens. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C122F3DA-A8F1-426B-B1BC-FBC714A553A5">
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:04640639-1F09-4703-BD8D-DDE324CB5CC6">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C7210469-AFB5-4F34-8DE5-70D809640FF5">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:11889468-ECDB-493B-8E8D-449CF0F064EF">
    <rdfs:label>Citalopram</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2E9A6622-EB8C-4043-9C3A-C957738EEAFA">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:21BF8638-7FCA-4267-A195-B96685142B06">
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:95BD23BD-F5B9-4E4D-B595-916CFD631406">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PRECAUTIONS (42232-9)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PRECAUTIONS (42232-9)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B55BA90D-D154-4640-8258-0D3B09980F2A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdfs:label>ER_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2F95F308-3C1E-43D7-882A-244ED74B53D9">
    <pav:createdOn>2014-03-20 19:58:37 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:22CD49DD-C11F-4F6D-BA7B-ED26605122FB"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-20 20:25:07 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:552CC9B8-E36B-4BAD-9B40-367A8C7E175A"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:E759DEDB-032A-42D8-A570-A39875F7E5AD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:55F29EC1-BB42-4A08-9250-037C597742FD"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:EEB30041-1F0E-4377-AB3B-87C0A4BDC452"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:E2F3A1BE-A0E3-424C-9092-15F166B370F7</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EA543A32-7699-4976-A0CD-C4ADD9B4D43C">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EA543A32-7699-4976-A0CD-C4ADD9B4D43C"/>
    <domeo:uuid>EA543A32-7699-4976-A0CD-C4ADD9B4D43C</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>If the patient's CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium tablets is usually 2 to 5 mg per day. Modify this dose based on consideration of patient-specific clinical factors.</ao:exact>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-20 20:36:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1AFA922C-41D4-47D7-8D81-D0AC7B2BAEAB">
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FACFAB8E-E4E7-4839-99E1-C538E44B51EF">
    <ao:prefix>The dose of warfarin sodium tablets must be individualized by monitoring the PT/INR. Not all factors causing warfarin dose variability are known. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>FACFAB8E-E4E7-4839-99E1-C538E44B51EF</domeo:uuid>
    <ao:exact>The maintenance dose needed to achieve a target PT/INR is influenced by:\n●\n     Clinical factors including age, race, body weight, sex, concomitant medications, and comorbidities and\n●\n     Genetic factors (CYP2C9 and VKORC1 genotypes).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FACFAB8E-E4E7-4839-99E1-C538E44B51EF"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-20 20:33:05 -0400</pav:createdOn>
    <ao:suffix>             </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:933CA11C-6BFB-48DE-B380-6FEE37EE76B4">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64FCF20E-F646-4CC6-AB1F-4E5521777093">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:64FCF20E-F646-4CC6-AB1F-4E5521777093"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>64FCF20E-F646-4CC6-AB1F-4E5521777093</domeo:uuid>
    <ao:exact>Advise patients that some people have a genetic variation that results in codeine changing into morphine more rapidly and completely than other people. Most people are unaware of whether they are an ultra-rapid codeine metabolizer or not.</ao:exact>
    <ao:suffix> These higher-than-normal levels of morphine in the blood may lead to life-threatening or fatal respiratory depression or signs of overdose such as extreme sleepiness, confusion, or shallow breathing. Children with this genetic variation who were prescri</ao:suffix>
    <pav:createdOn>2014-03-20 19:10:01 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6597CD9-7B75-4A58-92F4-C9646C4344D3">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E6597CD9-7B75-4A58-92F4-C9646C4344D3"/>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> </ao:prefix>
    <domeo:uuid>E6597CD9-7B75-4A58-92F4-C9646C4344D3</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <pav:createdOn>2014-03-20 18:58:54 -0400</pav:createdOn>
    <ao:exact>These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultra-rapid metabolizers may have life-threatening or fatal respiratory depression or experience signs of overdose (such as extreme sleepiness, confusion, or shallow breathing)</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:85D52AA7-FDC8-4655-9611-1744EA3D7D23">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9069D351-D482-4BF4-8AA3-57AE8389B287">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:29C001AD-36AB-40D7-9EB0-9665BBBA6974">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D6E7684E-AD52-4896-985F-553E0FF6C3A0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Carbamazepine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F8D4350A-1668-4224-8A2F-998908C92922">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:21B20BF5-599F-4195-A261-8E38ECFDAB40">
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:768FB537-C83F-4098-9460-4F159200346A">
    <ao:body rdf:resource="urn:linkedspls:uuid:14B3ABE9-0D4F-4C2B-B55C-066483D76530"/>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:3CB5705F-1919-41F9-A808-F0BF6A54032A"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:E368A4BA-B700-4817-87D3-03625826549A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6205D3D3-85CB-4157-9A8E-85DEEFC406E4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-20 22:20:04 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:2B3ED51E-0FAA-492A-B6C3-EED409DA6CA1"/>
    <pav:lineageUri>urn:domeoserver:annotation:93CA4874-3759-438C-AB6E-DA4244B4943A</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:B2697248-A2E1-49C7-BE41-D98A166EBA4F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:656B8A7B-3ECD-464A-B060-D14ED2AD96C8"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C5682862-173B-4C14-A67F-4A642EE35D23">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E81BD5D1-A9EF-4142-B75D-7087E758B27C">
    <pav:lastSavedOn>2014-04-14 14:31:20 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8A656D94-29CF-4067-B1C7-E0B5241CA8CB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B8EA9953-FB04-4512-8E6B-27BDF9A1249E"/>
    <pav:lineageUri>urn:domeoserver:annotation:2DC5D146-5DD8-4B22-B7F6-9F284F6CFC60</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:BE4FB3BE-A47B-41C1-AC11-48D531C0C5F1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-04-14 14:31:13 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:0A7AE602-7166-4012-ACBA-4BC5FB8AED95"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3FC9605F-B92B-4A1D-9BEB-A309956EA46F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-03-20 19:03:51 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Codeine is secreted into human milk. In women with normal codeine metabolism (normal CYP2D6 activity), the amount of codeine secreted into human milk is low and dose-dependent. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3FC9605F-B92B-4A1D-9BEB-A309956EA46F"/>
    <ao:exact>However, some women are ultra-rapid metabolizers of codeine. These women achieve higher-than-expected serum levels of codeine’s active metabolite, morphine, leading to higher-than-expected levels of morphine in breast milk and potentially dangerously high serum morphine levels in their breastfed infants. Therefore, maternal use of codeine can potentially lead to serious adverse reactions, including death, in nursing infants.</ao:exact>
    <domeo:uuid>3FC9605F-B92B-4A1D-9BEB-A309956EA46F</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3D152E4D-029F-4E54-BBF7-ACD9D674C2F0">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:30A60BD8-5A6F-4229-B800-4178C57A1D14">
    <pav:createdOn>2014-03-20 20:29:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>) and long duration of warfarin therapy. </ao:prefix>
    <ao:exact>Identification of risk factors for bleeding and certain genetic variations in CYP2C9 and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:30A60BD8-5A6F-4229-B800-4178C57A1D14"/>
    <domeo:uuid>30A60BD8-5A6F-4229-B800-4178C57A1D14</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ACD0C5E9-2198-4239-A2E5-E1B699A8AF6E">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A8FE1AD1-497E-4CCE-996B-14B4022E3B4E">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1F7AE149-3B24-4669-9A5C-0DA275CE38CC">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1F7AE149-3B24-4669-9A5C-0DA275CE38CC"/>
    <ao:prefix>.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-04-14 14:26:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact> For HLA-B*5701-positive patients, treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances when the potential benefit outweighs the risk.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid>1F7AE149-3B24-4669-9A5C-0DA275CE38CC</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4541C54B-FCC9-492E-9947-595488AC3029">
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ADD89EDA-BA30-4500-91DB-2D2B34A120A1">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68E7E8B1-2529-456F-844F-CA5D738A8342">
    <domeo:uuid>68E7E8B1-2529-456F-844F-CA5D738A8342</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:68E7E8B1-2529-456F-844F-CA5D738A8342"/>
    <pav:createdOn>2014-03-20 19:02:57 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Deaths have also occurred in nursing infants who were exposed to high levels of morphine in breast milk because their mothers were ultra-rapid metabolizers of codeine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:prefix> </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E128EDCB-5790-4905-9875-43ECE6F280A4">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:947BE3D3-B7B3-4CF5-8AD3-E13A57F92EDB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:658C3999-25F4-4784-A873-265CB917A6A1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E2779FF-0284-4754-9414-2DB12979F639"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5C6E13E4-36D8-4209-A18C-8196EB971DC7"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:B1BB96BB-6FAE-4D26-A388-29434E105251"/>
    <pav:createdOn>2014-03-19 16:01:20 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:EC33851C-7A20-4EE4-A17C-405C15941404"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:ACBD6300-DBC2-4A8F-A5C4-6646AE6B399B</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:77878550-8F6C-4F7E-A467-A6BC25C4D823"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C1A6D1E9-7185-4973-A126-3C314015855A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0886EC50-FACB-487C-AF46-0B8888567E2E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:23E053EE-42F8-472A-BA10-FF0F216B26A7">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:694CA4DF-FB37-4ED1-978B-D265DBD7A3D7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine tablets.</ao:suffix>
    <ao:exact> Patients with intermediate TPMT activity may be at increased risk of myelotoxicity if receiving conventional doses of azathioprine tablets. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:694CA4DF-FB37-4ED1-978B-D265DBD7A3D7"/>
    <domeo:uuid>694CA4DF-FB37-4ED1-978B-D265DBD7A3D7</domeo:uuid>
    <ao:prefix>inversely with 6-TGN levels in erythrocytes and presumably other hematopoietic tissues, since these cells have negligible xanthine oxidase (involved in the other inactivation pathway) activities, leaving TPMT methylation as the only inactivation pathway.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-19 15:40:37 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A87899C-DF27-487F-8056-D135597121C3">
    <ao:body rdf:resource="urn:linkedspls:uuid:F0AE356A-0EB9-438E-9217-7E967EEC2AC4"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-19 16:35:41 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:249F4FFB-9BF7-4E49-80B8-B79F8EB25B25"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:21DD16EE-FA7C-4344-8260-A84AEB3E29CD</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF8BAE66-1A7E-496F-83AD-CED870C08374"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-19 17:13:40 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7A6F08EF-D022-4FB7-9355-EBD844ECAF10"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:AF990637-4CBB-451A-B1CB-8B4F4D2356C1"/>
    <pav:lineageUri>urn:domeoserver:annotation:D4413759-3A4E-4A3E-8108-C3AEF345674D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:D0F08E66-A881-4851-9FA8-55144057E492"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D4E24E7-D8E0-438C-B181-28EC31680D28">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0D4E24E7-D8E0-438C-B181-28EC31680D28"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <domeo:uuid>0D4E24E7-D8E0-438C-B181-28EC31680D28</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Retrospective case-control studies have found that in patients of Chinese ancestry there is a strong association between the risk of developing SJS/TEN with carbamazepine treatment and the presence of an inherited variant of the HLA-B gene, HLA-B*1502. The occurrence of higher rates of these reactions in countries with higher frequencies of this allele suggests that the risk may be increased in allele-positive individuals of any ethnicity.</ao:exact>
    <ao:suffix>Across Asian populations, nota</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-19 16:49:06 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:733702D3-3AF2-47A3-8F50-44D9D0D506F6">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Azathioprine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4C019E08-FDDB-44A4-827F-E8B96A8743B4">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7656A536-9D48-4624-B0F8-E912B1CE145D">
    <ao:exact>Prior to initiating Carbamazepine Extended-Release Capsule therapy, testing for HLA-B*1502 should be performed in patients with ancestry in populations in which HLA-B*1502 may be present. In deciding which patients to screen, the rates provided above for the prevalence of HLA-B*1502 may offer a rough guide, keeping in mind the limitations of these figures due to wide variability in rates even within ethnic groups, the difficulty in ascertaining ethnic ancestry, and the likelihood of mixed ancestry.</ao:exact>
    <domeo:uuid>7656A536-9D48-4624-B0F8-E912B1CE145D</domeo:uuid>
    <pav:createdOn>2014-03-19 16:51:31 -0400</pav:createdOn>
    <ao:suffix> Carbamazepine Extended-Release Capsules should not be used in patients positive for HLA-B*1502 unless the benefits clearly outweigh the risks. Tested patients who are found to be negative for the allele are thought to have a low risk of SJS/TEN</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7656A536-9D48-4624-B0F8-E912B1CE145D"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:140278A4-AFD4-43AC-A3A0-071109D0C7DF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1CF222F1-AADE-429E-BD4D-86F6B8CE7BF6">
    <ao:exact> NEVER restart ZIAGEN or any other abacavir-containing product following a hypersensitivity reaction to abacavir, regardless of HLA-B*5701 status </ao:exact>
    <pav:createdOn>2014-04-14 14:18:38 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1CF222F1-AADE-429E-BD4D-86F6B8CE7BF6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>ZIAGEN is contraindicated in patients with previously demonstrated hypersensitivity to abacavir or any other component of the products.</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>1CF222F1-AADE-429E-BD4D-86F6B8CE7BF6</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8E980092-8C70-4922-A9D1-6D9173A4D90C">
    <ao:body rdf:resource="urn:linkedspls:uuid:30DF004E-B63A-4FB0-A1EA-336B7DEC5787"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:A3B5C43E-64BB-4BDA-84A2-F4695C4A88EB"/>
    <pav:lastSavedOn>2014-03-20 20:40:11 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:31652C2C-DD89-4154-8144-014752FE2F0D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:47F47714-22F3-4F66-9F42-D32E479B2AFA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:03A0817D-F24D-4221-8BA6-3731CC15BAB1"/>
    <pav:lineageUri>urn:domeoserver:annotation:101A2852-D959-423D-AFE5-2DAF74E8BB63</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:17270663-D028-419C-86D6-D27A27CAF0B1"/>
    <pav:createdOn>2014-03-20 20:38:09 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B1F7DBB8-550E-46FD-9327-2344FC5C3CF4">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6FBAFF2A-C87D-4FFE-AFF2-DFA06BF3D938">
    <sio:SIO_000111>USE IN SPECIFIC POPULATIONS (43684-0)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#USE IN SPECIFIC POPULATIONS (43684-0)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:332D6CE3-0165-43D9-B008-7A2EE57C659B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Use specific</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:19FCCE47-6B34-402C-9399-56FD06BA444B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CCC5CEBF-4F5C-40BC-8432-C8616DEB89B8">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E3BF2EFB-927E-43FB-9F53-841BB201C8CB">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E3BF2EFB-927E-43FB-9F53-841BB201C8CB"/>
    <ao:suffix> HLA-B*5701-negative patients may develop a suspected hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir.</ao:exact>
    <pav:createdOn>2014-04-14 13:58:11 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>E3BF2EFB-927E-43FB-9F53-841BB201C8CB</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BAC5935C-9A78-4CFA-949D-FDA6F537CE63">
    <pav:lastSavedOn>2014-03-20 20:25:07 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:3548156E-1ABB-4659-8621-34BAA76E6E81"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:28DF2363-5C26-415A-854F-BC5E5EEB77C5"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:A172BEBB-9732-4502-8250-4C80D5F01B6C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4E6299BE-003A-4F7F-8242-78481F6A96D6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6F81C705-D6E2-49D1-9733-D5F9B9AB13D9"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:C18BF956-ACC7-4F76-992F-882DB148E736"/>
    <pav:createdOn>2014-03-20 20:02:22 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:968A785F-0FD3-485A-91A5-F75C203C76B6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:E2F3A1BE-A0E3-424C-9092-15F166B370F7</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:343392C4-02AA-49C7-8FB6-3024CD27DF99">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:36C1ADC1-4097-44A1-801A-59A82C0B58A5">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DBB743F3-2F25-44E1-BF1B-0AF4A2A59B6E">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86871666-E251-4BFA-A5AD-9568B8EB0C1B">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:399C64BA-4B01-4E80-B680-B32F7D76D2EB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:74C31B89-4CE7-44DD-93F6-9133D4960032">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F52DD4D1-B020-4D5D-A1DD-FBC62006D5D2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ABADA501-5B06-4F8C-A13C-76EE0D173F4B">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:06E50AF2-762B-492C-9206-8A2F9517B7E1">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>serious skin reactions</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6C63E8C2-CE98-4F8A-B039-7CE26562B1EE">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:11D1EAA3-3937-4086-A7D7-AB8C01669617">
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DBD1F540-47B0-493A-B41A-ACC8A6BACA62">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DBD1F540-47B0-493A-B41A-ACC8A6BACA62"/>
    <ao:exact> TPMT activity is controlled by a genetic polymorphism.1, 2, 3 For Caucasians and African Americans, approximately 10% of the population inherit one non-functional TPMT allele (heterozygous) conferring intermediate TPMT activity, and 0.3% inherit two TPMT non-functional alleles (homozygous) for low or absent TPMT activity. Non-functional alleles are less common in Asians. </ao:exact>
    <domeo:uuid>DBD1F540-47B0-493A-B41A-ACC8A6BACA62</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <pav:createdOn>2014-03-19 15:53:32 -0400</pav:createdOn>
    <ao:prefix>6-MP undergoes two major inactivation routes (Figure 1). One is thiol methylation, which is catalyzed by the enzyme thiopurine S-methyltransferase (TPMT), to form the inactive metabolite methyl-6-MP (6-MeMP).</ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A222BC1F-1597-4155-9E31-1C20D7A5648E">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF29538B-2B45-4554-B2BA-23EB29D76597">
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9389F7F5-892D-4B03-95B8-4480A7685CC3">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F61D97EB-8403-42C8-9DED-0D17173ADB71">
    <pav:lastSavedOn>2014-04-14 14:29:30 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:13DDC676-F835-48F3-8F51-F14D640EC90D</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-04-14 14:04:20 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DA50FDB4-AF3D-40C9-BBA7-C916D99F7425"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B4D3A216-653D-42EB-8DD3-CB10AAF831D8"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:35309FCF-FCD0-4723-868F-BD8FEFF9D0B7"/>
    <pav:previousVersion>urn:domeoserver:annotationset:77702DAE-17B5-4010-957C-3EBC5127E1C3</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:9488A015-DE92-4E36-85C8-27717D2B062C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:933CA11C-6BFB-48DE-B380-6FEE37EE76B4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C86FA709-0FC4-468A-AA0F-5DD174E1DB26"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D1044D44-5910-474A-A8A4-E6EA9C153399"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EBB10675-34D8-4A43-8109-97337AEB25AF"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C29D2C65-749E-4E86-B844-84B4799E8AEA">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB7B1A47-6A4E-495B-9486-581B1FD967CB">
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:2F920888-8A39-4289-B904-A78C98383580</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6AFF6CA5-93B5-4762-9F50-93791048BE2F"/>
    <pav:createdOn>2014-03-20 22:28:52 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:AB3D56E6-E54E-45F7-ABF8-8433482E0BEF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7D285AB3-7273-4A95-A578-5A4DA7E750FB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EAB6F24D-AA43-449F-911E-1E56666A1A02"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:34E8E3AD-68FE-4EE5-96EA-4C3965E2F421"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9494055D-F4FE-4CCF-8ADB-74AF27A0398D"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:0BB2E8FE-EEA1-43A2-8258-4855094167CF"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A21C7433-3A87-4C9E-BCB4-BA91D8813366">
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C8371F64-1E7B-4D94-8A91-8CDDE9B4E470">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>life-threatening respiratory depression, fatal respiratory depression, signs of overdose</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:809C2CC9-DE0B-426E-AF39-1670091D60EE">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6C3F6F4-5F35-42B4-B9EE-987B9F024547">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B8E0E60B-7D65-4C3A-8CE4-45C49E699E26">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1BC80E01-8BD0-40A4-AEF3-A77C9162ED89">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A6B987CA-7179-4CC6-9E0C-49AEDD8B1333">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:51705378-2D9E-48E5-961A-8B2F152D3F73">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D875C28-82A2-4F65-AB8F-35471B6413D0">
    <ao:context rdf:resource="urn:domeoclient:uuid:D750DAE1-7CF7-4673-9D17-42F414F5B26A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2883AF53-1B2C-4B8C-860E-836D46EFBC8B"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:21DD16EE-FA7C-4344-8260-A84AEB3E29CD</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:38D8DE2E-C3F7-4183-A814-38D09BF25F4A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E543270D-1D3E-46C8-9E89-C1AF04CA5213"/>
    <pav:createdOn>2014-03-19 16:53:17 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-19 17:13:40 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3404B806-583F-43ED-AEB1-AC92F1892C39"/>
    <pav:lineageUri>urn:domeoserver:annotation:E43596E5-3FDF-4A88-8B77-680B666244B4</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D0993E5E-D9C1-4F6B-A459-7D75E85C5CF7">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A180150E-99C2-4938-B28B-33BC6B91E08A">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4DD36BFE-C659-4270-8CDB-6026EECED60F">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4DD36BFE-C659-4270-8CDB-6026EECED60F"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <domeo:uuid>4DD36BFE-C659-4270-8CDB-6026EECED60F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose. Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose.\nIn all patients, subsequent dosage adjustments must be made based on the results of PT/INR determinations.17, 18\n\nTable 5Range of Expected Therapeutic Warfarin Doses Based on CYP2C9 and VKORC1 Genotypes*\nVKORC1CYP2C9*Ranges are derived from multiple published clinical studies. Other clinical factors (e.g., age, race, body weight, sex, concomitant medications, and comorbidities) are generally accounted for along with genotype in the ranges expressed in the Table. VKORC11639 G(rs9923231) variant is used in this table. Other co-inherited VKORC1 variants may also be important determinants of warfarin dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3 and *3/*3 may require more prolonged time (&gt;2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen.*1/*1*1/*2*1/*3*2/*2*2/*3*3/*3GG5 to 7 mg5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mgAG5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mgAA3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg</ao:exact>
    <pav:createdOn>2014-03-20 20:39:16 -0400</pav:createdOn>
    <ao:prefix>CLINICAL PHARMACOLOGY and PRECAUTIONS ). </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0A3C5A93-9BF2-4BEC-8574-4DFEA6F8F7A9">
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DD8496FC-857D-4CC7-B7D7-B4102EB3A560">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1414ECBC-E784-4C48-BE39-8A6FD5C45B30">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1414ECBC-E784-4C48-BE39-8A6FD5C45B30"/>
    <domeo:uuid>1414ECBC-E784-4C48-BE39-8A6FD5C45B30</domeo:uuid>
    <ao:exact>Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity if receiving conventional doses of azathioprine.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> TPMT genotyping or phenotyping can help identify patients who are at an increased risk for developing azathioprine toxicity.</ao:suffix>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <pav:createdOn>2014-03-19 15:46:58 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C96DFCF4-B0B5-411A-AFDD-65D2AF3ABDA3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CD38F700-9A3D-43BC-ADBC-B0DF3A711ECC">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:73DCCFF2-F6C1-4008-8B91-3A58F4C755B9">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EDDDD608-4E61-4DF5-BA25-8A9EC1ACEDE0">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:49190F98-EB06-4A32-9340-5356EE1B85B9">
    <ao:item rdf:resource="urn:domeoclient:uuid:0D2953B7-3453-41E8-A669-77E054F7AD5C"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896e94ef0008"/>
    <pav:lineageUri>urn:domeoserver:annotationset:DDFB4248-DE12-4A78-B612-E7FCB9F0E3CF</pav:lineageUri>
    <pav:createdOn>2014-03-19 17:15:36 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:C6DD3001-916E-424F-B04E-B44658253B7C"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:0AEF77FA-96B6-4AF1-9C46-DE8DEDD82590"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:annotatesResource>
    <pav:lastSavedOn>2014-03-19 17:45:50 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:1AC11904-C8D2-4A4F-BA0E-1FD807187A70"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6C961CB2-F6D5-490A-B247-E2E0EC342D63"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <permissions:permissions rdf:nodeID="Na79dd3c5fe7d4813ad500d5600d2e386"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:deleted>false</domeo:deleted>
    <rdfs:label>Default Set</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1314343-110C-47F5-A059-25796F7F6822">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62549B39-78C4-40E5-B0CB-7213E18247E0">
    <ao:body rdf:resource="urn:linkedspls:uuid:64246E83-D29F-4245-9FE5-A55D44FA12CE"/>
    <pav:createdOn>2014-03-19 15:51:34 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8953F953-4F43-4928-9D69-4A1790C216C9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9D8FCB5B-C705-4983-8ECE-0DC4D2DDBE8E"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F448032B-6068-49E2-A2B6-358BE03226E7"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:48659AF4-AE22-4758-A99C-7AB7840DD2C1"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:0C05564D-3B4C-4092-96DF-C85D9DA3D12D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:30BA5092-1050-4308-B908-7F1D078CBD32</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:3078509C-1D14-4C4F-A370-C79590D53AE3"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFE9BDB9-329C-4806-8ECD-73344FAA71B6">
    <pav:createdOn>2014-03-19 16:09:16 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>(see CLINICAL PHARMACOLOGY, WA</ao:suffix>
    <domeo:uuid>CFE9BDB9-329C-4806-8ECD-73344FAA71B6</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CFE9BDB9-329C-4806-8ECD-73344FAA71B6"/>
    <ao:exact>It is recommended that consideration be given to either genotype or phenotype patients for TPMT. Phenotyping and genotyping methods are commercially available. The most common non-functional alleles associated with reduced levels of TPMT activity are TPMT*2, TPMT*3A and TPMT*3C. Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity. Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. TPMT testing may also be considered in patients with abnormal CBC results that do not respond to dose reduction. Early drug discontinuation in these patients is advisable. TPMT TESTING CANNOT SUBSTITUTE FOR COMPLETE BLOOD COUNT (CBC) MONITORING IN PATIENTS RECEIVING AZATHIOPRINE TABLETS </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2C51BD0E-D330-4A02-B381-E294154E7A95">
    <ao:body rdf:resource="urn:linkedspls:uuid:8EC147BF-A56C-42AA-9287-D412A6568342"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:68E7E8B1-2529-456F-844F-CA5D738A8342"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:E54B7AE2-65CC-474A-9474-0EC8F30C93AB"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:C12BD5A7-F40F-4028-8B23-EB11A5B0C2FB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:84EFD47E-46AD-4992-91C3-51A9478B5B64"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FE5A4286-CE47-46D4-A546-95B7776B1A3E"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-20 18:54:32 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:86883BB8-D51E-4847-9B7D-50B082CDA3D7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6BB856A9-F8D3-4849-B8E6-4B89E8567BF7"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:287E0CDE-7EED-4D32-903B-D83C1B03208E</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:26FFBF0B-E195-48B5-AB92-712C0452D63F">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>These higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies. Advise nursing mothers to watch for signs of morphine toxicity in their infants which includes increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. Instruct nursing mothers to talk to the baby’s doctor immediately if they notice these signs and, if they cannot reach the doctor right away, to take the baby to an emergency room or call 911 (or local emergency services).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:26FFBF0B-E195-48B5-AB92-712C0452D63F"/>
    <domeo:uuid>26FFBF0B-E195-48B5-AB92-712C0452D63F</domeo:uuid>
    <ao:prefix>Advise patients that nursing mothers taking codeine can have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-20 19:15:59 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55369393-EE8A-44FA-AE5C-15E3C85D41EB">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#USE IN SPECIFIC POPULATIONS (43684-0)</poc:productLabelSection>
    <sio:SIO_000111>USE IN SPECIFIC POPULATIONS (43684-0)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8D887387-F3F3-4768-9757-1F38D8339194">
    <pav:previousVersion>urn:domeoserver:annotationset:77702DAE-17B5-4010-957C-3EBC5127E1C3</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:5CBB3B7E-876F-4964-982B-A149DA1F68B3"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:37CA3A6B-B6D5-4421-8FBC-643139576CB9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D41448E3-82D4-456C-8A6F-D9944559DD85"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:174B6D8E-BA1E-4D2C-9429-C67E22863A31"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9D951946-FEAD-49A1-BA43-647570308852"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <pav:lastSavedOn>2014-04-14 14:29:30 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:13DDC676-F835-48F3-8F51-F14D640EC90D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:1F3E892B-CDA5-4AD4-A0C4-86FFDCA51043"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2014-04-14 14:24:04 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E02FDE18-6063-4150-B30F-DFD6BEA38790"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:068A961C-4C85-4256-B4EF-CE547C6F4679"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:975B0E4D-CD6B-4EB2-A1DD-272946DFD796">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75D0BF23-D5EA-4329-91F7-28BBF30BF05D">
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:268ADDD9-94A3-46B3-B733-1A8F8A153747"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:8071FE0B-A9B2-482C-9943-6EB722950AF6"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:21DD16EE-FA7C-4344-8260-A84AEB3E29CD</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:F400B881-01F8-4222-AFD6-D3F8B092E286"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3C073DF6-1B5E-4DF7-8F70-98F8EA093887"/>
    <pav:lineageUri>urn:domeoserver:annotation:4C72ED5E-6B90-440A-8E97-1E232FC7FE6D</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:172BC00D-8382-4639-9CE8-3E3C0E0C3F09"/>
    <pav:lastSavedOn>2014-03-19 17:13:40 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B2EFE435-FABA-49D7-A275-E413E595C352"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0135FE33-C55B-48FF-B0AA-D1A2DEC61A1D"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-03-19 17:03:35 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:718A1F81-7F7D-4FE0-A98E-EE7D2655C8D9"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:6A5A3C98-AF0A-48AC-9785-FA5F3DA64368"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:44FAFCC4-E498-409C-B96D-77953D07D4DE">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:085ECEB2-432F-4BCD-9F0B-828C2694033E">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitiviy</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A3580061-C7A5-4F2D-AC04-8F8AA09751FE">
    <rdfs:label>Tamoxifen</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A407CD9D-EB51-4069-99B0-62441488DF51">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA8DA3A2-45C9-4593-B7B4-4DAB1AE50C7B">
    <dct:description>The pharmacogenomic biomarker is not associated with clinically relevant pharmacodynamic effect</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacodynamicImpact>
    <rdfs:label>Not Important</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D1777314-B777-4730-A945-CAA44C34C68D">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1DDC2DA3-6B7A-4158-A95C-3638A487A766">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:174B6D8E-BA1E-4D2C-9429-C67E22863A31">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23BCB91A-EF16-452F-A13D-DF92BF632DF1">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:E45A822D-AEB7-4D54-B405-0A4E701F3B8B"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F6C27D95-BED7-4283-A7A8-6893B2B92998"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:17BCAF59-21BC-405B-8201-7C5C5095E12E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BB62F955-624A-4D57-89E3-A845A1E0C9B2"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:642AE10F-0A86-4274-9E80-EB5E74A54D3D"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:DF39ED9A-C769-48DE-805D-1687D7C5950F"/>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E21984D9-39A1-4A90-8596-A54355C4E290"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:AE27F4C6-AD6F-4844-B21C-2142B423021B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:F3B014F9-24FC-4282-B33F-6BE7106DC3F8</pav:lineageUri>
    <pav:createdOn>2014-03-20 18:49:53 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FC8E65FD-917C-40E2-8515-76AA9E71CD0B">
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F6512FEE-BDC6-477E-9110-59CB3E6DA941">
    <pav:createdOn>2014-03-20 19:15:03 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:65B50CBD-A4E7-4462-B0FB-4CDC9240613D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B6293EBB-548E-4526-9A1C-8052838F775F"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6440899A-1A6E-407B-A3E2-1F5A8038B9B3"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B2CCECE-9EC1-44D5-B80E-9A833BEEE5C3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E820684B-9D57-4B4D-A73A-D4931EC2BD28"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:E9C13579-71B7-4CE0-B4B3-004DD38AB73A"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:0D41A164-99DC-4BF6-8EEE-F57FB1B2A9AF"/>
    <pav:lineageUri>urn:domeoserver:annotation:9039B309-0565-4B24-8771-AF9A6F12D699</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4D1AD809-0CDA-48D6-A56C-5764FD5EA9DC"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E4FD57AA-5888-43AA-A881-4C6E34CAAAFA">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EEC9B89B-643D-424F-AC6B-841381243C1D">
    <domeo:uuid>EEC9B89B-643D-424F-AC6B-841381243C1D</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Death associated with pancytopenia has been reported in patients with absent TPMT activity receiving azathioprine.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EEC9B89B-643D-424F-AC6B-841381243C1D"/>
    <pav:createdOn>2014-03-19 16:04:36 -0400</pav:createdOn>
    <ao:prefix>PRECAUTIONS: Laboratory Tests ). </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A7F1A289-67EB-4DA5-866B-6AD0BF2EDE18">
    <domeo:uuid>A7F1A289-67EB-4DA5-866B-6AD0BF2EDE18</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A7F1A289-67EB-4DA5-866B-6AD0BF2EDE18"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Respiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-03-20 18:47:19 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86638828-3118-4DFB-8090-100B156FE8CF">
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:68B74CAD-61BE-446C-965A-9121CF4D874F">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3B983561-19E5-459C-847C-1CF1D4B9CED4">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:84DB2E2F-3B1E-478C-8BE4-8B29EF42F52C">
    <ao:exact>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-19 14:31:27 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:84DB2E2F-3B1E-478C-8BE4-8B29EF42F52C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> (5.1)</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E20AB0C9-9DE7-4111-BE3C-1EAE90E85BAC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED">
    <ao:item rdf:resource="urn:domeoclient:uuid:DB7B1A47-6A4E-495B-9486-581B1FD967CB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E71FE8C7-6F4E-4994-89E6-4CD04DCB3739"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E001988C-65C5-466E-8290-5CD2EA3F6252"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:464DE32B-0AC3-41E4-AF18-D97ACF984784"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3F2727A3-91B7-46DF-86FA-3003491BC820"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5270F8BA-EAC7-4C56-9B5D-8DCBA0419674"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C710F5D3-69C0-42C9-99BB-26C9B724250E"/>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:0F83DE8E-56B0-4A8B-8436-9900AB37E71F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:28FB9894-294D-4AF9-9A23-72B6607DF835"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:309F99D7-D68C-4BDF-BAF0-CBD35C2C992A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AE29FADF-5969-4BB7-B98E-DF8FBE87A54B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BBD155D7-A4D5-419B-A076-59199B650705"/>
    <pav:lineageUri>urn:domeoserver:annotationset:E3E24248-8D5C-4FC4-9FC6-B263EF37E2D8</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:EE66F905-19CC-45FA-95EA-E201611DC028"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <permissions:permissions rdf:nodeID="N22e59f4c03194ae5987f6b4e01b67814"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896e94ef0008"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D5F11F6B-7CAC-4FC3-811F-9D17899FDE76"/>
    <pav:createdOn>2014-03-20 22:07:58 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:227BA78D-A810-46CD-BDC6-11E6B431B582"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:96393F2F-EC36-4589-94C4-DC6DFCB2312B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:888C0059-0DB0-4480-BA73-5C9EE986AF67"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8D82EE50-C8EC-4407-BCEB-862623BE43F2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:059A9475-981D-45CC-90D3-8423D4048B6E"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:DABA53EA-77F0-4679-9064-7C6B291E66FF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CF98706C-A5C4-4C91-B4DA-6F434307A706"/>
    <rdfs:label>Default Set</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:768FB537-C83F-4098-9460-4F159200346A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8CDBF9B4-EDB3-42AF-B230-AB55E8DF4770"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:12304022-DDB7-4CAD-AC8D-C36E675AE299">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6440899A-1A6E-407B-A3E2-1F5A8038B9B3">
    <domeo:uuid>6440899A-1A6E-407B-A3E2-1F5A8038B9B3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6440899A-1A6E-407B-A3E2-1F5A8038B9B3"/>
    <ao:exact>Advise patients that nursing mothers taking codeine can have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. These higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:suffix>. Advise nursing mothers to watch for signs of morphine toxicity in their infants which includes increased sleepiness (more than usual), difficulty breastfeeding, breathing difficulties, or limpness. Instruct nursing mothers to talk to the baby’s doctor </ao:suffix>
    <pav:createdOn>2014-03-20 19:15:03 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8F13F4CF-9694-4090-AAFE-A3962211B89E">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A47EAFF1-DDE8-4DB0-AFAB-BC566DDEF27E">
    <rdfs:label>Azathioprine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C8B0641D-5EF7-4993-B856-B3F1D88A7986">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A169662F-4C0C-4255-91CA-78FAD9A63123">
    <rdfs:label>Citalopram</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:87650245-E4B7-4482-A532-2162F9407D34">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A07E8945-D86E-4589-AB9F-776A7460CB34">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3788A0F0-64AC-42E0-8B16-BEC05E7A37C9">
    <ao:context rdf:resource="urn:domeoclient:uuid:814368D4-EF69-4CA0-BEDA-9D499407BAE0"/>
    <pav:lineageUri>urn:domeoserver:annotation:2ACE7AFE-9D76-41E4-AE6E-9AB346230E5B</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6FBAFF2A-C87D-4FFE-AFF2-DFA06BF3D938"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:14CE3D92-9CA1-4893-9254-13BF408A5068"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:6A4988F2-7E09-497A-9ECA-1A02D3854480"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6D42686C-E032-4A10-8268-4DB590BD0613"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:57BF6DD7-6AB9-47A2-A320-1AC06DB218C5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C84FC6E2-EF57-4825-9413-13B8F0211063"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7BC1A0B2-5D63-4652-B43A-5AF52D4C0F83"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BD4157B4-A052-45E8-B62F-F1A812E8C7AB"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdOn>2014-03-20 19:13:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6875E169-0EA6-4711-B3BC-69FB556F838B">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6C6AC11B-0C8B-4AD2-AF50-A5C1E71CA0AA">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E64D1BEE-DB99-42E4-87F5-B2748A80B7AD">
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0071CFBB-57EB-4CCD-9932-E6D4379EE341">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:2A602B2F-02AB-4E05-A03D-F79B1D47EC2E"/>
    <pav:lineageUri>urn:domeoserver:annotation:2B07DB96-0BCC-43DB-A28F-98C7C8F0287E</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:5DF37C5A-7DC6-44A5-A8C2-DE1C228509F0"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:6A42E3A3-BDCF-4094-930E-A318AB2A67DA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA3C4B11-6B7D-45F0-93B8-31BF707209C7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-19 14:56:04 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:2C4F78DC-61B5-43D1-A36B-DA50320D1595"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4B00053F-C116-4276-B0F7-90AB868A7550"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C39C1F18-36AB-468E-914F-356DB58806F4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:75240CD0-BE1C-4707-BD6B-478E05C4467B"/>
    <pav:lastSavedOn>2014-03-19 15:09:38 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9B40E5C5-3CFB-4714-A088-BF9949C167E9">
    <rdfs:label>CYP2C9</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:36E6A7B0-2575-4B2E-AEF8-98AD2F7F42FE">
    <pav:createdOn>2014-03-20 18:56:53 -0400</pav:createdOn>
    <domeo:uuid>36E6A7B0-2575-4B2E-AEF8-98AD2F7F42FE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Some individuals may be ultra-rapid metabolizers because of a specific CYP2D6 genotype (gene duplications denoted as *1/*1xN or *1/*2xN). The prevalence of this CYP2D6 phenotype varies widely and has been estimated at 0.5 to 1% in Chinese and Japanese, 0.5 to 1% in Hispanics, 1 to 10% in Caucasians, 3% in African Americans, and 16 to 28% in North Africans, Ethiopians, and Arabs. Data are not available for other ethnic groups.</ao:exact>
    <ao:suffix> These individuals convert codeine into its active metabolite, morphine, more rapidly and completely than other people. This rapid conversion results in higher than expected serum morphine levels. Even at labeled dosage regimens, individuals who are ultr</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:36E6A7B0-2575-4B2E-AEF8-98AD2F7F42FE"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5B9CE094-EF08-4EB5-9ABA-F60BEE4812A3">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB450397-838F-4918-A73F-B6CB95A87A1C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:111CEACC-F91E-446D-B3FC-B76210CDB7AF">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MECHANISM OF ACTION (43679-0)</poc:productLabelSection>
    <sio:SIO_000111>MECHANISM OF ACTION (43679-0)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:38D8DE2E-C3F7-4183-A814-38D09BF25F4A">
    <rdfs:label>Carbamazepine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:975882E7-9E51-430F-8E88-FB828E01DDDB">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Not Important</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is not associated any clinically relevant pharmacokinetic with respect to the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:04F17089-EB4F-448F-A658-F68748B6A0D4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOKINETICS (43682-4)</poc:productLabelSection>
    <sio:SIO_000111>PHARMACOKINETICS (43682-4)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:61204C24-4321-40D5-A2A1-7724FE6BFB33">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2C4F78DC-61B5-43D1-A36B-DA50320D1595">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:07FEB76A-DD19-4A65-B9EB-28774DD45CE8">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>ultra-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13248F26-F2CE-4C65-BB39-3D605803B3DA">
    <ao:prefix>The citalopram dose should be limited in certain populations. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:13248F26-F2CE-4C65-BB39-3D605803B3DA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The maximum dose should be limited to 20 mg/day in patients who are CYP2C19 poor metabolizers or those patients who may be taking concomitant cimetidine or another CYP2C19 inhibitor, since higher citalopram exposures would be expected.</ao:exact>
    <ao:suffix> The maximum dose should also be limited to 20 mg/day in patients with hepatic impairment and in patients who are greater than 60 years of age because of expected higher exposures. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-19 17:25:20 -0400</pav:createdOn>
    <domeo:uuid>13248F26-F2CE-4C65-BB39-3D605803B3DA</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3B667FA8-40E7-4E2C-9B60-47819070F07C">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:456C97BA-AD85-4C4D-B482-F52F3568E94F">
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-20 19:14:04 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:343392C4-02AA-49C7-8FB6-3024CD27DF99"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CF69785D-3536-4A5E-B2D1-807B3169000F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CDE5BA77-3284-4D8A-A5E7-120368C083F6"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:5F02DE64-E4F4-4FEC-954A-8D36064F9717"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:348B2B17-CCFC-4D07-A5FB-95995E5C6D47"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:414EDB35-206D-4166-AF2C-9F3EB92FD4A7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:12A922D2-655D-4338-A8AE-D353EA98A4C7"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:FCD90C4F-99C9-4AB7-99F6-0231C9CC76A2</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:25A24201-EB9D-487D-9890-2A94BFEBFDE2">
    <pav:createdOn>2014-04-14 14:28:57 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:25A24201-EB9D-487D-9890-2A94BFEBFDE2"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid>25A24201-EB9D-487D-9890-2A94BFEBFDE2</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CDC6726D-F01E-422C-A6B9-A8E2CBA8EF72">
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:12AF3EC0-5149-462D-B594-7D4A5B58A3C0">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9b8eea6e707d45cbbb788e88f3711898">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56FBC717-C251-4B51-876F-9D9C56BF108A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:56FBC717-C251-4B51-876F-9D9C56BF108A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:exact>Some published studies suggest that intermediate metabolizers have decreased active metabolite exposure and diminished antiplatelet effects.</ao:exact>
    <pav:createdOn>2014-03-20 22:46:11 -0400</pav:createdOn>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>56FBC717-C251-4B51-876F-9D9C56BF108A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21DD16EE-FA7C-4344-8260-A84AEB3E29CD">
    <ao:item rdf:resource="urn:domeoclient:uuid:847E5DB7-F232-483C-9589-B27ADD46F1C3"/>
    <permissions:permissions rdf:nodeID="N9b8eea6e707d45cbbb788e88f3711898"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3F78835B-41A0-475E-BA87-66E2DF3543B5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7A87899C-DF27-487F-8056-D135597121C3"/>
    <pav:lineageUri>urn:domeoserver:annotationset:F770364D-CF0B-4304-B036-D05D28092F3C</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:37B35D47-83BF-45C0-9194-419BB92327E7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DEC669BD-5814-4556-84AF-453AD02F16AF"/>
    <pav:createdOn>2014-03-19 16:31:11 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B84B8305-B20A-4B3F-9282-8E038F655EE6"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:DF75D1C2-568E-434C-BCC0-87919E941465"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896e94ef0008"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:76AE2DE6-D061-490E-B6E9-FBD44DF4A906"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:75D0BF23-D5EA-4329-91F7-28BBF30BF05D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:051CE9F4-6A7F-4393-9BD7-8562144EE760"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:annotatesResource>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:75175564-C163-4DF5-AB09-CA5D7087AA39"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:54753E26-CF9E-470B-A0CF-545B6D537B9D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3D875C28-82A2-4F65-AB8F-35471B6413D0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2014-03-19 17:13:40 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:30DF004E-B63A-4FB0-A1EA-336B7DEC5787">
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:831642BA-AFB2-42BB-83BD-94A20F56AF4F">
    <ao:body rdf:resource="urn:linkedspls:uuid:F6C3F6F4-5F35-42B4-B9EE-987B9F024547"/>
    <pav:createdOn>2014-04-14 13:50:34 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:12304022-DDB7-4CAD-AC8D-C36E675AE299"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:38C9DC5F-6481-408B-BA01-E4D5615706F1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CC76684A-68AE-44B6-8B8B-E2C2F561BF9C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:10A3D618-1DE9-43B7-A29E-746D91F3084E"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:267922F0-150C-4837-AD72-3B878579D8CE"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1AFA922C-41D4-47D7-8D81-D0AC7B2BAEAB"/>
    <pav:lastSavedOn>2014-04-14 14:29:30 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:77702DAE-17B5-4010-957C-3EBC5127E1C3</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:13DDC676-F835-48F3-8F51-F14D640EC90D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:7662C575-92BB-4040-82BA-BA5F98AFA8AB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:7C4C951E-9D8E-44FF-801A-BDE9ADEE3048"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6E8C3116-4C83-460F-B4A9-FDC40A4495C9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E0107363-A1EB-491B-84DF-E54542AAA8DF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:38EFA0C1-70C0-492E-A761-1908DF799548">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-19 15:09:38 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:9A89058D-EBAD-4276-81A5-A7EE55AA0DAD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:03A365F1-7882-4439-AA6B-7328F66283DA"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-19 14:55:19 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:FAA5C863-7065-4DD5-A9C9-48444810C976"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:7EFF2058-2F99-4E70-BFA4-0B85BC4A44B0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5BC07AE5-1D49-481A-957D-90BE740895FF"/>
    <pav:lineageUri>urn:domeoserver:annotation:6E49BC70-E963-4DDC-AAB1-4E719ED53334</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:29B26F09-DDF1-4768-A4CE-2E3D10C9ACA8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:19FCCE47-6B34-402C-9399-56FD06BA444B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:72B97D5E-D7C1-456A-BBE7-ABD7DB0DC3F0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:ACD0C5E9-2198-4239-A2E5-E1B699A8AF6E"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C663D1B-B0AB-4F60-A689-EE835C935346">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:917F36A5-ED04-4F3B-8974-7FC95FDAA350"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D57D0BEE-F8FD-481D-A147-06C62753C684"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:46231A2B-0712-4D96-B7E2-610C19A1CBB5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8F632807-BF89-4B0D-97C1-9B9FA9B97580"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:525547FF-6B3E-4DA0-9B71-DA8E0BE42F59"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4DE23BEF-58E5-4064-9C4E-F3EF6C71BFB0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:A4296738-BC58-499E-9E03-DC8866FD4D10"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:41BE4F6D-2884-4FF8-994E-F9CF87FDD1B0</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2014-03-19 15:52:27 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EFE396DB-81F0-4AC0-8B87-1686C1A96C72">
    <ao:prefix>) and long duration of warfarin therapy. </ao:prefix>
    <domeo:uuid>EFE396DB-81F0-4AC0-8B87-1686C1A96C72</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Identification of risk factors for bleeding and certain genetic variations in CYP2C9 and VKORC1 in a patient may increase the need for more frequent INR monitoring and the use of lower warfarin doses</ao:exact>
    <ao:suffix> (see CLINICAL PHARMACOLOGY:</ao:suffix>
    <pav:createdOn>2014-03-20 20:28:44 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EFE396DB-81F0-4AC0-8B87-1686C1A96C72"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AFF6CA95-CE75-4F8F-B143-753BF6CD8B43">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0CC6ECD-5A08-470E-A24D-C36BFA00A465">
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E45A822D-AEB7-4D54-B405-0A4E701F3B8B">
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:042D8280-D0A4-4723-AC94-3C1C7811607B">
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6982E4BC-F901-498C-847B-315128ECB57A">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:A8D21F2E-215D-4736-9381-37B11F078479</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:2C116106-25B9-4F51-B9F4-275BAE844D6C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lastSavedOn>2014-03-20 22:01:22 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:807EA959-BCD2-4A5B-B326-7812677F173F"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D92B3265-2BD2-4471-B165-9C0BFAC0471A"/>
    <pav:createdOn>2014-03-20 21:15:14 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:5B3A7C05-9902-476C-85DF-1A73D7737071</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:A3580061-C7A5-4F2D-AC04-8F8AA09751FE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A03186E9-9F14-468D-9D74-FD873279CE9B"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:03A365F1-7882-4439-AA6B-7328F66283DA">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D0F08E66-A881-4851-9FA8-55144057E492">
    <rdfs:label>Carbamazepine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F20362F8-6662-4FC3-939F-3ECF49746AE8">
    <ao:body rdf:resource="urn:linkedspls:uuid:2E6A9AB4-9923-4B76-BAF7-A7D7AE523DE9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CB1C8141-94E6-4B3D-9C57-A646D76E3B24"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:23E053EE-42F8-472A-BA10-FF0F216B26A7"/>
    <pav:lineageUri>urn:domeoserver:annotation:9FD4AE26-3E63-49A6-8CF3-38779457EF28</pav:lineageUri>
    <pav:createdOn>2014-03-20 18:56:53 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:6C070480-01AA-492E-B72C-A2B5B1A693A1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D035860-EC07-4DDE-B01C-43C426004F86"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:36E6A7B0-2575-4B2E-AEF8-98AD2F7F42FE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BF72D2B3-0470-4308-862A-459FD083143B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:5D01E24F-EF6C-4B5D-95BD-11FBAE29CC5D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3B5C43E-64BB-4BDA-84A2-F4695C4A88EB">
    <ao:prefix>CLINICAL PHARMACOLOGY and PRECAUTIONS ). </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-20 20:38:09 -0400</pav:createdOn>
    <domeo:uuid>A3B5C43E-64BB-4BDA-84A2-F4695C4A88EB</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A3B5C43E-64BB-4BDA-84A2-F4695C4A88EB"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The patient's CYP2C9 and VKORC1 genotype information, when available, can assist in selection of the starting dose. Table 5 describes the range of stable maintenance doses observed in multiple patients having different combinations of CYP2C9 and VKORC1 gene variants. Consider these ranges in choosing the initial dose.\nIn all patients, subsequent dosage adjustments must be made based on the results of PT/INR determinations.17, 18\n\nTable 5Range of Expected Therapeutic Warfarin Doses Based on CYP2C9 and VKORC1 Genotypes*\nVKORC1CYP2C9*Ranges are derived from multiple published clinical studies. Other clinical factors (e.g., age, race, body weight, sex, concomitant medications, and comorbidities) are generally accounted for along with genotype in the ranges expressed in the Table. VKORC11639 G(rs9923231) variant is used in this table. Other co-inherited VKORC1 variants may also be important determinants of warfarin dose. Patients with CYP2C9 *1/*3, *2/*2, *2/*3 and *3/*3 may require more prolonged time (&gt;2 to 4 weeks) to achieve maximum INR effect for a given dosage regimen.*1/*1*1/*2*1/*3*2/*2*2/*3*3/*3GG5 to 7 mg5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mgAG5 to 7 mg3 to 4 mg3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mgAA3 to 4 mg3 to 4 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg0.5 to 2 mg</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E814119-6F39-4A90-9695-C4357BC61540">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:84EFD47E-46AD-4992-91C3-51A9478B5B64">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Excretion Increase</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#excretion-increase</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a increase in excretion of the drug</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DEC669BD-5814-4556-84AF-453AD02F16AF">
    <ao:context rdf:resource="urn:domeoclient:uuid:7656A536-9D48-4624-B0F8-E912B1CE145D"/>
    <pav:lastSavedOn>2014-03-19 17:13:40 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:6C6AC11B-0C8B-4AD2-AF50-A5C1E71CA0AA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:56C97B35-66FE-4232-BADA-B9032627F3AA"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:9FC53C46-B34A-4B30-9420-DE11D722FE1C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:21DD16EE-FA7C-4344-8260-A84AEB3E29CD</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-19 16:51:31 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:D5F7A60B-F3F8-4BFC-B1CB-C2155CC88088</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:D6E7684E-AD52-4896-985F-553E0FF6C3A0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E5CC1B4-0FBE-43E8-A08F-1CE5CEBDCF82"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1905F1D3-6661-404C-80A2-3303E0AFBEB7">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2D1E4C83-436F-425B-894F-D74698251674">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B72ABCA-FC47-4A17-8E1E-09457FEE9E88">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:43C2902C-8868-45FA-ABB0-3A30A3DE954D">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C1A6D1E9-7185-4973-A126-3C314015855A">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:56C97B35-66FE-4232-BADA-B9032627F3AA">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F554429E-2AF1-4FD2-817F-ACCA570855FC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DC17624C-3F5B-452A-92F0-8FECF2C76223">
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5C6E13E4-36D8-4209-A18C-8196EB971DC7">
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B14156CF-2DA9-4776-8AA8-EFBDED3D52FE">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>lactation</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A8D5151C-AD2F-44C2-B6F8-50D176982EFA">
    <pav:createdOn>2014-03-20 19:06:42 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:exact>Respiratory depression and death have occurred in children with obstructive sleep apnea who received codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). These children may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A8D5151C-AD2F-44C2-B6F8-50D176982EFA"/>
    <ao:suffix> Codeine is contraindicated for post-operative pain management in all pediatric patients undergoing tonsillectomy and/or adenoidectomy </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>A8D5151C-AD2F-44C2-B6F8-50D176982EFA</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:88A10D43-5AEF-49A4-8D15-491A2F78D4EB">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B6293EBB-548E-4526-9A1C-8052838F775F">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#excretion-increase</poc:PharmacokineticImpact>
    <rdfs:label>Excretion Increase</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a increase in excretion of the drug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E59BB935-7486-4094-8016-6B78B73AB63B">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:63666A64-8F0B-4A9C-86C1-4F786FDE1FC0">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:63666A64-8F0B-4A9C-86C1-4F786FDE1FC0"/>
    <pav:createdOn>2014-03-20 22:45:24 -0400</pav:createdOn>
    <ao:prefix>Tests are available to determine a patient’s CYP2C19 genotype.   </ao:prefix>
    <domeo:uuid>63666A64-8F0B-4A9C-86C1-4F786FDE1FC0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metabolizer groups, evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg per day and 600 mg followed by 150 mg per day, each for a total of 5 days. Decreased active metabolite exposure and diminished inhibition of platelet aggregation were observed in the poor metabolizers as compared to the other groups. When poor metabolizers received the 600 mg/150 mg regimen, active metabolite exposure and antiplatelet response were greater than with the 300 mg/75 mg regimen (see Table 3). An appropriate dose regimen for this patient population has not been established in clinical outcome trials.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:10A3D618-1DE9-43B7-A29E-746D91F3084E">
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F6C27D95-BED7-4283-A7A8-6893B2B92998">
    <ao:exact>WARNING: DEATH RELATED TO ULTRA-RAPID METABOLISM OF CODEINE TO MORPHINE\nRespiratory depression and death have occurred in children who received codeine following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine due to a CYP2D6 polymorphism.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F6C27D95-BED7-4283-A7A8-6893B2B92998"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-20 18:49:53 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <domeo:uuid>F6C27D95-BED7-4283-A7A8-6893B2B92998</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7BE97BD6-BC19-4947-8AB3-022240F6D937">
    <pav:lastSavedOn>2014-03-20 22:01:22 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B068EC60-B8C8-4AAC-B96A-D64F3E94BE01"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B84CD8FE-68DC-40CD-BB96-5CD2D1B661AC"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FC8E65FD-917C-40E2-8515-76AA9E71CD0B"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E204D49E-36BC-4D03-B5AA-D62C5CDB95AF"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:5B3A7C05-9902-476C-85DF-1A73D7737071</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-03-20 21:58:42 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:2A0EC2A2-A34C-401A-AC11-054C35219FF9</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:2CA520FF-8DAB-487D-9DC5-BDD159F714D5"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:718A1F81-7F7D-4FE0-A98E-EE7D2655C8D9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:370FC4A2-3B97-4E36-A22C-2AB668893D29">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6F87C146-25D6-4E61-B095-3CCD2F31965D">
    <ao:body rdf:resource="urn:linkedspls:uuid:668AFD12-0294-42CF-9F9E-1E8578E29EF1"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7AA7955D-C25C-40D2-91DC-39F41614113F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7218EDD3-BDC4-4270-B694-240FD138C1F2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:79C839CE-21FF-4CE1-AB0F-C9062A517CBA</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:72CD3609-EB45-4BE7-A017-0E8840F5A78C"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:738089B1-21DC-46E1-9B72-69F59723CC92"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6AB876CD-2DA8-45FE-AAB5-E10EF0D2630A"/>
    <pav:createdOn>2014-03-19 15:46:19 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:ABADA501-5B06-4F8C-A13C-76EE0D173F4B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52A65A83-BAFE-4FA8-ABB9-1CF763F24A21">
    <rdfs:label>ER_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:488A5C56-4D60-4046-8C9D-69D96FCF2E4C">
    <domeo:uuid>488A5C56-4D60-4046-8C9D-69D96FCF2E4C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:488A5C56-4D60-4046-8C9D-69D96FCF2E4C"/>
    <ao:suffix> Physicians may consider alternative therapies for patients who have low or absent TPMT activity (homozygous for non-functional alleles). Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous)</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Patients with low or absent TPMT activity are at an increased risk of developing severe, life-threatening myelotoxicity from azathioprine tablets if conventional doses are given.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <pav:createdOn>2014-03-19 16:15:11 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5A18A56F-E016-44DA-8AD6-FA3E2DD90422">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:051CE9F4-6A7F-4393-9BD7-8562144EE760">
    <ao:context rdf:resource="urn:domeoclient:uuid:0BB4BC53-F881-41BC-82BD-F5176ED69192"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:86151E98-5111-444A-8D4D-268CF8AE92B2"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:9E2DEA87-B14E-4146-B5A4-2ACDCAB5D4CB"/>
    <pav:lastSavedOn>2014-03-19 17:13:40 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:A13BCBD5-6597-4B12-B7CA-DBBE28D55288"/>
    <pav:lineageUri>urn:domeoserver:annotation:52208946-13D9-4787-B9F2-F278C0D5F6FD</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:A56BDA41-6FBB-42B1-B760-90D3207ED7E4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B0D17B5A-26D1-4856-A168-06DC94D6CDD3"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:21DD16EE-FA7C-4344-8260-A84AEB3E29CD</domeo:belongsToSet>
    <pav:createdOn>2014-03-19 17:05:35 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:DA053393-1C8E-45E7-A954-3B5EFAEB0021"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:11C8E3FD-125F-4078-9895-5BB2B0F47413"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4DD88B55-16A5-4026-A0F1-FD447FAB41B5">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:143ED0B2-1183-47E7-8FD0-6A745AE90E20">
    <rdfs:label>Azathioprine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D9D7F622-E7CE-405D-8F1B-3D694C9F1350">
    <pav:createdOn>2014-03-20 20:36:12 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:EA543A32-7699-4976-A0CD-C4ADD9B4D43C"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:1C779291-80DE-4640-BF40-012EF3D479B0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:7A232365-EBBE-4B09-ACA5-6241FB1F568F"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:FB5A7F5E-A414-4A2C-A48B-70390FCEF68D"/>
    <pav:lineageUri>urn:domeoserver:annotation:5076913B-0D1E-4985-9089-F0D6D40CD33A</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E68C8718-225C-4D4A-A225-4283D9CCC53F"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:36C1ADC1-4097-44A1-801A-59A82C0B58A5"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lastSavedOn>2014-03-20 20:40:11 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:525547FF-6B3E-4DA0-9B71-DA8E0BE42F59">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>LABORATORY TESTS (34075-2)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#LABORATORY TESTS (34075-2)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BCDA1F7F-6CEA-4FCF-ABF0-C2D16F3F4B91">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4DE26374-B1A7-4E60-A7F0-2045ACABBB4F">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:02015096-BC32-4D01-A1C4-0FABFA6BEA3D">
    <ao:body rdf:resource="urn:linkedspls:uuid:562B32AB-D232-4372-8312-4DDEB3325606"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:F471D628-31A3-49FE-A989-AA7B9EAD1D52"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9B607061-A310-4096-926A-8CD6D3A23B41"/>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:9165D130-2F21-405C-A4BC-1E9150B2A169"/>
    <pav:lineageUri>urn:domeoserver:annotation:5B657E54-6690-48B4-B478-9A6C09804960</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:B14156CF-2DA9-4776-8AA8-EFBDED3D52FE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A5DA69F3-FE26-4B23-8B10-DE4FAD465EFE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6C63E8C2-CE98-4F8A-B039-7CE26562B1EE"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <pav:createdOn>2014-03-20 19:02:36 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:80B1A553-5D75-488A-9451-0DECDEE80FCC">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACOKINETICS (43682-4)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOKINETICS (43682-4)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E1E902EF-9315-4204-BEE2-7DEB1FEEC648">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:CDC42789-15A9-4B6D-8CB6-4A27311D6443"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:4B8802E1-4B84-4A89-B293-E5C117C02DE0</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-20 22:01:22 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:E692F298-8406-43F1-B0B7-B2CDCEFE7189"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdOn>2014-03-20 21:17:47 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:F134FD27-E0FD-4202-A44B-EF9501C3826D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:13AA4D6E-A2AD-4CDF-8385-FCEFDEE8FAFA"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:5B3A7C05-9902-476C-85DF-1A73D7737071</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:406AD9C1-4916-4EBE-BDCE-B58A89D96444"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:888C0059-0DB0-4480-BA73-5C9EE986AF67">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:A17E1145-4AB0-4D2F-A1C8-F061DF949B56"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:37BF6FD0-C8C1-45D6-A2CF-2802F66916C5"/>
    <pav:lineageUri>urn:domeoserver:annotation:73420F47-9677-4FB2-8F19-3A67321F585F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:04640639-1F09-4703-BD8D-DDE324CB5CC6"/>
    <pav:createdOn>2014-03-20 22:30:05 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:97BD4CBF-0F7A-4B5C-B742-9B5922081427"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:21A9E2FE-10C9-4D49-9D70-47D6B83F6BC8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:399C64BA-4B01-4E80-B680-B32F7D76D2EB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E7A8CFAA-6C0D-47D3-AFB5-E3B47ECE2B68">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1F088F02-171F-42E6-8931-69F5EC5DF809">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:51B988E7-A8D7-443D-887C-1936AF43CA77">
    <ao:exact>20 mg/day is the maximum recommended dose for patients who are greater than 60 years of age, patients with hepatic impairment, and for CYP2C19 poor metabolizers or those patients taking cimetidine or another CYP2C19 inhibitor.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>51B988E7-A8D7-443D-887C-1936AF43CA77</domeo:uuid>
    <pav:createdOn>2014-03-19 17:42:52 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:51B988E7-A8D7-443D-887C-1936AF43CA77"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CITALOPRAM-16bda7b5-a5a5-4478-9df3-beb396bd677f.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> (see </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AD7743D9-096E-4D1E-83A2-682326657AEF">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77F66199-92F3-48F4-A384-9428CD969009">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:274437C4-DBA4-47A5-B351-0CFF6F55443B">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F06F1104-C4A2-49B6-A9CA-457753888C50">
    <rdfs:label>Citalopram</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16C8E827-DCF4-4847-9720-20A316160CAD">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>DOSAGE AND ADMINISTRATION : Laboratory control ). </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16C8E827-DCF4-4847-9720-20A316160CAD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <domeo:uuid>16C8E827-DCF4-4847-9720-20A316160CAD</domeo:uuid>
    <ao:exact>Numerous factors, alone or in combination, including changes in diet, medications, botanicals and genetic variations in the CYP2C9 and VKORC1 enzymes (seeCLINICAL PHARMACOLOGY,Pharmacogenomics) may influence the response of the patient to warfarin.</ao:exact>
    <pav:createdOn>2014-03-20 20:17:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E820684B-9D57-4B4D-A73A-D4931EC2BD28">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E523D50-2BD4-4E5F-B9E1-C7C72F464990">
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:24A4AB19-56D9-4F4E-BB6D-ADFC1BD34080">
    <rdfs:label>Tamoxifen</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5217D8E8-8873-4079-9259-5A816D82124A">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdfs:label>Clopidogrel</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:70F70517-9BF8-4F58-80D7-69E0A3B8B6C5">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0041B636-EF47-4624-8FBF-2D8D460F68A1">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D82616FF-F1E3-4588-B77D-A0700BBCF108">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E87AEBD-C936-4B6D-B590-6027FE7629A5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D0AFD7D1-C7EC-43E6-B600-C3B8DFF8BC0F">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA0753D5-7FF1-475C-BBBD-AFB1463982F2">
    <ao:suffix>Symptoms may include:</ao:suffix>
    <ao:prefix>These serious skin reactions are more likely to happen within the first four months of Carbamazepine Extended-Release Capsules treatment but may occur at later times.  These reactions can happen in anyone, but are more likely in people of Asian descent. </ao:prefix>
    <domeo:uuid>CA0753D5-7FF1-475C-BBBD-AFB1463982F2</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-19 17:12:18 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CA0753D5-7FF1-475C-BBBD-AFB1463982F2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>If you are of Asian descent you may need a genetic blood test before you take Carbamazepine Extended-Release Capsules to see if you are at a higher risk for serious skin reactions with this medicine. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EBB10675-34D8-4A43-8109-97337AEB25AF">
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E54B7AE2-65CC-474A-9474-0EC8F30C93AB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F83DE8E-56B0-4A8B-8436-9900AB37E71F">
    <ao:body rdf:resource="urn:linkedspls:uuid:4C019E08-FDDB-44A4-827F-E8B96A8743B4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:144AB067-995B-44BE-BF17-08B8597C8092"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E7F9B66C-EC4C-4447-ACA9-A22AFBDD7206"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:8723B05B-A9E1-4639-B855-00F252E0878C"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdOn>2014-03-20 22:41:59 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:68B74CAD-61BE-446C-965A-9121CF4D874F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:520CA0FA-D19C-40AA-A90B-D7F11AD8D1B2</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ECA57656-0536-490E-955F-FEB7DCA6DEF0">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PRECAUTIONS (42232-9)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PRECAUTIONS (42232-9)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B5AD8E6-E2B4-46FC-99AC-4DBE87305E50">
    <ao:exact>The HLA-B*1502 allele has not been found to predict risk of less severe adverse cutaneous reactions from carbamazepine, such as anticonvulsant hypersensitivity syndrome or non-serious rash (maculopapular eruption [MPE]).</ao:exact>
    <domeo:uuid>7B5AD8E6-E2B4-46FC-99AC-4DBE87305E50</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>Over 90% of carbamazepine treated patients who will experience SJS/TEN have this reaction within the first few months of treatment. This information may be taken into consideration in determining the need for screening of genetically at-risk patients currently on Carbamazepine Extended-Release Capsules. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7B5AD8E6-E2B4-46FC-99AC-4DBE87305E50"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-19 17:01:09 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D41448E3-82D4-456C-8A6F-D9944559DD85">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A81D290A-F33A-4C41-AB78-B3D2EE0BFE51">
    <rdfs:label>Azathioprine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:72CD3609-EB45-4BE7-A017-0E8840F5A78C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N544fac4adede4133ba2aec3ba6a6b846">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF72D2B3-0470-4308-862A-459FD083143B">
    <rdfs:label>Metabolism Increase</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:134676FD-D77B-4168-89F4-5B90E0DB8E5D">
    <ao:suffix> In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>The relationship between CYP2C19 genotype and clopidogrel bisulfate treatment outcome was evaluated in retrospective analyses of clopidogrel bisulfate-treated subjects in CHARISMA (n=2428) and TRITON-TIMI 38 (n=1477), and in several published cohort studies. In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolizers.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:134676FD-D77B-4168-89F4-5B90E0DB8E5D"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <pav:createdOn>2014-03-20 22:49:57 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>134676FD-D77B-4168-89F4-5B90E0DB8E5D</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B02C332C-3C59-4BBA-B444-05ACCC3ACFED">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D14FC746-3F6A-4E55-9F96-4E22C6CABA23"/>
    <pav:lastSavedOn>2014-04-14 14:29:30 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:8E857264-3015-4517-8025-FC549049A8C6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4A4AB16B-1B3D-419F-9593-65CD7E99748F"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E251F8E1-C292-4633-B60C-A011B458874C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:13DDC676-F835-48F3-8F51-F14D640EC90D</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:77702DAE-17B5-4010-957C-3EBC5127E1C3</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:15D65839-A53D-4735-B711-A3288B1C37A5"/>
    <pav:createdOn>2014-04-14 14:20:48 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:C5DE0C66-0DB1-4801-BB15-10B7AC5C4B36"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EB922C3B-B19C-4E73-93B4-C1EA9B2578D4"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:C4F7EF34-16EC-444F-8EC0-25496D966989"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1CB76367-170A-4454-908D-5B114277C285"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0AEF77FA-96B6-4AF1-9C46-DE8DEDD82590">
    <pav:lastSavedOn>2014-03-19 17:45:50 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:5CEF4B5F-B6B3-4C9F-BB4A-36AD8365FA6F"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:A169662F-4C0C-4255-91CA-78FAD9A63123"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3A7EF0C3-B14A-4D3F-BA67-2B6E71AE4577"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:13248F26-F2CE-4C65-BB39-3D605803B3DA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C96DFCF4-B0B5-411A-AFDD-65D2AF3ABDA3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E4FD57AA-5888-43AA-A881-4C6E34CAAAFA"/>
    <pav:createdOn>2014-03-19 17:25:20 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:49190F98-EB06-4A32-9340-5356EE1B85B9</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:C6C694AB-464C-4C23-BDD3-B878E059ED09</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E50A73B-9509-42A1-A8A3-16D898A5146C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EC33851C-7A20-4EE4-A17C-405C15941404">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9D8FCB5B-C705-4983-8ECE-0DC4D2DDBE8E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>*2, *3A, *3C</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E759DEDB-032A-42D8-A570-A39875F7E5AD">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F2314090-70D9-4C6F-A607-F132BEB66275">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AE4F92D8-FEA4-4B14-97CA-1F03130C26F5">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AE4F92D8-FEA4-4B14-97CA-1F03130C26F5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>In women aged 60 to 70 years, there was a trend toward a beneficial effect of tamoxifen without any clear relationship to estrogen- or progesterone-receptor status.</ao:suffix>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In the NSABP B-09 study in women age 50 to 59 years, only women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estrogen- and progesterone-receptor levels less than 10 fmol. </ao:exact>
    <pav:createdOn>2014-03-20 21:19:00 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <domeo:uuid>AE4F92D8-FEA4-4B14-97CA-1F03130C26F5</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1AC11904-C8D2-4A4F-BA0E-1FD807187A70">
    <ao:body rdf:resource="urn:linkedspls:uuid:5B898CA8-06CF-4BC5-A5CE-22DD70C9926F"/>
    <pav:lineageUri>urn:domeoserver:annotation:79BAE810-055A-4D80-91AB-908511801B19</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:B10A7A17-4E70-4111-BF93-B06639793C58"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:61204C24-4321-40D5-A2A1-7724FE6BFB33"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:49190F98-EB06-4A32-9340-5356EE1B85B9</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:05876B0E-1AED-42F3-861C-BC3C9D098451"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1FAB4375-A7DA-4C51-8154-B457F9FE858A"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:975882E7-9E51-430F-8E88-FB828E01DDDB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-03-19 17:22:16 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-19 17:45:50 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CDE5BA77-3284-4D8A-A5E7-120368C083F6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:35C2D07D-C264-4CB5-89B8-6F3E94E24465">
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F1EDE4F8-4A2C-4149-A8A2-B73AB772FB2E">
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:7BF39C6E-9E74-45B6-8360-C61C71489C66</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:B753CDD1-D145-4047-BFFA-9C8883FE3B21"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E3DE94EC-6351-493E-A771-C49FA6868128"/>
    <pav:createdOn>2014-03-20 18:48:34 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E87AEBD-C936-4B6D-B590-6027FE7629A5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:CB123277-1091-420D-8CBE-9A559F8DE5FD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E59BB935-7486-4094-8016-6B78B73AB63B"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:A6B8C5E4-B65B-42D2-92C1-6E13D63CD586"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3BD796FE-2AFC-4D99-826F-91329C46BFD8"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:3F502466-0B17-4A5B-A2F2-E415808690A0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB62F955-624A-4D57-89E3-A845A1E0C9B2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6D42686C-E032-4A10-8268-4DB590BD0613">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3F502466-0B17-4A5B-A2F2-E415808690A0">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86660018-204F-46DD-8151-FDA019715902">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01238</dailymed:pharmgxDrug>
    <rdfs:label>Aripiprazole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF0A819E-CE05-4A94-AD95-1F9019D8E061">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:FD2CDD01-8EEB-4842-9F2B-CDECA35F97D4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:67789CF4-92A0-4DFE-B8E1-E760689FB691"/>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A7F1A289-67EB-4DA5-866B-6AD0BF2EDE18"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-03-20 18:47:19 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:8BBFDA4C-F86F-49C1-A0CA-1389579B4ABE"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:7DEBBDAD-F4DB-450F-A395-A296EB54D545"/>
    <pav:lineageUri>urn:domeoserver:annotation:1303FC3D-45AC-4B7E-BB9E-C602DA5C28B0</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:4C367B21-F0B7-4204-89B3-D2618F7E1351"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:07FEB76A-DD19-4A65-B9EB-28774DD45CE8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2E9A6622-EB8C-4043-9C3A-C957738EEAFA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C1738AC0-4097-4AA4-860C-E84948776EB8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>respiratory depression, death</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:904FEF36-1C9C-48B8-B905-AFEF7485F6FE">
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>ER_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3078509C-1D14-4C4F-A370-C79590D53AE3">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#LABORATORY TESTS (34075-2)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>LABORATORY TESTS (34075-2)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A550D1FF-C849-4071-8505-6521E13346EE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOKINETICS (43682-4)</poc:productLabelSection>
    <sio:SIO_000111>PHARMACOKINETICS (43682-4)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5F14DDDE-5746-4056-B0EB-0730B9877BAF">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B0D17B5A-26D1-4856-A168-06DC94D6CDD3">
    <rdfs:label>Carbamazepine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:38479107-6F0D-4BAB-B37C-E0DB18985DBB">
    <poc:MedicalCondition>high INR</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C5DE0C66-0DB1-4801-BB15-10B7AC5C4B36">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B36FC230-23E3-414F-83AF-3187711E4DC4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75175564-C163-4DF5-AB09-CA5D7087AA39">
    <ao:body rdf:resource="urn:linkedspls:uuid:F6DBB891-633E-4CA5-BBED-47EEE93F23BB"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:A43B5A83-65F2-41A5-AC1A-B3D84E6EFB34</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:F427B10D-DCD0-4581-A634-BD506C0FB5FE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F57D1287-65BD-4DBE-BD3E-C09A3D946ADD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CA8DA3A2-45C9-4593-B7B4-4DAB1AE50C7B"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lastSavedOn>2014-03-19 17:13:40 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-03-19 17:01:09 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:21DD16EE-FA7C-4344-8260-A84AEB3E29CD</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:E734BCF1-1BFA-46A3-A518-2D55813C1447"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7B5AD8E6-E2B4-46FC-99AC-4DBE87305E50"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3F404EB0-8907-4375-A4CE-302469F6CE01"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B1BB96BB-6FAE-4D26-A388-29434E105251">
    <domeo:uuid>B1BB96BB-6FAE-4D26-A388-29434E105251</domeo:uuid>
    <ao:prefix>One of the pathways for inactivation of azathioprine is inhibited by allopurinol. </ao:prefix>
    <ao:exact>Patients receiving azathioprine tablets and allopurinol concomitantly should have a dose reduction of azathioprine tablets, to approximately ⅓ to ¼ the usual dose. It is recommended that a further dose reduction or alternative therapies be considered for patients with low or absent TPMT activity receiving azathioprine tablets and allopurinol because both TPMT and XO inactivation pathways are affected</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-19 16:01:20 -0400</pav:createdOn>
    <ao:suffix> (see </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B1BB96BB-6FAE-4D26-A388-29434E105251"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DF39ED9A-C769-48DE-805D-1687D7C5950F">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0CD9201-E82C-44F3-A548-518FCB0F8EF9">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A55C5F9D-CE0B-400C-8014-0AAA5D450CBF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A55C5F9D-CE0B-400C-8014-0AAA5D450CBF"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <domeo:uuid>A55C5F9D-CE0B-400C-8014-0AAA5D450CBF</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and *3 alleles are nonfunctional. </ao:exact>
    <pav:createdOn>2014-03-20 22:38:41 -0400</pav:createdOn>
    <ao:suffix> CYP2C19*2 and *3 account for the majority of reduced function alleles in white (85%) and Asian (99%) poor metabolizers. Other alleles associated with absent or reduced metabolism are less frequent, and include, but are not limited to, CYP2C19*4, *5, *6,</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C6DD3001-916E-424F-B04E-B44658253B7C">
    <ao:body rdf:resource="urn:linkedspls:uuid:959C7BF5-A36B-47E0-B303-34232C155773"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D1D8DA5E-E9CC-4D40-8F1A-0F9C8E871003"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:51B988E7-A8D7-443D-887C-1936AF43CA77"/>
    <pav:lastSavedOn>2014-03-19 17:45:50 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:EDA7E7F1-638D-446C-815A-A90FB639C9E4</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:E43FD4CC-CBBF-44A2-A48A-025056BC8821"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:49190F98-EB06-4A32-9340-5356EE1B85B9</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-19 17:42:52 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EFC93F78-DB18-4BB9-B9A7-9921E94DF61B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:659097F0-CA95-4E11-87F3-B628FE3AB2F6"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2B9C984E-CEDF-4811-80A1-F75F94A333FA">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:411E83BB-2A2D-48B3-9CC1-26FC791C1671">
    <ao:body rdf:resource="urn:linkedspls:uuid:BBEF447E-89DE-4835-87B5-04584A17642B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:143ED0B2-1183-47E7-8FD0-6A745AE90E20"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:4684CF8D-CAC9-40FB-A861-90DF5934EEC8"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C8B0641D-5EF7-4993-B856-B3F1D88A7986"/>
    <pav:lineageUri>urn:domeoserver:annotation:041312A4-557D-4ECF-B99A-420614CE95DA</pav:lineageUri>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A538A4E-C356-4731-A0D9-9E5B753194CE"/>
    <pav:createdOn>2014-03-19 15:39:24 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:7045985B-8325-48BE-BBA1-23BBE98F773A"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:87FA6A3B-13A4-46BB-8108-F72177F44C54"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:584E2975-B2BA-492A-8D6E-0060FC808B81">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:584E2975-B2BA-492A-8D6E-0060FC808B81"/>
    <pav:createdOn>2014-03-20 20:09:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>K cycle, through inhibition of vitamin K epoxide reductase (VKOR), a multiprotein enzyme complex. Certain single nucleotide polymorphisms in the VKORC1 gene (especially the -1639G&gt;A allele) have been associated with lower dose requirements for warfarin. </ao:prefix>
    <ao:exact>In 201 Caucasian patients treated with stable warfarin doses, genetic variations in the VKORC1 gene were associated with lower warfarin doses. In this study, about 30% of the variance in warfarin dose could be attributed to variations in the VKORC1 gene alone; about 40% of the variance in warfarin dose could be attributed to variations in VKORC1 and CYP2C9 genes combined.5 About 55% of the variability in warfarin dose could be explained by the combination of VKORC1 and CYP2C9 genotypes, age, height, body weight, interacting drugs, and indication for warfarin therapy in Caucasian patients.5 Similar observations have been reported in Asian patients.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>584E2975-B2BA-492A-8D6E-0060FC808B81</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8DA0EAB4-1460-4BAD-9318-332AEE052E6F">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C510443C-5D39-4984-92B1-66C651D763F8">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:562C7374-8D06-4E84-B627-A2DD4C8724F2">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:23DA55C9-D21B-497B-BB23-1A122F42DB5E">
    <rdfs:label>Recommended</rdfs:label>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FBDB937C-1ECC-43F6-AD77-306885A170D2">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76AE2DE6-D061-490E-B6E9-FBD44DF4A906">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:C37509E1-0CB4-4187-B773-4A68A2655640"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoclient:uuid:21DD16EE-FA7C-4344-8260-A84AEB3E29CD</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B00C133-7878-488F-8C2B-482585068503"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0041B636-EF47-4624-8FBF-2D8D460F68A1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6DFCB39D-C974-4B20-9F50-2D30EB5F23C7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:34E7D630-3B35-43B0-AF03-327F9936EEF5"/>
    <pav:lastSavedOn>2014-03-19 17:13:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:629D59DB-5FBD-44FB-ADB8-71BCFC6E8EB9</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdOn>2014-03-19 17:08:03 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:63B2C21B-611C-40CD-8C4D-2F089E0D457B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6F81C705-D6E2-49D1-9733-D5F9B9AB13D9">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0C05564D-3B4C-4092-96DF-C85D9DA3D12D">
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4C55291A-ABA6-436F-B897-73BC705396A2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6AB876CD-2DA8-45FE-AAB5-E10EF0D2630A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:80169097-6751-4C6C-911B-B7D60C8CC2AC">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D285AB3-7273-4A95-A578-5A4DA7E750FB">
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#increase-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to increase the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Increase from baseline</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0F59389-90C3-4613-B2D4-FDBCEA6672F4">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D75DFCB7-9EDF-433A-A085-7AEB57EA4738">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:4C7833FE-E5E1-40BD-826D-BA9CEA48B474"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C42FD849-B54A-449A-8C00-5C53DB675D83"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:330AA821-EF93-4F3F-B17D-E252A0FA4E2E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:286B6F87-0802-488E-ACF0-99D5D33DA185"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0835671D-6203-4CA8-A147-428ECC753391"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B1F7DBB8-550E-46FD-9327-2344FC5C3CF4"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3092E8A1-2F97-4A8C-9DA0-646015CDCAF4"/>
    <pav:createdOn>2014-04-14 13:46:18 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:77702DAE-17B5-4010-957C-3EBC5127E1C3</pav:previousVersion>
    <pav:lastSavedOn>2014-04-14 14:29:30 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:2CE2C5DF-B221-4257-9366-793880469BB9"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:DBCE382C-A0BC-45A4-B295-40A72AA17EFA"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:13DDC676-F835-48F3-8F51-F14D640EC90D</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6F6B2D02-8BBC-419F-9821-E6FBB9339357">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E43FD4CC-CBBF-44A2-A48A-025056BC8821">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D33813B-065B-4E5C-B61B-1395C3854AAD">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Before starting ZIAGEN, tell your doctor about all of your medical conditions, including if you:\nhave been tested and know whether or not you have a particular gene variation called HLA-B*5701.</ao:exact>
    <ao:prefix>have a liver that does not function properly. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-19 15:02:47 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1D33813B-065B-4E5C-B61B-1395C3854AAD"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:53DDCB7D-A534-4685-9A88-72F9D60B1D79">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D72742CB-6E6A-4D6D-A623-22D40BC78ED8">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Use specific</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DAF496AA-6469-45CE-9F26-E5D4567B24A6">
    <dct:description>The pharmacogenomic biomarker is not associated with clinically relevant pharmacodynamic effect</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacodynamicImpact>
    <rdfs:label>Not Important</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:47B35D46-09E7-4CF4-A006-78B31BE7CCD4">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B1FFD629-C717-4C46-B744-8540409605AB">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2A5B7268-7A7A-4FD9-B5A5-81F7999F51A5">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B30E1265-CA89-4A74-B9B1-D97387332D21">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B4C399AF-0017-42F0-803E-494E69F18558">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F39CDDD-47C0-413D-BB06-545F83AB70BB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <domeo:uuid>7F39CDDD-47C0-413D-BB06-545F83AB70BB</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7F39CDDD-47C0-413D-BB06-545F83AB70BB"/>
    <ao:suffix>(12.5) </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-20 22:23:45 -0400</pav:createdOn>
    <ao:exact>Tests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:92402A2C-AB91-484F-9D03-27250A8159D3">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2038B1B9-B6D0-425B-A700-00834013A177">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60888F43-22F9-49A5-975F-8BD8F7B386D2">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Clopidogrel</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7BC1A0B2-5D63-4652-B43A-5AF52D4C0F83">
    <rdfs:label>Alternative Recommended</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B10A7A17-4E70-4111-BF93-B06639793C58">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Citalopram</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:54753E26-CF9E-470B-A0CF-545B6D537B9D">
    <pav:lastSavedOn>2014-03-19 17:13:40 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:BEEA6941-40F7-430F-85E4-1D1860A227BF"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:B30E1265-CA89-4A74-B9B1-D97387332D21"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:84E7042D-771B-40E7-AECF-02BAA9A5E8B4"/>
    <pav:lineageUri>urn:domeoserver:annotation:6192B8DE-2E9B-4EB3-A2A9-866846D1940E</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:B8E0E60B-7D65-4C3A-8CE4-45C49E699E26"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:47CCE04A-BF55-44E9-927C-94DFD660FCAB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:355D3C19-D444-4E01-991E-60998F4C0E73"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-03-19 16:48:53 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:21DD16EE-FA7C-4344-8260-A84AEB3E29CD</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:0D4E24E7-D8E0-438C-B181-28EC31680D28"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6B5A5933-4BD0-4B40-A541-6D2F82FF0FC5">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CFBF78C8-CA07-4FEB-A6F7-6ACD860BF582">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB3D56E6-E54E-45F7-ABF8-8433482E0BEF">
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-20 22:29:03 -0400</pav:createdOn>
    <ao:exact>CYP2C19 poor metabolizer status is associated with diminished antiplatelet response to clopidogrel. Although a higher dose regimen in poor metabolizers increases antiplatelet response [see Clinical Pharmacology (12.5)], an appropriate dose regimen for this patient population has not been established.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AB3D56E6-E54E-45F7-ABF8-8433482E0BEF"/>
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <domeo:uuid>AB3D56E6-E54E-45F7-ABF8-8433482E0BEF</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:227BA78D-A810-46CD-BDC6-11E6B431B582">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-03-20 22:23:31 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:7D45C7FF-43D3-46D0-A4AC-B36A3DB1D61D"/>
    <pav:lineageUri>urn:domeoserver:annotation:909EB735-841F-4646-929D-FDA131AD5FE5</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:121CECC9-16C6-44C0-B062-D491DABD7F22"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D2FE7E01-562F-4D47-B9C6-FAA7E17EEE8A"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:906D2DEF-111F-40B8-A11B-9714274E2E9D"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C81287DE-8A8E-474C-ABD1-46DB45373A4E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1AD05FFC-8908-4A8E-9870-FC7C724C2C95"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E6A31654-265C-488E-B64A-BEEF81375401"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BBC07988-801B-4827-92EF-2E665B8075E7">
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdfs:label>ER_receptor</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B068224B-82C0-4964-AC65-7378AACB8351">
    <rdfs:label>intermediate-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA7509B9-BE8D-41BC-BD05-A33DD7051A6C">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9E73876B-10AC-409A-A828-4AB857992E20">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL STUDIES (34092-7)</poc:productLabelSection>
    <sio:SIO_000111>CLINICAL STUDIES (34092-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA8B7722-407C-4E13-B8AD-B23FDAB4C77F">
    <pav:createdOn>2014-03-20 19:06:42 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:4D916816-26E6-4394-A742-ECDCE196F2DA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:632F7249-A1AA-4717-BE8B-17672E7612AD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9DADE962-3039-4370-84F3-46F5077250A0"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:3FAE84F2-0F2F-499B-A7B6-7E43583797CB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A21C7433-3A87-4C9E-BCB4-BA91D8813366"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:D9A042CF-78F9-4448-82F2-13124D9555A4"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:E5B530C4-EC1D-48F5-B711-5C0135DBB0B6</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:7FBF44D3-9A3B-4BCC-A104-612F0214ED2A"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A8D5151C-AD2F-44C2-B6F8-50D176982EFA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5B99B41A-A06F-483A-B796-FF0AEC0CD216">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#INDICATIONS AND USAGE (34067-9)</poc:productLabelSection>
    <sio:SIO_000111>INDICATIONS AND USAGE (34067-9)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B0ADFEE-17F3-4E13-B976-84247AB7814F">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DEBF80EA-8241-48D8-8257-730A33EFEC1F">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Not Important</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is not associated with clinically relevant pharmacodynamic effect</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:423FC157-938C-41DB-A7E6-49D962EE43E3">
    <ao:body rdf:resource="urn:linkedspls:uuid:B1614A64-A7C3-4344-8AB8-564254D0DF15"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A542E6A1-C70C-4410-8E29-D648DC62169B"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:9069D351-D482-4BF4-8AA3-57AE8389B287"/>
    <pav:lineageUri>urn:domeoserver:annotation:8B33FEFA-404B-4756-9F8A-042DA34D3545</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:2F04CC4F-762C-41FF-A1CF-2142A5D5BE78"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:EEC9B89B-643D-424F-AC6B-841381243C1D"/>
    <pav:createdOn>2014-03-19 16:04:36 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:640B1775-B04F-42B9-9B68-0774955FCC87"/>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:11D183FE-EFBF-40D7-B7E9-31A55FF71D35">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6205D3D3-85CB-4157-9A8E-85DEEFC406E4">
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5BE813F9-5F5F-4492-9EDD-F0745867B9C5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0E9B5FD6-EC91-4BC5-AF81-8AB55F862322">
    <ao:body rdf:resource="urn:linkedspls:uuid:A81D290A-F33A-4C41-AB78-B3D2EE0BFE51"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:A0D58291-9E95-4BB2-A875-80E619169B9E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:35C2D07D-C264-4CB5-89B8-6F3E94E24465"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:814E8442-DCE2-4ADD-9362-74B75A8D768D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F8AA27F7-14D2-42E8-95F6-B665098D6514"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:274437C4-DBA4-47A5-B351-0CFF6F55443B"/>
    <pav:createdOn>2014-03-19 16:16:46 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:B9456D70-64E6-4683-BAD7-4CB0A469B620</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8300C6E1-442F-43F3-9412-59C34B272DE8">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FE5A4286-CE47-46D4-A546-95B7776B1A3E">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0A74FE6F-5F92-456D-AA6D-7A1F907EF1A7">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6A4988F2-7E09-497A-9ECA-1A02D3854480">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:35628CF2-F997-441C-B71C-6E3047E3E202">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:82F5062E-31A0-414E-BBFB-6F8ACED740D1">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F471D628-31A3-49FE-A989-AA7B9EAD1D52">
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4EDC9DEF-73AC-4123-8526-7D4132AF8B8D">
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:12A922D2-655D-4338-A8AE-D353EA98A4C7">
    <dct:description>The pharmacogenomic biomarker is associated with a increase in excretion of the drug</dct:description>
    <rdfs:label>Excretion Increase</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#excretion-increase</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7A232365-EBBE-4B09-ACA5-6241FB1F568F">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A81E4B42-7133-4D90-89EC-725EF963A8E9">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>*2, *3A, *3C</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BC1982C7-B09F-4EBD-B2EE-4843A4A42789">
    <domeo:uuid>BC1982C7-B09F-4EBD-B2EE-4843A4A42789</domeo:uuid>
    <pav:createdOn>2014-03-20 21:19:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> women with both estrogen- and progesterone-receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward adverse effect in women with both estrogen- and progesterone-receptor levels less than 10 fmol. </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BC1982C7-B09F-4EBD-B2EE-4843A4A42789"/>
    <ao:exact>In women aged 60 to 70 years, there was a trend toward a beneficial effect of tamoxifen without any clear relationship to estrogen- or progesterone-receptor status.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A17E1145-4AB0-4D2F-A1C8-F061DF949B56">
    <ao:suffix>Proton Pump Inhibitors Avoid c</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A17E1145-4AB0-4D2F-A1C8-F061DF949B56"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-20 22:32:23 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Clopidogrel is a prodrug. Inhibition of platelet aggregation by clopidogrel is achieved through an active metabolite. The metabolism of clopidogrel to its active metabolite can be impaired by genetic variations in CYP2C19 [see Boxed Warning] and by concomitant medications that interfere with CYP2C19.</ao:exact>
    <domeo:uuid>A17E1145-4AB0-4D2F-A1C8-F061DF949B56</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D0D80898-E33B-4022-8E8C-1079A65A4782">
    <domeo:uuid>D0D80898-E33B-4022-8E8C-1079A65A4782</domeo:uuid>
    <pav:createdOn>2014-03-19 16:19:07 -0400</pav:createdOn>
    <ao:exact>Azathioprine tablets should be administered with caution to patients having one non-functional allele (heterozygous) who are at risk for reduced TPMT activity that may lead to toxicity if conventional doses are given. Dosage reduction is recommended in patients with reduced TPMT activity</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D0D80898-E33B-4022-8E8C-1079A65A4782"/>
    <ao:prefix>. </ao:prefix>
    <ao:suffix>. Early drug discontinuation may be considered in patients with abnormal CBC results that do not respond to dose reduction.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:14CE3D92-9CA1-4893-9254-13BF408A5068">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:708591B4-F61B-476A-B315-B75ABE1E1E96">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5CEF4B5F-B6B3-4C9F-BB4A-36AD8365FA6F">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:947BE3D3-B7B3-4CF5-8AD3-E13A57F92EDB">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BEEA6941-40F7-430F-85E4-1D1860A227BF">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5270F8BA-EAC7-4C56-9B5D-8DCBA0419674">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:881D902E-9897-41F1-99ED-713026EBB9B4</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:5E523D50-2BD4-4E5F-B9E1-C7C72F464990"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6EBFDA88-B53D-40EA-B2A3-A4B3D66F4049"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:EEC4F49F-7CE6-4FC4-B310-082538226DBA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:EFD1CBA4-AE43-4A97-80B1-FDCEFB94778B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:39D1765E-4C7C-4568-AA22-98067A21B747"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:A222BC1F-1597-4155-9E31-1C20D7A5648E"/>
    <pav:createdOn>2014-03-20 22:15:05 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:47B35D46-09E7-4CF4-A006-78B31BE7CCD4"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:CDB1C167-A81B-4DF3-AEFF-433DA666D9E6"/>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E368A4BA-B700-4817-87D3-03625826549A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E368A4BA-B700-4817-87D3-03625826549A"/>
    <ao:suffix> Poor metabolizers with acute coronary syndrome or undergoing percutaneous coronary intervention treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates than do patients with normal CYP2C19 function. Tests are av</ao:suffix>
    <pav:createdOn>2014-03-20 22:23:55 -0400</pav:createdOn>
    <ao:exact>The effectiveness of clopidogrel bisulfate is dependent on its activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19 [see Warnings and Precautions (5.1)]. Clopidogrel bisulfate at recommended doses forms less of that metabolite and has a smaller effect on platelet function in patients who are CYP2C19 poor metabolizers.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <domeo:uuid>E368A4BA-B700-4817-87D3-03625826549A</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:814E8442-DCE2-4ADD-9362-74B75A8D768D">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>low-or-absent-activity</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F3EBB707-A58D-47BE-BA15-8E869B3C1408">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5070D7DE-F3EE-4B7A-B4F7-56FC944E7CCD">
    <rdfs:label>Recommended</rdfs:label>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF990637-4CBB-451A-B1CB-8B4F4D2356C1">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AF990637-4CBB-451A-B1CB-8B4F4D2356C1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES UNLESS THE BENEFIT CLEARLY OUTWEIGHS THE RISK </ao:exact>
    <ao:suffix>(SEE </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <domeo:uuid>AF990637-4CBB-451A-B1CB-8B4F4D2356C1</domeo:uuid>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-19 16:35:41 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0135FE33-C55B-48FF-B0AA-D1A2DEC61A1D">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:93260602-F817-48EA-9B73-B2503594B2F0">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A4ED175-6888-4AE9-9908-DE1F0A533EB7">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOKINETICS (43682-4)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACOKINETICS (43682-4)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E912A0F-BF34-45F1-A11D-D9ECCC6AC2DB">
    <dct:description>A recommended monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Recommended</rdfs:label>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:MonitoringRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:38C9DC5F-6481-408B-BA01-E4D5615706F1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3780F7CF-E5F2-40B4-8003-6D6860CF2526">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1AB22EA0-5F80-4945-90BC-00B104FDF449">
    <dct:description>The pharmacogenomic biomarker is associated with a increase in excretion of the drug</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#excretion-increase</poc:PharmacokineticImpact>
    <rdfs:label>Excretion Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6616F81E-9E32-4964-B665-1159F90D3792">
    <pav:lineageUri>urn:domeoserver:annotation:4DA99BBD-594F-48D3-AA3B-6DA6AC296D95</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:BEE69943-3E37-498C-866B-5107E90B6DB6"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:35CB04AA-5402-4D4E-81F2-97BBC502F27B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:5B52ABCB-7FE9-4E60-94F1-D5DB30DA6457"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-03-19 22:48:30 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:36738F6D-EF53-44BD-AD7F-C1524D4E7066"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <domeo:belongsToSet>urn:domeoclient:uuid:D4DA286E-73B7-4DA4-8095-952301ABA032</domeo:belongsToSet>
    <pav:lastSavedOn>2014-03-19 22:53:11 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:09C7AB6B-2D81-4698-9435-A87162BE3610"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A3D3C8D7-AAB7-4C87-9E7A-704CD7F9AACA">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D2C4F3D-694F-439C-AE25-E1B3A375A950">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2F04CC4F-762C-41FF-A1CF-2142A5D5BE78">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:41F02CF2-FB4F-4D83-8AB6-E4FE27855F37">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:F9EEF8DB-BC07-4A2A-854A-C3944AF34AB7">
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lastSavedOn>2014-05-05 13:25:49 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:B008075C-601D-4ABA-A13F-DADC209C4FF8</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <pav:createdOn>2014-03-19 15:26:52 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:C4125A44-1047-411C-BCBB-96E8BFAD8D73"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:DB437975-829F-4500-9C33-882424E93B6B</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>ADoherty
</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:B01F30E9-B810-44B0-89FE-485A1B0468A8"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896e94ef0008"/>
    <permissions:permissions rdf:nodeID="N7097c381d6f7496dbde3f6f7f88dcda0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99D6EA05-465E-467A-B6FD-26A96C37CA70">
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E4AF7BA8-EC06-4619-BCB2-5C85DAF8AD61">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOKINETICS (43682-4)</poc:productLabelSection>
    <sio:SIO_000111>PHARMACOKINETICS (43682-4)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E204D49E-36BC-4D03-B5AA-D62C5CDB95AF">
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9A89058D-EBAD-4276-81A5-A7EE55AA0DAD">
    <ao:prefix>Studies have shown that carriage of the HLA-B*5701 allele is associated with a significantly increased risk of a hypersensitivity reaction to abacavir. </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-19 14:55:19 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9A89058D-EBAD-4276-81A5-A7EE55AA0DAD"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:exact>CNA106030 (PREDICT-1), a randomized, double-blind study, evaluated the clinical utility of prospective HLA-B*5701 screening on the incidence of abacavir hypersensitivity reaction in abacavir-naive HIV-1-infected adults (n = 1,650). In this study, use of pre-therapy screening for the HLA-B*5701 allele and exclusion of subjects with this allele reduced the incidence of clinically suspected abacavir hypersensitivity reactions from 7.8% (66/847) to 3.4% (27/803). Based on this study, it is estimated that 61% of patients with the HLA-B*5701 allele will develop a clinically suspected hypersensitivity reaction during the course of abacavir treatment compared with 4% of patients who do not have the HLA-B*5701 allele.\nScreening for carriage of the HLA -B*5701 allele is recommended prior to initiating treatment with abacavir. Screening is also recommended prior to reinitiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir. For HLA-B*5701-positive patients, initiating or reinitiating treatment with an abacavir-containing regimen is not recommended and should be considered only with close medical supervision and under exceptional circumstances where potential benefit outweighs the risk.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:109FAE27-F5C3-4E5D-A565-40573444D2B8">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7097c381d6f7496dbde3f6f7f88dcda0">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8FEB9CC5-B9C9-440B-9DF4-33282FA9CEBC">
    <rdfs:label>Carbamazepine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A46086E-FF21-48B1-B671-934A55E76909">
    <poc:MedicalCondition>risk of bleeding</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BBD155D7-A4D5-419B-A076-59199B650705">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:1905F1D3-6661-404C-80A2-3303E0AFBEB7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:777CD777-5CBD-48B9-93A3-7991C8871E58"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:17630195-269F-4F67-8B08-1642B985FF9E"/>
    <pav:createdOn>2014-03-20 22:15:40 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7F39CDDD-47C0-413D-BB06-545F83AB70BB"/>
    <pav:lineageUri>urn:domeoserver:annotation:7B9303B1-111E-43CA-81B2-45F686DA82B8</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:C510443C-5D39-4984-92B1-66C651D763F8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2F7BDBAE-756A-482C-931B-156CF386F13B">
    <poc:MedicalCondition>risk of bleeding</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:997340C9-004B-4BA9-8E41-DCCC93877594">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8E857264-3015-4517-8025-FC549049A8C6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86F97ED0-2C1A-46D0-ADB8-AFB0FD398137">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:11C8E3FD-125F-4078-9895-5BB2B0F47413">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D0345A71-8F6C-4414-AA43-7B6F6C5DECCA">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3F2727A3-91B7-46DF-86FA-3003491BC820">
    <ao:body rdf:resource="urn:linkedspls:uuid:534E6100-5B39-4920-B728-A99BB9158F38"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:109FAE27-F5C3-4E5D-A565-40573444D2B8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:9C1C8B5A-70E8-433D-9A33-36FABEF46CE4"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:362B00C2-9799-4BC9-884C-53DA2628C782"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:41016AAF-9332-438E-A35B-94F6746112BF"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BDB90288-4764-40BA-A75F-B351262547D3"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:C023DBF2-5016-4C6E-9A87-12D7EF5B9C4F</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:06E9A7A4-188B-4FD1-9759-E93F396566E7"/>
    <pav:createdOn>2014-03-20 22:39:26 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:B36FC230-23E3-414F-83AF-3187711E4DC4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A03186E9-9F14-468D-9D74-FD873279CE9B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL STUDIES (34092-7)</poc:productLabelSection>
    <sio:SIO_000111>CLINICAL STUDIES (34092-7)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D17DEB87-4BEF-4CF3-A8DB-A059D9E41A81">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-03-19 14:45:36 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D17DEB87-4BEF-4CF3-A8DB-A059D9E41A81"/>
    <ao:exact>If the patient is of unknown HLA-B*5701 status, screening for the allele is recommended prior to reinitiation of ZIAGEN.</ao:exact>
    <ao:prefix>itivity reaction, and if reinitiation of ZIAGEN or any other abacavir-containing product is under consideration, carefully evaluate the reason for discontinuation of ZIAGEN to ensure that the patient did not have symptoms of a hypersensitivity reaction. </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EEB30041-1F0E-4377-AB3B-87C0A4BDC452">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C9</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:595B8AC5-E3D5-4E81-A0E6-A95FC4BACDD0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C86FA709-0FC4-468A-AA0F-5DD174E1DB26">
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:28DF2363-5C26-415A-854F-BC5E5EEB77C5">
    <ao:suffix> Patients carrying at least one copy of the CYP2C9*2 allele required a mean daily warfarin dose that was 17% less than the mean daily dose for patients homozygous for the CYP2C9*1 allele. For patients carrying at least one copy of the CYP2C9*3 allele, th</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>A meta-analysis of 9 qualified studies including 2775 patients (99% Caucasian) was performed to examine the clinical outcomes associated with CYP2C9 gene variants in warfarin-treated patients.3 In this meta-analysis, 3 studies assessed bleeding risks and 8 studies assessed daily dose requirements. The analysis suggested an increased bleeding risk for patients carrying either the CYP2C9*2 or CYP2C9*3 alleles.</ao:exact>
    <domeo:uuid>28DF2363-5C26-415A-854F-BC5E5EEB77C5</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-20 20:02:22 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:28DF2363-5C26-415A-854F-BC5E5EEB77C5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:38E9AC24-472D-4E6F-BD3A-301209D96170">
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AA680961-423A-43CC-956A-05167805B7F3">
    <pav:lastSavedOn>2014-03-11 17:28:08 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:B300FDFE-4BB0-4631-BE80-9623FABA6B14"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:agents rdf:resource="urn:person:uuid:080e14304488c4b70144896e94ef0008"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:9D3AA319-9C23-4A34-8153-490CB098742D"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-03-11 17:24:04 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <permissions:permissions rdf:nodeID="N544fac4adede4133ba2aec3ba6a6b846"/>
    <rdfs:label>Default Set</rdfs:label>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:A5A6BAEF-2284-4EBA-BC2B-2C236F1E1953</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB9915C0-1869-41E0-9C17-0B5A3867E70F">
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B1614A64-A7C3-4344-8AB8-564254D0DF15">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6935F08E-8BBA-4930-85D2-B5D54EEA0D24">
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1F3E892B-CDA5-4AD4-A0C4-86FFDCA51043">
    <rdfs:label>Recommend</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7B837903-CB79-4F77-9017-75910F285B45">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A9BDEBDF-56CE-4C76-93F7-5A4E57E3EC4C">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FA6FEC88-82CF-4290-8B9A-93A451707E75">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BDB90288-4764-40BA-A75F-B351262547D3">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C7C7CFB7-46C2-4C99-8550-35FC75802F77">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ABE2012B-44F0-45AF-9056-37E53CE301A4">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6EBFDA88-B53D-40EA-B2A3-A4B3D66F4049">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5CBB3B7E-876F-4964-982B-A149DA1F68B3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0FB0FD62-2FF1-4EDF-ACF0-DDCE801F9F9E">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:07018B80-896F-4037-97BD-E62570D90896">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A542E6A1-C70C-4410-8E29-D648DC62169B">
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>Death associated with pancytopenia</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:947765BA-B0F4-430E-BE23-3094A2EBE8C6">
    <domeo:uuid>947765BA-B0F4-430E-BE23-3094A2EBE8C6</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Benefit is less clear for women with ER poor breast cancer in whom the proportional reduction in recurrence was 10% (2p = 0.007) for all durations taken together, or 9% (2p = 0.02) if contralateral breast cancers are excluded. The corresponding reduction in mortality was 6% (NS). The effects of about 5 years of tamoxifen on recurrence and mortality were similar regardless of age and concurrent chemotherapy. There was no indication that doses greater than 20 mg per day were more effective.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>out 5 years of tamoxifen, the proportional reductions in mortality were 12%, 17% and 26%, respectively (trend significant at 2p &lt; 0.003). The corresponding reductions in breast cancer recurrence were 21%, 29% and 47% (trend significant at 2p &lt; 0.00001). </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:947765BA-B0F4-430E-BE23-3094A2EBE8C6"/>
    <pav:createdOn>2014-03-20 21:18:51 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE66F905-19CC-45FA-95EA-E201611DC028">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:7E1B6B9C-3BFB-4DA7-B9F5-9A83B3CD4012</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:562C7374-8D06-4E84-B627-A2DD4C8724F2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-03-20 22:45:24 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:288E9102-375C-4335-8BF9-34A4E5332C92"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:7D2C4F3D-694F-439C-AE25-E1B3A375A950"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:63666A64-8F0B-4A9C-86C1-4F786FDE1FC0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:853C9107-EDC0-4B10-8520-945B2E4CE113"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6D3142E3-C6CB-466B-AC41-14267A22DC59"/>
    <rdfs:label>SPL Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:386D05E2-9CFF-469B-B0FB-AABF67E3F139">
    <pav:createdOn>2014-03-19 15:31:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Coadministration of ABILIFY with known inhibitors of CYP2D6, such as quinidine or fluoxetine in EMs, approximately doubles aripiprazole plasma exposure, and dose adjustment is needed</ao:exact>
    <ao:suffix> </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>s have about an 80% increase in aripiprazole exposure and about a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to EMs. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:386D05E2-9CFF-469B-B0FB-AABF67E3F139"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3D4F4559-2283-409C-A0F9-08D0F189EBDA">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9C93C849-2DE0-4CBE-9D2E-DA2AB0530965">
    <rdfs:label>TPMT</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DA053393-1C8E-45E7-A954-3B5EFAEB0021">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:225D0593-0F65-4C63-95B6-E46596A47E7E">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B1C0FB9-E3F3-4EBA-ACAA-939C4A2F15D5">
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:prefix> </ao:prefix>
    <pav:createdOn>2014-03-19 16:08:24 -0400</pav:createdOn>
    <ao:exact>TPMT genotyping or phenotyping can help identify patients who are at an increased risk for developing azathioprine toxicity</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7B1C0FB9-E3F3-4EBA-ACAA-939C4A2F15D5"/>
    <domeo:uuid>7B1C0FB9-E3F3-4EBA-ACAA-939C4A2F15D5</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E5FD17E7-CB15-4DD1-AD11-B0EFC1C8D0D1">
    <sio:SIO_000111>PHARMACOKINETICS (43682-4)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOKINETICS (43682-4)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D2FC18AA-9712-4180-8420-0DA19F207ECE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:51840A8F-E4BA-4DCE-89DE-6B9833FE7C19">
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A087626-5413-403C-A734-C03C00484FD6">
    <domeo:uuid>5A087626-5413-403C-A734-C03C00484FD6</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5A087626-5413-403C-A734-C03C00484FD6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>When poor metabolizers received the 600 mg/150 mg regimen, active metabolite exposure and antiplatelet response were greater than with the 300 mg/75 mg regimen (see Table 3). An appropriate dose regimen for this patient population has not been establishe</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <ao:exact>A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metabolizer groups, evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg per day and 600 mg followed by 150 mg per day, each for a total of 5 days. Decreased active metabolite exposure and diminished inhibition of platelet aggregation were observed in the poor metabolizers as compared to the other groups. </ao:exact>
    <pav:createdOn>2014-03-20 22:44:21 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7DEA616A-43CA-4798-9823-513B1B5AD919">
    <rdfs:label>Do not start</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#do-not-start</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is not associated with any drug selection recommendation.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E13235C1-A9F7-4F57-BDCF-72938209FBCA">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#USE IN SPECIFIC POPULATIONS (43684-0)</poc:productLabelSection>
    <sio:SIO_000111>USE IN SPECIFIC POPULATIONS (43684-0)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CD7A5DE3-B966-40F9-B6DD-C4405D8D9D02">
    <rdfs:label>Warfarin</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF618930-45D6-49B6-9888-1F2A03961467">
    <domeo:uuid>AF618930-45D6-49B6-9888-1F2A03961467</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AF618930-45D6-49B6-9888-1F2A03961467"/>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-04-14 14:30:40 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:534E6100-5B39-4920-B728-A99BB9158F38">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:570FED41-B0A2-4F08-8D2E-59501A361178">
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-negative</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>gene-haplotype-negative</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58C404E3-EC75-4C0F-B9E8-658653FEA5A8">
    <pav:createdOn>2014-03-19 15:41:20 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:4CA5E677-842C-4D24-97A8-620514D87273"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0CE6C18C-1529-4219-B4D8-B35E2193D68F"/>
    <pav:lineageUri>urn:domeoserver:annotation:9D6C50DC-0FD2-4526-85A0-506C18A65F92</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:DC74E568-7776-43A7-88B6-E5B65BCA3B95"/>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:7CA2045D-B35C-48B8-B157-D840D85050A8"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:857F4EFE-0FC2-4B64-9203-9763734FF417"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:39A29CC1-E63D-49E7-95DF-8C5435A68D70"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D35B4597-1344-48A3-9073-D141AD298E55"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:36738F6D-EF53-44BD-AD7F-C1524D4E7066">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DA47A1ED-4A05-4A02-B376-308E15EAA84E">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C19</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D1EAF051-F5FD-472A-B36C-EFAA72D24733">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>intermediate-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A13BCBD5-6597-4B12-B7CA-DBBE28D55288">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E3DE94EC-6351-493E-A771-C49FA6868128">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>respiratory depression, death</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:814368D4-EF69-4CA0-BEDA-9D499407BAE0">
    <ao:prefix>ceived codeine in the post-operative period following tonsillectomy and/or adenoidectomy and had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <domeo:uuid>814368D4-EF69-4CA0-BEDA-9D499407BAE0</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:814368D4-EF69-4CA0-BEDA-9D499407BAE0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>These children may be particularly sensitive to the respiratory depressant effects of codeine that has been rapidly metabolized to morphine. Codeine is contraindicated for post-operative pain management in all pediatric patients undergoing tonsillectomy and/or adenoidectomy</ao:exact>
    <pav:createdOn>2014-03-20 19:13:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BEA86691-81E4-4B89-AD1A-4E918E43CED1">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOKINETICS (43682-4)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACOKINETICS (43682-4)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C278ABBD-DE26-4B8D-97D3-4312AD509BB0">
    <rdfs:label>Azathioprine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3A7EF0C3-B14A-4D3F-BA67-2B6E71AE4577">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A6B8C5E4-B65B-42D2-92C1-6E13D63CD586">
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Increase</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DD147F9C-BFFF-472E-A982-C4136D85B262">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>VKORC1</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F676C298-0089-445D-A9F5-0C5FE5A96A09">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2CA520FF-8DAB-487D-9DC5-BDD159F714D5">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/TAMOXIFEN-7ee3d3d2-85d1-4018-8e70-5ed8a64ae1f0.html</ao:hasSource>
    <ao:prefix>Tamoxifen citrate tablets are a prescription medicine that is like estrogen (female hormone) in some ways and different in other ways. In the breast, tamoxifen can block estrogen's effects. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-20 21:58:42 -0400</pav:createdOn>
    <domeo:uuid>2CA520FF-8DAB-487D-9DC5-BDD159F714D5</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2CA520FF-8DAB-487D-9DC5-BDD159F714D5"/>
    <ao:suffix>.</ao:suffix>
    <ao:exact>Because it does this, tamoxifen may block the growth of breast cancers that need estrogen to grow (cancers that are estrogen- or progesterone-receptor positive)</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A65064F-9472-420E-AF20-016F63E68883">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F57D1287-65BD-4DBE-BD3E-C09A3D946ADD">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:07638D4B-0972-4F15-982F-380CBCA245EF">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A509C3C1-79A4-4C5F-82C8-1785B52A5B76">
    <sio:SIO_000111>CLINICAL STUDIES (34092-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL STUDIES (34092-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E784DB61-BA27-4B3F-9EE7-1D1B27899F12">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Letrozole</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE4FB3BE-A47B-41C1-AC11-48D531C0C5F1">
    <domeo:uuid>BE4FB3BE-A47B-41C1-AC11-48D531C0C5F1</domeo:uuid>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BE4FB3BE-A47B-41C1-AC11-48D531C0C5F1"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <pav:createdOn>2014-04-14 14:31:13 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9A685D2C-0B73-4C52-A00C-D056ADF96A0C">
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:61E1822F-ACC7-4361-AF07-FFB1FB4522E1">
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:47CCE04A-BF55-44E9-927C-94DFD660FCAB">
    <poc:MedicalCondition>Toxic epidermal necrolysis, Stevens-Johnson Syndrome</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:54E68980-2A91-4156-9812-000324FF6AA6">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CD7435AE-EAF0-4D90-9338-E1766641DEA8">
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:33DFCB1C-B95D-45BD-9781-477E4B5118A1">
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1F132845-D7D5-44BD-BC30-74AA604F9AFD">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C636DDBA-45C2-45BB-99D4-0A818A94731E">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:21A9E2FE-10C9-4D49-9D70-47D6B83F6BC8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:464AED20-F655-4945-AF18-7042C0EBABEC">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86151E98-5111-444A-8D4D-268CF8AE92B2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A required monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:MonitoringRecommendation>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
    <rdfs:label>Required</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F427B10D-DCD0-4581-A634-BD506C0FB5FE">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>anticonvulsant hypersensitivity syndrome, non-serious rash</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:18611A83-6C34-4526-B84E-847C0318CF09">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5068F1DA-26C7-4793-BA0D-1AF56AC4AB6F">
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DBA5D636-95FA-4E98-99EC-6A8B826AC897">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:091D0AF1-54D0-439E-8F7E-F03DEEBD1C89">
    <domeo:uuid>091D0AF1-54D0-439E-8F7E-F03DEEBD1C89</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:091D0AF1-54D0-439E-8F7E-F03DEEBD1C89"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact> TPMT genotyping or phenotyping (red blood cell TPMT activity) can help identify patients who are at an increased risk for developing azathioprine tablets toxicity.2, 3, 7, 8, 9 Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <pav:createdOn>2014-03-19 15:42:39 -0400</pav:createdOn>
    <ao:suffix> (see</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C7B7A1F5-2837-4503-B82F-E26857CD2B90">
    <rdfs:label>Recommend</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8FD53E73-5C42-4B07-A010-9BA11B740DC3">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8071FE0B-A9B2-482C-9943-6EB722950AF6">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdfs:label>Carbamazepine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:83C90105-5813-4D15-85BB-4732B9C7B3DC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:83B1759A-375E-4EDF-BE66-3B416808B8A4">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E4A19D01-A42A-4688-9E0E-C59D62B8E9BA">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0A7AE602-7166-4012-ACBA-4BC5FB8AED95">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8FCFBC4B-2D11-4A03-B03F-702FDEA66364">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EDDC8D7C-06F1-4AB4-82D8-BB6BF3AC682A">
    <domeo:belongsToSet>urn:domeoclient:uuid:5B3A7C05-9902-476C-85DF-1A73D7737071</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:52A65A83-BAFE-4FA8-ABB9-1CF763F24A21"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:91705977-64A5-48C1-92F9-A25510FF3AB2"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:65DC62F2-954D-42E0-9CEE-DFF0AC96DA2A"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2014-03-20 21:08:22 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-20 22:01:22 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:BB55A758-0347-4AF7-BEAB-4BC902011464</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:471A7EED-7EB6-4664-99C2-ECC7326C6BA7"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2E41EF2C-18AC-4086-AAE1-5992CF6DAB7A"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB58E868-7CBD-4BB0-BF71-DABA7507AEFF">
    <pav:createdOn>2014-03-20 20:16:17 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AB58E868-7CBD-4BB0-BF71-DABA7507AEFF"/>
    <ao:prefix>). </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>AB58E868-7CBD-4BB0-BF71-DABA7507AEFF</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Numerous factors, alone or in combination, including changes in diet, medications, botanicals and genetic variations in the CYP2C9 and VKORC1 enzymes (seeCLINICAL PHARMACOLOGY,Pharmacogenomics) may influence the response of the patient to warfarin.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2FC2D65B-C101-4C01-9723-FE0D2DD18E01">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:99A6ABE1-7C62-4DE1-B04E-6FDBBD34469B">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Codeine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F02DE64-E4F4-4FEC-954A-8D36064F9717">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-20 19:14:04 -0400</pav:createdOn>
    <ao:suffix>These higher levels of morphine in breast milk may lead to life-threatening or fatal side effects in nursing babies. Advise nursing mothers to watch for signs of morphine toxicity in their infants which includes increased sleepiness (more than usual), di</ao:suffix>
    <domeo:uuid>5F02DE64-E4F4-4FEC-954A-8D36064F9717</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CODEINE-fa3ed180-298a-4f9d-9d05-15182d7218bf.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5F02DE64-E4F4-4FEC-954A-8D36064F9717"/>
    <ao:exact>Advise patients that nursing mothers taking codeine can have higher morphine levels in their breast milk if they are ultra-rapid metabolizers. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FAFDE9FE-DF29-4F7A-93AE-8511529B033F">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77CA826D-4332-410E-944B-15B9F1D6857D">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#INDICATIONS AND USAGE (34067-9)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>INDICATIONS AND USAGE (34067-9)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:837B6602-715D-4F18-A3ED-28CE066A752A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:837B6602-715D-4F18-A3ED-28CE066A752A"/>
    <domeo:uuid>837B6602-715D-4F18-A3ED-28CE066A752A</domeo:uuid>
    <ao:suffix> (see </ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-19 16:03:15 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:exact>TPMT genotyping or phenotyping can help identify patients with low or absent TPMT activity (homozygous for non-functional alleles) who are at increased risk for severe, life-threatening myelosuppression from azathioprine tablets</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C84FC6E2-EF57-4825-9413-13B8F0211063">
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:22A6FD62-21E2-42E4-B243-856567377D1C">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F15E322-D2CA-4F51-9094-89C0F1480643">
    <pav:previousVersion>urn:domeoserver:annotationset:77702DAE-17B5-4010-957C-3EBC5127E1C3</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:13DDC676-F835-48F3-8F51-F14D640EC90D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:77F66199-92F3-48F4-A384-9428CD969009"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:F44860B2-A936-4534-9F34-3CA5DCE5BADD"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:4F74761E-8714-4796-A952-DBB32E1378D1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:39F539CF-D918-4263-81D4-0E8F9E2C7BA6"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:93260602-F817-48EA-9B73-B2503594B2F0"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2014-03-19 14:38:49 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0512FEF8-51B5-4B7A-83E9-0D3F8EA92C48"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:1CF222F1-AADE-429E-BD4D-86F6B8CE7BF6"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0A3C5A93-9BF2-4BEC-8574-4DFEA6F8F7A9"/>
    <pav:lastSavedOn>2014-04-14 14:29:30 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:0A74FE6F-5F92-456D-AA6D-7A1F907EF1A7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0F75FD68-ED1E-476B-97B2-4ADFC4307BD2">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>cardiovascular events, death, myocardial infarction, stroke, stent thrombosis</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C12BD5A7-F40F-4028-8B23-EB11A5B0C2FB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F400B881-01F8-4222-AFD6-D3F8B092E286">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>Toxic Epidermal Necrosis, Stevens-Johnson Syndrome</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A9FA8158-3484-4254-A774-4ED4FB44B337">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Tamoxifen</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:37BF6FD0-C8C1-45D6-A2CF-2802F66916C5">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F9E37760-DF14-4EF7-AFA1-B814F95E946E">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48659AF4-AE22-4758-A99C-7AB7840DD2C1">
    <pav:createdOn>2014-03-19 15:51:34 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The most common non-functional alleles associated with reduced levels of TPMT activity are TPMT*2, TPMT*3A and TPMT*3C. Patients with two non-functional alleles (homozygous) have low or absent TPMT activity and those with one non-functional allele (heterozygous) have intermediate activity.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:48659AF4-AE22-4758-A99C-7AB7840DD2C1"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> Accurate phenotyping (red blood cell TPMT activity) results are not possible in patients who have received recent blood transfusions. TPMT testing may also be considered in patients with abnormal CBC results that do not respond to dose reduction. Early </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <domeo:uuid>48659AF4-AE22-4758-A99C-7AB7840DD2C1</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:393D42B6-EA22-479F-9BBD-C69B63B73A63">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:393D42B6-EA22-479F-9BBD-C69B63B73A63"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> Therapeutic doses of warfarin decrease the total amount of the active form of each vitamin K dependent clotting factor made by the liver by approximately 30% to 50%.</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>393D42B6-EA22-479F-9BBD-C69B63B73A63</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>Warfarin is thought to interfere with clotting factor synthesis by inhibition of the C1 subunit of the vitamin K epoxide reductase (VKORC1) enzyme complex, thereby reducing the regeneration of vitamin K1 epoxide. The degree of depression is dependent upon the dosage administered and, in part, by the patient's VKORC1 genotype.</ao:exact>
    <pav:createdOn>2014-03-20 20:16:36 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:62EC1291-B05D-4AD1-97C7-016291F58DDA">
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5DF37C5A-7DC6-44A5-A8C2-DE1C228509F0">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2E41EF2C-18AC-4086-AAE1-5992CF6DAB7A">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL STUDIES (34092-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>CLINICAL STUDIES (34092-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:959C282F-18BC-4D7F-B5CC-77D9B157A0C6">
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1AD05FFC-8908-4A8E-9870-FC7C724C2C95">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7045985B-8325-48BE-BBA1-23BBE98F773A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:96EF0A7A-C38D-4310-A5AD-DCA532C96A59">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:44C16CD2-5AFA-4FAB-B34B-D3D24872A619">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B77C6E10-65A5-4B74-AD37-6FA51CDE3044">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:96DEB430-2EA2-4E60-89AD-D232852FFEE5">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <rdfs:label>Alternative Recommended</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:65033D61-BB48-4B9A-90E7-A2E9978D5DA6">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4C7833FE-E5E1-40BD-826D-BA9CEA48B474">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdfs:label>HLA-B</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34710D04-23D6-4A7D-A3F3-D3F13D01D010">
    <rdfs:label>Influences Drug Response</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74A863F8-7B50-49CA-8318-E36E17B8C2AD">
    <pav:createdOn>2014-03-19 16:06:56 -0400</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:DD8496FC-857D-4CC7-B7D7-B4102EB3A560"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:41C8DD7A-65D4-4F5D-AF9A-2FE4C02CA551"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:06806261-22DA-4044-B6AD-E53187E7947D"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:317C0EA5-B0A0-4E0D-BCEC-125F7C8B8883"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C278ABBD-DE26-4B8D-97D3-4312AD509BB0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:3FBC108B-E038-4A02-BBF9-4FD4DDF1D554</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7A526AF5-A26E-4663-B3C4-F248A63D9CFA">
    <rdfs:label>Azathioprine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2B3ED51E-0FAA-492A-B6C3-EED409DA6CA1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B068EC60-B8C8-4AAC-B96A-D64F3E94BE01">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:362B00C2-9799-4BC9-884C-53DA2628C782">
    <ncit:Alleles>*2, *3</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9D951946-FEAD-49A1-BA43-647570308852">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:96900B00-F7D0-4B92-9193-B2375101EAF1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>*4, *5, *6, *7, *8</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9356452C-B0C6-4623-92D2-84FAEB4BF736">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PRECAUTIONS (42232-9)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PRECAUTIONS (42232-9)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:656B8A7B-3ECD-464A-B060-D14ED2AD96C8">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2785A080-7F3F-4620-A188-EFD008FF16ED">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6DFCB39D-C974-4B20-9F50-2D30EB5F23C7">
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E05DB31E-A46C-40FF-B18A-135DE2F2FE48">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E05DB31E-A46C-40FF-B18A-135DE2F2FE48"/>
    <pav:createdOn>2014-04-14 14:27:58 -0400</pav:createdOn>
    <ao:suffix> Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>HLA-B*5701-negative patients may develop a hypersensitivity reaction to abacavir; however, this occurs significantly less frequently than in HLA-B*5701-positive patients.</ao:exact>
    <domeo:uuid>E05DB31E-A46C-40FF-B18A-135DE2F2FE48</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F654E302-4271-4ED9-B9AC-E44B926B80F6">
    <ao:exact>Risk Factor: HLA-B*5701 Allele: Studies have shown that carriage of the HLA-B*5701 allele is associated with a significantly increased risk of a hypersensitivity reaction to abacavir.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-19 14:48:21 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>If symptoms consistent with hypersensitivity are not identified, reintroduction can be undertaken with continued monitoring for symptoms of a hypersensitivity reaction. Make patients aware that a hypersensitivity reaction can occur with reintroduction of ZIAGEN or any other abacavir-containing product and that reintroduction of ZIAGEN or any other abacavir-containing product needs to be undertaken only if medical care can be readily accessed by the patient or others. </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F654E302-4271-4ED9-B9AC-E44B926B80F6"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:344D4D68-4BAF-49E2-8BD2-AC75E874A331">
    <ao:body rdf:resource="urn:linkedspls:uuid:809C2CC9-DE0B-426E-AF39-1670091D60EE"/>
    <pav:createdOn>2014-03-20 21:24:48 -0400</pav:createdOn>
    <pav:lastSavedOn>2014-03-20 22:01:22 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D8A55E0C-91C8-48B0-BD33-2650DAA3AE53"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:9733B1CD-C65E-4371-9EB6-E91D60ACB2AA</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:B3879AE2-F04F-487C-B275-9E75F71109F4"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:5B3A7C05-9902-476C-85DF-1A73D7737071</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:904FEF36-1C9C-48B8-B905-AFEF7485F6FE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:77CA826D-4332-410E-944B-15B9F1D6857D"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2A5514D7-FF90-48B7-B138-FD3916F3B3FA">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:249F4FFB-9BF7-4E49-80B8-B79F8EB25B25">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E251F8E1-C292-4633-B60C-A011B458874C">
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> Prior to initiating therapy with abacavir, screening for the HLA-B*5701 allele is recommended; this approach has been found to decrease the risk of a hypersensitivity reaction. Screening is also recommended prior to reinitiation of abacavir in patients </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>E251F8E1-C292-4633-B60C-A011B458874C</domeo:uuid>
    <pav:createdOn>2014-04-14 14:20:48 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E251F8E1-C292-4633-B60C-A011B458874C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <ao:exact>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:946FE3A8-81C0-4961-AF40-EAF6F7268D4E">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F32C2053-82E9-4FD1-836F-8149193CCD98">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:41A245A9-4AD2-4C8C-B264-2E8CC092E666">
    <domeo:belongsToSet>urn:domeoclient:uuid:89B3BF73-ECCA-4BCC-9B32-13F8337B5EC0</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:F99697EA-5CF3-470C-81D9-C4EF8C7CFC0F</pav:lineageUri>
    <pav:createdOn>2014-03-19 15:46:58 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:96EF0A7A-C38D-4310-A5AD-DCA532C96A59"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:4DD88B55-16A5-4026-A0F1-FD447FAB41B5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C8EC904E-70AE-4D29-97C6-2E08F4E806F3"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2354E261-14B7-45D7-8DDA-A6A0B76A8109"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:lastSavedOn>2014-03-19 16:20:19 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:62EC1291-B05D-4AD1-97C7-016291F58DDA"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:26E2F610-3861-4BE4-A906-B6282DA91710"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:1414ECBC-E784-4C48-BE39-8A6FD5C45B30"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:777CD777-5CBD-48B9-93A3-7991C8871E58">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7CA2045D-B35C-48B8-B157-D840D85050A8">
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F690C8FB-747D-409B-98B4-0C18F0BDF5B4">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:906D2DEF-111F-40B8-A11B-9714274E2E9D">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C37509E1-0CB4-4187-B773-4A68A2655640">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#LABORATORY TESTS (34075-2)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>LABORATORY TESTS (34075-2)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17BCAF59-21BC-405B-8201-7C5C5095E12E">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B5B52E0-9DAC-4CB4-B1C4-0F3EAFFB91E4">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01238</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Aripiprazole</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0DE0AC90-9691-47BD-A883-1AC4F8A597A3">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>extensive-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EFD1CBA4-AE43-4A97-80B1-FDCEFB94778B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C81287DE-8A8E-474C-ABD1-46DB45373A4E">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7244F12F-1C68-4476-A926-6F110F163218">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:764C0ACF-BCB4-41BD-84E4-FB5CFB4BF8A0">
    <rdfs:label>Azathioprine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A6763EEC-9065-43A4-BFDA-C0410A212881">
    <ao:prefix>Some published studies suggest that intermediate metabolizers have decreased active metabolite exposure and diminished antiplatelet effects.  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2014-03-20 22:49:45 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A6763EEC-9065-43A4-BFDA-C0410A212881"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <domeo:uuid>A6763EEC-9065-43A4-BFDA-C0410A212881</domeo:uuid>
    <ao:exact>The relationship between CYP2C19 genotype and clopidogrel bisulfate treatment outcome was evaluated in retrospective analyses of clopidogrel bisulfate-treated subjects in CHARISMA (n=2428) and TRITON-TIMI 38 (n=1477), and in several published cohort studies. In TRITON-TIMI 38 and the majority of the cohort studies, the combined group of patients with either intermediate or poor metabolizer status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolizers. In CHARISMA and one cohort study, the increased event rate was observed only in poor metabolizers.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D9A042CF-78F9-4448-82F2-13124D9555A4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#USE IN SPECIFIC POPULATIONS (43684-0)</poc:productLabelSection>
    <sio:SIO_000111>USE IN SPECIFIC POPULATIONS (43684-0)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4684CF8D-CAC9-40FB-A861-90DF5934EEC8">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>intermediate-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:39F539CF-D918-4263-81D4-0E8F9E2C7BA6">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:03A0817D-F24D-4221-8BA6-3731CC15BAB1">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:65B50CBD-A4E7-4462-B0FB-4CDC9240613D">
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B211438A-E8DA-4137-A21B-834C2FE11556">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:790B16C1-64F0-4219-B594-344C794C3A69">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:36FEF956-CB04-4A80-A0CB-BCE97758C351">
    <ao:context rdf:resource="urn:domeoclient:uuid:E1E53C32-75F9-4E3B-835F-235CB7A6316D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:86871666-E251-4BFA-A5AD-9568B8EB0C1B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:C1738AC0-4097-4AA4-860C-E84948776EB8"/>
    <pav:createdOn>2014-03-20 19:12:02 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:DBB743F3-2F25-44E1-BF1B-0AF4A2A59B6E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2A5514D7-FF90-48B7-B138-FD3916F3B3FA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:8FD53E73-5C42-4B07-A010-9BA11B740DC3"/>
    <pav:lineageUri>urn:domeoserver:annotation:88F1F2D1-4E66-473A-937D-1288A08429C2</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:B77C6E10-65A5-4B74-AD37-6FA51CDE3044"/>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:718393AB-AE6E-4A8E-BB27-D5AFEEB92B89"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:41927305-045E-43DF-BF77-E61DF51C69D5">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Warfarin</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:51372240-0FF1-46A6-8C2F-C9BA81F53A52">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6A5A3C98-AF0A-48AC-9785-FA5F3DA64368">
    <rdfs:label>Alternative Recommended</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0512FEF8-51B5-4B7A-83E9-0D3F8EA92C48">
    <sio:SIO_000111>CONTRAINDICATIONS (34070-3)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CONTRAINDICATIONS (34070-3)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B97602D5-1BED-471F-BD91-5F10B24278CE">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:64246E83-D29F-4245-9FE5-A55D44FA12CE">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0D41A164-99DC-4BF6-8EEE-F57FB1B2A9AF">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B06937D6-3BA3-4694-8368-7BCAF8FD2788">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:658C3999-25F4-4784-A873-265CB917A6A1">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EDD525B8-1877-42B2-9255-44B871888B01">
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdfs:label>HLA-B</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D39F3BCB-9288-4357-95F5-CCC21A19753E">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:22F2A90E-E97E-49BE-AAA8-3643DE41845D">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7C4C951E-9D8E-44FF-801A-BDE9ADEE3048">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B1A2835-2E09-461E-BBDE-905DF0D100F0">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2354E261-14B7-45D7-8DDA-A6A0B76A8109">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>TPMT</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E8E1303-5FCE-471A-B82D-3E6CDA2D262C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86185D7F-20A4-4606-AEA1-FE698024BBE1">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Carbamazepine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D750DAE1-7CF7-4673-9D17-42F414F5B26A">
    <ao:suffix> </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2014-03-19 16:53:17 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Tested patients who are found to be negative for the allele are thought to have a low risk of SJS/TEN</ao:exact>
    <domeo:uuid>D750DAE1-7CF7-4673-9D17-42F414F5B26A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D750DAE1-7CF7-4673-9D17-42F414F5B26A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:917F36A5-ED04-4F3B-8974-7FC95FDAA350">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>intermediate-activity</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:97BD4CBF-0F7A-4B5C-B742-9B5922081427">
    <rdfs:label>Concomitant medication concern</rdfs:label>
    <dct:description>A concomitant medication of concern is mentioned.</dct:description>
    <sio:SIO_000628>dailymed:ConcomitantMedicationOfConcern</sio:SIO_000628>
    <dailymed:ConcomitantMedicationOfConcern>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#concomitant-medication-concern</dailymed:ConcomitantMedicationOfConcern>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6AFF6CA5-93B5-4762-9F50-93791048BE2F">
    <rdfs:label>poor-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7FBF44D3-9A3B-4BCC-A104-612F0214ED2A">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:21512851-50BF-4561-9F41-61A5C4960B12">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:09C7AB6B-2D81-4698-9435-A87162BE3610">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:59DEDDBC-F3EF-4CDD-B293-B9FB573EE032">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6D3142E3-C6CB-466B-AC41-14267A22DC59">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clopidogrel</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:15D65839-A53D-4735-B711-A3288B1C37A5">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9C0BC915-82A5-4369-B176-F4722F09AE0C">
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:659097F0-CA95-4E11-87F3-B628FE3AB2F6">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e14304488c4b70144896e94ef0008">
    <foafx:middlename></foafx:middlename>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:title></foafx:title>
    <foafx:lastname>Doherty</foafx:lastname>
    <foafx:homepage></foafx:homepage>
    <foafx:email>dohertyallison@gmail.com</foafx:email>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <foafx:firstname>Allison</foafx:firstname>
    <foafx:name>ADoherty</foafx:name>
    <rdfs:label>ADoherty</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4BC940B0-14FC-410D-B129-38FB2DD22422">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D85B4938-A869-4D0D-8B34-F6E21FA6F439">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:820B501F-7AC9-4307-8366-DBB27F816F99">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7D45C7FF-43D3-46D0-A4AC-B36A3DB1D61D">
    <rdfs:label>CYP2C19</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E8E570A-A44C-40C0-9C80-1CFEA54A881E">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1112824-175A-4D8B-BBBB-626DE8042CF6">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7EFF2058-2F99-4E70-BFA4-0B85BC4A44B0">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7218EDD3-BDC4-4270-B694-240FD138C1F2">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Azathioprine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:041E9114-BFF4-457E-A928-3273DE95930A">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8F632807-BF89-4B0D-97C1-9B9FA9B97580">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>*2, *3A, *3C</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9C3ED506-C942-4716-BB2D-BA9AD96C12AB">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A538A4E-C356-4731-A0D9-9E5B753194CE">
    <ao:prefix>6-MP undergoes two major inactivation routes (Figure 1). One is thiol methylation, which is catalyzed by the enzyme thiopurine S-methyltransferase (TPMT), to form the inactive metabolite methyl-6-MP (6-MeMP). </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A538A4E-C356-4731-A0D9-9E5B753194CE"/>
    <domeo:uuid>7A538A4E-C356-4731-A0D9-9E5B753194CE</domeo:uuid>
    <ao:exact>TPMT activity is controlled by a genetic polymorphism.1, 2, 3 For Caucasians and African Americans, approximately 10% of the population inherit one non-functional TPMT allele (heterozygous) conferring intermediate TPMT activity, and 0.3% inherit two TPMT non-functional alleles (homozygous) for low or absent TPMT activity. Non-functional alleles are less common in Asians. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2014-03-19 15:53:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/AZATHIOPRINE-040d010a-b1b2-4db7-905d-8aa7f1bab0cd.html</ao:hasSource>
    <ao:suffix>TPMT activity correlates inversely with 6-TGN levels in erythrocytes and presumably other hematopoietic tissues, since these cells have negligible xanthine oxidase (involved in the other inactivation pathway) activities, leaving TPMT methylation as the o</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F448032B-6068-49E2-A2B6-358BE03226E7">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4D916816-26E6-4394-A742-ECDCE196F2DA">
    <poc:MedicalCondition>respiratory depression, death</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0BB4BC53-F881-41BC-82BD-F5176ED69192">
    <ao:suffix> The role of other possible factors in the development of, and morbidity from, SJS/TEN, such as AED dose, compliance, concomitant medications, co-morbidities, and the level of dermatologic monitoring have not been studied.</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <pav:createdOn>2014-03-19 17:05:35 -0400</pav:createdOn>
    <domeo:uuid>0BB4BC53-F881-41BC-82BD-F5176ED69192</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Application of HLA-B*1502 genotyping as a screening tool has important limitations and must never substitute for appropriate clinical vigilance and patient management. Many HLA-B*1502-positive Asian patients treated with carbamazepine will not develop SJS/TEN, and these reactions can still occur infrequently in HLA-B*1502-negative patients of any ethnicity.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0BB4BC53-F881-41BC-82BD-F5176ED69192"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9DADE962-3039-4370-84F3-46F5077250A0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:611B4F99-3AA6-4E9F-9932-DBA32D027D64">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <rdfs:label>VKORC1</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3E60CFA3-8CF6-4E28-B0FE-CFD577274D72">
    <rdfs:label>Recommend</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A7758925-D681-48DC-A2EB-CF8FCBD330C8">
    <ao:context rdf:resource="urn:domeoclient:uuid:1F7AE149-3B24-4669-9A5C-0DA275CE38CC"/>
    <pav:lineageUri>urn:domeoserver:annotationset:13DDC676-F835-48F3-8F51-F14D640EC90D</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2014-04-14 14:29:30 -0400</pav:lastSavedOn>
    <pav:createdOn>2014-04-14 14:26:27 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:7DEA616A-43CA-4798-9823-513B1B5AD919"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:B573E1F3-D13D-42D0-A610-72F4F658192F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:1E912A0F-BF34-45F1-A11D-D9ECCC6AC2DB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6875E169-0EA6-4711-B3BC-69FB556F838B"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:C7210469-AFB5-4F34-8DE5-70D809640FF5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:975B0E4D-CD6B-4EB2-A1DD-272946DFD796"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:595B8AC5-E3D5-4E81-A0E6-A95FC4BACDD0"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:22A6FD62-21E2-42E4-B243-856567377D1C"/>
    <pav:previousVersion>urn:domeoserver:annotationset:77702DAE-17B5-4010-957C-3EBC5127E1C3</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EB382F6A-3E55-4140-81FD-529415503DD2">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:29B26F09-DDF1-4768-A4CE-2E3D10C9ACA8">
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:06806261-22DA-4044-B6AD-E53187E7947D">
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A7B5E2D3-3FDB-4BC6-A57F-543654FA9B26">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Tamoxifen</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4427B796-F4E0-4147-86EB-A2E57E81AAD0">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FCEFC622-B8CA-44D0-9E12-E9DFD3669AA4">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>TPMT</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000016583</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CB1C8141-94E6-4B3D-9C57-A646D76E3B24">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2D6</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:80703674-6299-4823-BA1B-C4DB0986A1F5">
    <domeo:uuid>80703674-6299-4823-BA1B-C4DB0986A1F5</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:80703674-6299-4823-BA1B-C4DB0986A1F5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>Tested patients who are found to be negative for the allele are thought to have a low risk of SJS/TEN </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
    <ao:prefix> </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Carbamazepine Extended-Release Capsules should not be used in patients positive for HLA-B*1502 unless the benefits clearly outweigh the risks. </ao:exact>
    <pav:createdOn>2014-03-19 16:52:23 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3D15F27-B83B-43CF-8CBD-9EB95EEDAED3">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/WARFARIN-3d35df36-1a19-4559-91fe-252b7082295b.html</ao:hasSource>
    <ao:exact>If the patient's CYP2C9 and VKORC1 genotypes are not known, the initial dose of warfarin sodium tablets is usually 2 to 5 mg per day. Modify this dose based on consideration of patient-specific clinical factors. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F3D15F27-B83B-43CF-8CBD-9EB95EEDAED3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>F3D15F27-B83B-43CF-8CBD-9EB95EEDAED3</domeo:uuid>
    <pav:createdOn>2014-03-20 20:35:50 -0400</pav:createdOn>
    <ao:prefix>dose based on the expected maintenance dose, taking into account the above factors. Routine use of loading doses is not recommended as this may increase hemorrhagic and other complications and does not offer more rapid protection against clot formation. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>Consider lower initiation doses for elderly and/or debilitated patients (see</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:414EDB35-206D-4166-AF2C-9F3EB92FD4A7">
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PATIENT MEDICATION INFORMATION (68498-5)</poc:productLabelSection>
    <sio:SIO_000111>PATIENT MEDICATION INFORMATION (68498-5)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:78FCAD88-6AEB-423F-9B5D-DEA6A551B786">
    <poc:MedicalCondition>myelosuppression</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FFE334F5-EADA-48A9-9C71-93A006B991CE">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Efficacy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E355F710-73FD-453F-B1AA-BF17D98B29DF">
    <rdfs:label>Recommend</rdfs:label>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A0ED0120-25AD-40A5-B337-7AEB1CE08F04">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4CA5E677-842C-4D24-97A8-620514D87273">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A4296738-BC58-499E-9E03-DC8866FD4D10">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DA50FDB4-AF3D-40C9-BBA7-C916D99F7425">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:484121CB-C92D-490C-A450-25D30BC26DA9">
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A1C960C2-FD84-40FC-AC08-9AD3C56E51E0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>acute coronary syndrome, percutaneous coronary intervention</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0835671D-6203-4CA8-A147-428ECC753391">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>0835671D-6203-4CA8-A147-428ECC753391</domeo:uuid>
    <pav:createdOn>2014-04-14 13:46:18 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ABACAVIR-6a3b10fc-4b2a-45e3-16a1-ef79187a6dfb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Discontinue ZIAGEN as soon as a hypersensitivity reaction is suspected. Regardless of HLA-B*5701 status, permanently discontinue ZIAGEN if hypersensitivity cannot be ruled out, even when other diagnoses are possible.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0835671D-6203-4CA8-A147-428ECC753391"/>
    <ao:prefix>Patients who carry the HLA-B*5701 allele are at high risk for experiencing a hypersensitivity reaction to abacavir. (5.1) </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C0B1EF2F-B9D3-4FCB-BED1-ACD2887E8C2D">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B116C4D5-D059-4C0E-9ACF-67C01A265602">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0B767998-2127-4EF1-AA11-8FB04F279BAA">
    <poc:MedicalCondition>myelotoxicity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:84E7042D-771B-40E7-AECF-02BAA9A5E8B4">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C2C66B07-0775-4664-9FB4-AD89C89EFD17">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0C1A9B4F-DEC2-448A-8FA5-882ED83EAFC2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8E364A00-9E36-406E-8B4A-C359FA92A5DC">
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FAA5C863-7065-4DD5-A9C9-48444810C976">
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F5CB30B-363A-4D08-96DA-E83CAC1EA2A7">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACOKINETICS (43682-4)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOKINETICS (43682-4)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16C1652F-220E-4CC4-AC5C-5924F77FC89A">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B050FCFA-B2E9-452D-B857-ACCEC8B748FC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-decreased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an decrease in the efficacy of the drug.</dct:description>
    <rdfs:label>Decreased Efficacy</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CB123277-1091-420D-8CBE-9A559F8DE5FD">
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9C1C8B5A-70E8-433D-9A33-36FABEF46CE4">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69BAE4D0-A413-4DA0-9A58-F4F38BEC9D18">
    <ao:context rdf:resource="urn:domeoclient:uuid:E05DB31E-A46C-40FF-B18A-135DE2F2FE48"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:92B321FC-12CB-4490-8ECE-ADB36B8671FA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:44FAFCC4-E498-409C-B96D-77953D07D4DE"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:06FAD97E-5A2F-40B4-82A8-83569F3CDE07</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:77702DAE-17B5-4010-957C-3EBC5127E1C3</pav:previousVersion>
    <pav:lastSavedOn>2014-04-14 14:29:30 -0400</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:45EA0802-0C27-4F16-BD88-85E6B0E58899"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:6B5A5933-4BD0-4B40-A541-6D2F82FF0FC5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:11ECEDA8-E50E-41E3-8FBD-161149E12D2D"/>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:570FED41-B0A2-4F08-8D2E-59501A361178"/>
    <pav:lineageUri>urn:domeoserver:annotationset:13DDC676-F835-48F3-8F51-F14D640EC90D</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:21B20BF5-599F-4195-A261-8E38ECFDAB40"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:042D8280-D0A4-4723-AC94-3C1C7811607B"/>
    <pav:createdOn>2014-04-14 14:27:58 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CDC42789-15A9-4B6D-8CB6-4A27311D6443">
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL STUDIES (34092-7)</poc:productLabelSection>
    <sio:SIO_000111>CLINICAL STUDIES (34092-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1EAB2D72-EEBB-4792-AE12-53BB256D5230">
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F134FD27-E0FD-4202-A44B-EF9501C3826D">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdfs:label>ER_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF1A37D6-AEDA-48F2-A45F-2355A82206A8">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:640B1775-B04F-42B9-9B68-0774955FCC87">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#ADVERSE REACTIONS (34084-4)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>ADVERSE REACTIONS (34084-4)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D994E0B2-223A-465B-980E-73FF62AC8B7B">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:02E74D0E-3586-4121-BAAC-0DBD593E38D7">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B8BFADA5-C34A-4483-9C3C-F661DA89CE85">
    <rdfs:label>Increased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E920DEBC-AA60-423C-B3BF-D7C127930FCD">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:144AB067-995B-44BE-BF17-08B8597C8092">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:52B9C004-5A1A-4BB2-A551-C9850DD315EB">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:964FB36C-BB63-4DA5-BD48-BBA2F92383FE">
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A172BEBB-9732-4502-8250-4C80D5F01B6C">
    <poc:MedicalCondition>increased bleeding risk</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:86883BB8-D51E-4847-9B7D-50B082CDA3D7">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E39BF86B-CE64-46BC-A24B-114C31040DF6">
    <ao:body rdf:resource="urn:linkedspls:uuid:D1ADDFFF-3DB7-43B3-9E80-A13335BEBAC8"/>
    <pav:createdOn>2014-03-20 19:15:59 -0400</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:A7A766EA-7BFD-4F32-B2B8-70CC2A57E721"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:resource="urn:linkedspls:uuid:F374CAE1-4037-4056-9B02-3FB7229BAAD5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:A674DD98-DBE1-41B7-9DD2-18FE913C4BAD</pav:lineageUri>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:34CA7071-235A-4D52-82B4-09F2E160DEAE"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:76677AD5-7544-4407-9CBA-B12F9F433E0C"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:26FFBF0B-E195-48B5-AB92-712C0452D63F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:E9E50458-CD63-4142-BD5F-8356579E42C6"/>
    <pav:lastSavedOn>2014-03-20 19:16:55 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:5070D7DE-F3EE-4B7A-B4F7-56FC944E7CCD"/>
    <domeo:belongsToSet>urn:domeoclient:uuid:05B3B39D-C21F-42FB-BCB2-F89C9C37F9F5</domeo:belongsToSet>
    <ao:body rdf:resource="urn:linkedspls:uuid:48D2176F-5F8B-4993-A51B-337969C52A2C"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F2437485-F4C1-46BA-8F55-3A2734C01F73">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF98706C-A5C4-4C91-B4DA-6F434307A706">
    <domeo:belongsToSet>urn:domeoclient:uuid:9D3B386F-3E03-4830-AE7F-7763642571ED</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2014-03-20 22:42:52 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:4427B796-F4E0-4147-86EB-A2E57E81AAD0"/>
    <pav:lastSavedOn>2014-03-20 22:51:31 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e14304488c4b70144896e94ef0008</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:08ACA31F-17B2-4FEC-A7A0-B0F61243A2BE"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8E4638B7-B16A-4D3A-99CA-0403DD062E24"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:1B72ABCA-FC47-4A17-8E1E-09457FEE9E88"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C3E5F061-024B-422E-B7EC-73FBCEF4CECA"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:018BB3F5-AAC4-4F09-BF7A-7EF72942F2D5"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:0FB0FD62-2FF1-4EDF-ACF0-DDCE801F9F9E"/>
    <pav:lineageUri>urn:domeoserver:annotation:CE5DB959-1137-4B88-A8B4-886953C151A2</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3EC23021-7DE8-434F-9BF8-2280E24D021B">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL STUDIES (34092-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>CLINICAL STUDIES (34092-7)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D62B81DA-0F12-4CE9-9FCC-11BF50B39C52">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9F4CC90D-622C-4CAE-BF61-3570274C4C71">
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1B00C133-7878-488F-8C2B-482585068503">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2769A95A-FAE1-4921-9631-2E94C9BF581D">
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:08CC424F-2134-4DDC-A8C4-A5FE3DDAD858">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5010F461-BF1A-440D-84CC-7AAE239F97AE">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Efficacy</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:33CED7AF-D333-4B88-8EE7-51A7C0450AB5">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PRECAUTIONS (42232-9)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PRECAUTIONS (42232-9)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9D9999AD-FB08-4711-8283-408230FFF2CC">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:94E3545F-40DC-490F-A4F2-7788593E77D4">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CAFFD0F8-4834-4696-9950-BBB6C6B5F0C2">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C9</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:26061102-D4B3-4910-AC2D-FA5290506799">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:23BB932E-45FB-42A9-8902-7FFDBE68F3C1">
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7DEBBDAD-F4DB-450F-A395-A296EB54D545">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>respiratory depression, death</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:627D2B6E-0E5C-457E-8623-11C11BA016A8">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:348B2B17-CCFC-4D07-A5FB-95995E5C6D47">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:731D209C-5EFA-43B8-A1DB-088AD320A254">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:6C070480-01AA-492E-B72C-A2B5B1A693A1">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:47FD3A82-57E6-4F64-8B93-B05E50339AFA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:25247B65-25B8-4263-9212-BB85B73D1C58">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:502618F5-0CE3-4C0C-AF6B-646B7731D238">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
    <pav:createdOn>2014-03-20 22:23:51 -0400</pav:createdOn>
    <domeo:uuid>502618F5-0CE3-4C0C-AF6B-646B7731D238</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:502618F5-0CE3-4C0C-AF6B-646B7731D238"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> (2.3, 5.1)</ao:suffix>
    <ao:exact>Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E02FDE18-6063-4150-B30F-DFD6BEA38790">
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EA45E928-A8B1-42CE-A40C-5C1A3F7D3EB0">
    <pav:createdOn>2014-03-19 16:33:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact> STUDIES IN PATIENTS OF CHINESE ANCESTRY HAVE FOUND A STRONG ASSOCIATION BETWEEN THE RISK OF DEVELOPING SJS/TEN AND THE PRESENCE OF HLA-B*1502, AN INHERITED ALLELIC VARIANT OF THE HLA-B GENE. HLA-B*1502 IS FOUND ALMOST EXCLUSIVELY IN PATIENTS WITH ANCESTRY ACROSS BROAD AREAS OF ASIA.</ao:exact>
    <ao:prefix>, HAVE BEEN REPORTED DURING TREATMENT WITH CARBAMAZEPINE. THESE REACTIONS ARE ESTIMATED TO OCCUR IN 1 TO 6 PER 10,000 NEW USERS IN COUNTRIES WITH MAINLY CAUCASIAN POPULATIONS, BUT THE RISK IN SOME ASIAN COUNTRIES IS ESTIMATED TO BE ABOUT 10 TIMES HIGHER.</ao:prefix>
    <domeo:uuid>EA45E928-A8B1-42CE-A40C-5C1A3F7D3EB0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> PATIENTS WITH ANCESTRY IN GENETICALLY AT-RISK POPULATIONS SHOULD BE SCREENED FOR THE PRESENCE OF HLA-B*1502 PRIOR TO INITIATING TREATMENT WITH CARBAMAZEPINE EXTENDED-RELEASE CAPSULES. PATIENTS TESTING POSITIVE FOR THE ALLELE SHOULD NOT BE TREATED WITH C</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EA45E928-A8B1-42CE-A40C-5C1A3F7D3EB0"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CARBAMAZEPINE-ee15d911-73c7-4bc6-96f2-089a8aa64e18.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:45EA0802-0C27-4F16-BD88-85E6B0E58899">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1E5CC1B4-0FBE-43E8-A08F-1CE5CEBDCF82">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#recommended</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Recommend</rdfs:label>
    <dct:description>A recommended test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:668AFD12-0294-42CF-9F9E-1E8578E29EF1">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>intermediate-activity</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C4F7EF34-16EC-444F-8EC0-25496D966989">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C4F6317C-F28C-415A-9908-9B252949CEF9">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:406AD9C1-4916-4EBE-BDCE-B58A89D96444">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:268ADDD9-94A3-46B3-B733-1A8F8A153747">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:632F7249-A1AA-4717-BE8B-17672E7612AD">
    <rdfs:label>Metabolism Increase</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0A708736-453D-44F0-8285-2ED07935FE60">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F31E097-6939-4259-909F-89C84FD7447C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:552CC9B8-E36B-4BAD-9B40-367A8C7E175A">
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>*2, *3</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3F404EB0-8907-4375-A4CE-302469F6CE01">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EEC4F49F-7CE6-4FC4-B310-082538226DBA">
    <ao:exact>Poor metabolizers treated with clopidogrel bisulfate at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>EEC4F49F-7CE6-4FC4-B310-082538226DBA</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EEC4F49F-7CE6-4FC4-B310-082538226DBA"/>
    <ao:suffix> (12.5) </ao:suffix>
    <pav:createdOn>2014-03-20 22:23:38 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/CLOPIDOGREL-03bec9ad-cd22-44d3-9b82-2796157de1d1.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:57BF6DD7-6AB9-47A2-A320-1AC06DB218C5">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>respiratory depression</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:92B321FC-12CB-4490-8ECE-ADB36B8671FA">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-decreased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an decreased risk of toxicity.</dct:description>
    <rdfs:label>Decreased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34C7F252-0062-4084-85B9-D44C474C8E00">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>1639G(rs9923231)</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7662C575-92BB-4040-82BA-BA5F98AFA8AB">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:11ECEDA8-E50E-41E3-8FBD-161149E12D2D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77878550-8F6C-4F7E-A467-A6BC25C4D823">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A3DABBC2-F048-4AAF-9572-E463E73EFDF2">
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4A4AB16B-1B3D-419F-9593-65CD7E99748F">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2E6A9AB4-9923-4B76-BAF7-A7D7AE523DE9">
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7C2DA914-B2F9-4FA8-BD2A-A13628950AE5">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <rdfs:label>Letrozole</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.1alpha-050">
    <foafx:build>050</foafx:build>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
    <foafx:homepage></foafx:homepage>
    <foafx:version>2.1alpha</foafx:version>
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A2898998-BCA5-4476-9A7A-BEFE82F41B44">
    <rdfs:label>Azathioprine</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5D01E24F-EF6C-4B5D-95BD-11FBAE29CC5D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>*1/*1xN, *1/*2xN</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A7E98374-CD92-4BA1-A421-B4AAF18FD95E">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E4955692-2C70-4BC8-BF5F-ECB899015ED8">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#INDICATIONS AND USAGE (34067-9)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>INDICATIONS AND USAGE (34067-9)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:FB5A7F5E-A414-4A2C-A48B-70390FCEF68D">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Use specific</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CF69785D-3536-4A5E-B2D1-807B3169000F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>lactation</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D7789554-93DB-4789-BF51-0CE3DA15344D">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AE27F4C6-AD6F-4844-B21C-2142B423021B">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:807EA959-BCD2-4A5B-B326-7812677F173F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdfs:label>ER_receptor</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:65C194F0-EA24-44FE-B791-26F5A26398F4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E9E50458-CD63-4142-BD5F-8356579E42C6">
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D2FE7E01-562F-4D47-B9C6-FAA7E17EEE8A">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7CB63A09-E30C-4A2B-B101-6AC7950DBA21">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01238</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Aripiprazole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:50477C9C-C07C-4BF7-9255-E776B4E927D7">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C9</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CF070D3B-45DC-41F6-9FE6-8F8A14B5CCE6">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0BB2E8FE-EEA1-43A2-8258-4855094167CF">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DBCE382C-A0BC-45A4-B295-40A72AA17EFA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2AE1EF63-AB7F-4B86-B3C8-78D8BB81869B">
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:75240CD0-BE1C-4707-BD6B-478E05C4467B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BC8865C0-9E2F-4008-8E98-CFF867AC7FF5">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16E75B4D-108A-4272-8958-7E17188ED33A">
    <dct:description>The selected biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2883AF53-1B2C-4B8C-860E-836D46EFBC8B">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CA3C4B11-6B7D-45F0-93B8-31BF707209C7">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*5701</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7CFCE65D-C6A6-4397-9497-D4AA84C41038">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#INDICATIONS AND USAGE (34067-9)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>INDICATIONS AND USAGE (34067-9)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:77BCF8BD-CBFA-4952-8CAD-0DF8A9BC2580">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>lactation, death</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AAF90B4C-DC63-4760-8FC0-796F0F517E23">
    <dct:description>The selected biomarker.</dct:description>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
    <rdfs:label>ER_receptor</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker1>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B3879AE2-F04F-487C-B275-9E75F71109F4">
    <rdfs:label>Increased Efficacy</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EAB6F24D-AA43-449F-911E-1E56666A1A02">
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006102</dailymed:pharmgxBiomarker>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2C19</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9165D130-2F21-405C-A4BC-1E9150B2A169">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#excretion-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Excretion Increase</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a increase in excretion of the drug</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BDC2DC01-4301-40A7-8086-E7F3C5210DF7">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:018BB3F5-AAC4-4F09-BF7A-7EF72942F2D5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C8EC904E-70AE-4D29-97C6-2E08F4E806F3">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Azathioprine</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00993</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AA2A1633-B19F-4CE2-835E-FE12EB3A7340">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AA2A1633-B19F-4CE2-835E-FE12EB3A7340"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/LETROZOLE-63e54b62-a30d-4a56-9215-75e7a0b0bf02.html</ao:hasSource>
    <domeo:uuid>AA2A1633-B19F-4CE2-835E-FE12EB3A7340</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.</ao:exact>
    <pav:createdOn>2014-03-19 22:49:05 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:39A29CC1-E63D-49E7-95DF-8C5435A68D70">
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:444A5707-FFEE-4D8C-BC63-4289C317B0C5">
    <ao:suffix> PMs have about an 80% increase in aripiprazole exposure and about a 30% decrease in exposure to the active metabolite compared to EMs, resulting in about a 60% higher exposure to the total active moieties from a given dose of aripiprazole compared to EM</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/ARIPIPRAZOLE-217e52b5-3a7b-4bbe-af3c-b18de7d426c3.html</ao:hasSource>
    <domeo:uuid>444A5707-FFEE-4D8C-BC63-4289C317B0C5</domeo:uuid>
    <ao:exact>Approximately 8% of Caucasians lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are extensive metabolizers (EM).</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-03-11 17:27:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:444A5707-FFEE-4D8C-BC63-4289C317B0C5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4B00053F-C116-4276-B0F7-90AB868A7550">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacavir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9BAD21E0-A813-4CC6-BF58-E7E34520383C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>QT prolongation</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:67789CF4-92A0-4DFE-B8E1-E760689FB691">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Metabolism Increase</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:ACE64BA1-1115-4621-8E99-F15218492103">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01006</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Letrozole</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:55F29EC1-BB42-4A08-9250-037C597742FD">
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Variant Frequency</rdfs:label>
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5E50A73B-9509-42A1-A8A3-16D898A5146C">
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B4D3A216-653D-42EB-8DD3-CB10AAF831D8">
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5214C21A-B853-4722-BA59-29C024D30BC1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C60729CB-9B3A-4CB7-A3BE-139D9C75D74B">
    <dailymed:pharmgxBiomarker2>http://purl.obolibrary.org/obo/PR_000007204</dailymed:pharmgxBiomarker2>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>ER and PgR_receptor</rdfs:label>
    <dailymed:pharmgxBiomarker1>http://purl.obolibrary.org/obo/PR_000012621</dailymed:pharmgxBiomarker1>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000007205</dailymed:pharmgxBiomarker>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1F0E8B3A-F586-46EA-9CB4-CA63642105D5">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Warfarin</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA17AD62-DB44-44A7-9BF5-12DF3076DD2A">
    <rdfs:label>Warfarin</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00682</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:47F47714-22F3-4F66-9F42-D32E479B2AFA">
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>*1/*1, *1/*2, *1/*3, *2/*2, *2/*3, *3/*3</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F4BE61E-FC90-4CE1-B16F-1CCEFA05F994">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:31652C2C-DD89-4154-8144-014752FE2F0D">
    <rdfs:label>Use specific</rdfs:label>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#use-specific</poc:DoseSelectionRecommendation>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use specific dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F2E1EF2A-6933-46FD-8E56-3CD264CFFF03">
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2C116106-25B9-4F51-B9F4-275BAE844D6C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-efficacy-increased-from-baseline</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Efficacy</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with an increase in the efficacy of the drug. </dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:76677AD5-7544-4407-9CBA-B12F9F433E0C">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1CB76367-170A-4454-908D-5B114277C285">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Abacavir</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6ba7a2fbccac4f2e8040838077d708fc">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4F74761E-8714-4796-A952-DBB32E1378D1">
    <rdfs:label>HLA-B</rdfs:label>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2D5D0C6C-A326-4837-9705-A127A053E74C">
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>CYP2D6</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006121</dailymed:pharmgxBiomarker>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D1D8DA5E-E9CC-4D40-8F1A-0F9C8E871003">
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Citalopram</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00215</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C42FD849-B54A-449A-8C00-5C53DB675D83">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17630195-269F-4F67-8B08-1642B985FF9E">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4C367B21-F0B7-4204-89B3-D2618F7E1351">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7FD1DC92-DB35-47C7-8DB5-EB042CE34E34">
    <poc:MedicalCondition>overdose symptoms, lactation</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2C0DEEB7-91B1-41E9-80BE-BA8171BD1AA7">
    <rdfs:label>Abacavir</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB01048</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BBEF447E-89DE-4835-87B5-04584A17642B">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdfs:label>Metabolism Decrease</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C3E5F061-024B-422E-B7EC-73FBCEF4CECA">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>*2, *3, *4, *5, *6, *7, *8</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:34E7D630-3B35-43B0-AF03-327F9936EEF5">
    <rdfs:label>Carbamazepine</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00564</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C033DD05-A979-476F-B099-5B46FED13115">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:355D3C19-D444-4E01-991E-60998F4C0E73">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS (34071-1)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <sio:SIO_000111>WARNINGS (34071-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B66F17A9-EC80-4D4E-B55A-0281D4B9C2A7">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdfs:label>ultra-metabolizer</rdfs:label>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:330AA821-EF93-4F3F-B17D-E252A0FA4E2E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Discontinue/Do not restart</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to not restart the drug</dct:description>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#discontinue-do-not-restart</poc:DrugSelectionRecommendation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1C79CA9B-388B-440F-81D1-4A78C148CD26">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:317C0EA5-B0A0-4E0D-BCEC-125F7C8B8883">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DOSAGE AND ADMINISTRATION (34068-7)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>DOSAGE AND ADMINISTRATION (34068-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:27562935-5D9B-4A37-9270-D938370A5A0F">
    <ncit:Alleles>*1/*1, *1/*2, *1/*3, *2/*2, *2/*3, *3/*3, *5, *6, *9, *11</ncit:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:23A1ABEE-A833-45F0-A6AC-00D3AF79ADE4">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL PHARMACOLOGY (34090-1)</poc:productLabelSection>
    <rdfs:label>SPL Section</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000111>CLINICAL PHARMACOLOGY (34090-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D1044D44-5910-474A-A8A4-E6EA9C153399">
    <rdfs:label>Decreased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-decreased</poc:PharmacodynamicImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an decreased risk of toxicity.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N52117184b6254fc695c9c0fbe6e8c5e8">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C85F2569-E1BA-41FE-8EBF-518BE5F38995">
    <rdfs:label>VKORC1</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000017303</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6233671-F202-4725-8382-9CACBFF9139E">
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#CLINICAL STUDIES (34092-7)</poc:productLabelSection>
    <sio:SIO_000111>CLINICAL STUDIES (34092-7)</sio:SIO_000111>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C752899B-CF9A-46F9-96A0-E6AB69BA169E">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E21984D9-39A1-4A90-8596-A54355C4E290">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:9494055D-F4FE-4CCF-8ADB-74AF27A0398D">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdfs:label>Clopidogrel</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:642AE10F-0A86-4274-9E80-EB5E74A54D3D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>respiratory depression, death</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A69958AC-75DD-4DB5-95B7-115AA9D11FB2">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:D055AE88-C376-4C64-BF03-58DA3D8C4A16">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E7F9B66C-EC4C-4447-ACA9-A22AFBDD7206">
    <dct:description>Testing related to the pharmacogenomic biomarker is avaliable.</dct:description>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#take-note-that-tests-are-avaliable</poc:TestRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Take note that tests are avaliable</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:83B886FC-2F6C-447E-B922-9E1004D2BEFD">
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:562B32AB-D232-4372-8312-4DDEB3325606">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00318</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Codeine</rdfs:label>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F0AE356A-0EB9-438E-9217-7E967EEC2AC4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F6DBB891-633E-4CA5-BBED-47EEE93F23BB">
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>HLA-B*1502</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E5082080-9E96-4A7D-B916-6253B001E40A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:B4DF83AA-EC7E-49FD-85C2-57158CD44F16">
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7A6F08EF-D022-4FB7-9355-EBD844ECAF10">
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alternative Recommended</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:35CB04AA-5402-4D4E-81F2-97BBC502F27B">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#INDICATIONS AND USAGE (34067-9)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>INDICATIONS AND USAGE (34067-9)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BB3E419E-69E3-47C5-A04D-6193B228402D">
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <rdfs:label>HLA-B*5701</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:06E9A7A4-188B-4FD1-9759-E93F396566E7">
    <sio:SIO_000563>poc:VariantFrequency</sio:SIO_000563>
    <rdfs:label>Variant Frequency</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>The frequency or proportion at which a variant occurs in a specific population is mentioned.</dct:description>
    <poc:VariantFrequency>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#population-frequency-mentioned</poc:VariantFrequency>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1ADB949E-07A2-48D9-8316-7C7B105A8F0E">
    <rdfs:label>HLA-B</rdfs:label>
    <sio:SIO_000628>dailymed:HGNCGeneSymbol</sio:SIO_000628>
    <dct:description>The selected HGNCGeneSymbol.</dct:description>
    <dailymed:HGNCGeneSymbol>http://bio2rdf.org/hgnc:4932</dailymed:HGNCGeneSymbol>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3A13C9D0-35CB-4326-93DB-04D1BCE21136">
    <poc:MedicalCondition>life-threatening respiratory depression, fatal respiratory depression, signs of an overdose</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DA44CF9D-652F-4CB3-BDE7-8160F714C759">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Influences Drug Response</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#influences-drug-response</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker influences drug response</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:227586CE-1E8C-47CE-A2E6-A55AFC74F904">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CDB1C167-A81B-4DF3-AEFF-433DA666D9E6">
    <poc:MedicalCondition>acute coronary syndrome, percutaneous coronary intervention</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:17270663-D028-419C-86D6-D27A27CAF0B1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000006120</dailymed:pharmgxBiomarker>
    <rdfs:label>CYP2C9</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <dct:description>The selected biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A9FE9022-79EE-4050-8A20-C65B1555F57E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>*2, *3</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0FED8C9E-A7A7-4BC8-8996-A86A1CC42A81">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>respiratory depression, death</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5FA44327-04D3-4E57-91F7-BEB90393EF82">
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#BOXED WARNING (34066-1)</poc:productLabelSection>
    <sio:SIO_000111>BOXED WARNING (34066-1)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EB922C3B-B19C-4E73-93B4-C1EA9B2578D4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Alleles</rdfs:label>
    <ncit:Alleles>HLA-B*5701</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5CA6C5AE-7870-48BD-9F38-0DF2F4374D6D">
    <sio:SIO_000111>PHARMACOGENOMICS (66106-6)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PHARMACOGENOMICS (66106-6)</poc:productLabelSection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:26E2F610-3861-4BE4-A906-B6282DA91710">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>myelotoxicity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0CE6C18C-1529-4219-B4D8-B35E2193D68F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>myelotoxicity</poc:MedicalCondition>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F44860B2-A936-4534-9F34-3CA5DCE5BADD">
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5BC07AE5-1D49-481A-957D-90BE740895FF">
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:959C7BF5-A36B-47E0-B303-34232C155773">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to decrease the dose of the drug from the recommended baseline.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#decrease-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <rdfs:label>Decrease from baseline</rdfs:label>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BD4157B4-A052-45E8-B62F-F1A812E8C7AB">
    <poc:Comment>pediatrics</poc:Comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8C6A85F6-9525-446B-8CD3-3E0A9FE880F1">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:48DAFCD9-7E3A-4349-8AED-177E2B11DE9F">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#WARNINGS AND PRECAUTIONS (43685-7)</poc:productLabelSection>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>WARNINGS AND PRECAUTIONS (43685-7)</sio:SIO_000111>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:229EED02-11F2-4F51-AE34-1EE50968AC03">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E692F298-8406-43F1-B0B7-B2CDCEFE7189">
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00675</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Tamoxifen</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:5AB30AFB-FAB4-4851-A252-6DC5B019BF5C">
    <rdfs:label>MedicalCondition</rdfs:label>
    <poc:MedicalCondition>hypersensitivity</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:4D1AD809-0CDA-48D6-A56C-5764FD5EA9DC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MedicalCondition>life-threatening side effects, fatal side effects, lactation</poc:MedicalCondition>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:60BB6B78-9554-4AED-A8E0-25E6BA3CD14E">
    <dct:description>The drug of interest.</dct:description>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Clopidogrel</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc072075ff6044f6cb889d228c6442b8c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:39D1765E-4C7C-4568-AA22-98067A21B747">
    <rdfs:label>Clopidogrel</rdfs:label>
    <dailymed:pharmgxDrug>http://www.drugbank.ca/drugs/DB00758</dailymed:pharmgxDrug>
    <dct:description>The drug of interest.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0EF5824B-CA82-45E9-884B-B73638E3E247">
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PRECAUTIONS (42232-9)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <sio:SIO_000111>PRECAUTIONS (42232-9)</sio:SIO_000111>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>SPL Section</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:E543270D-1D3E-46C8-9E89-C1AF04CA5213">
    <rdfs:label>HLA-B*1502</rdfs:label>
    <dailymed:pharmgxBiomarker>http://purl.obolibrary.org/obo/PR_000002010</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5398fbdd09474f40a089d7e75f172dfb">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N60a51e347e8f49b2965286fa6dd65fa5">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:DFD7FA46-889E-4749-B556-55DE45D28952">
    <rdfs:label>Metabolism Decrease</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a decrease in metabolism of the drug.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C54930A3-93C6-4ACE-B9E0-56DBE72CD1F6">
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>poor-metabolizer</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:EFC9F4DB-F33E-4B41-97FA-E68BACCDAAD1">
    <rdfs:label>low-or-absent-activity</rdfs:label>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#</poc:Variant>
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:F7EC48B0-0AAD-4A4B-B2DE-786B06DF7675">
    <sio:SIO_000111>MECHANISM OF ACTION (43679-0)</sio:SIO_000111>
    <rdfs:label>SPL Section</rdfs:label>
    <poc:productLabelSection>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#MECHANISM OF ACTION (43679-0)</poc:productLabelSection>
    <dct:description>The section of the label where pharmacists identify clinical pharmgx statements</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na79dd3c5fe7d4813ad500d5600d2e386">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CC95AE15-E92F-4EA8-AF21-263E73007B0B">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>*2, *3</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:36E8A1E2-255C-46F2-B3B6-FE1C93F847ED">
    <rdfs:label>Alleles</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <ncit:Alleles>*2, *3</ncit:Alleles>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N22e59f4c03194ae5987f6b4e01b67814">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
</rdf:RDF>
